Macrocyclic immunomodulators

Macrocyclic compounds are developed to inhibit PD-1/PD-L1 interactions, addressing immune evasion in cancer and infectious diseases by enhancing immune responses and improving immunotherapy outcomes.

JP2024544009AInactive Publication Date: 2024-11-26BRISTOL MYERS SQUIBB CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532998
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-03
Filing Date
2022-12-02
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The interaction between PD-1 and PD-L1 leads to immune evasion by cancer cells, resulting in T cell exhaustion and reduced immune responses, necessitating drugs that can block this interaction to enhance immunotherapy efficacy.

Method used

Development of macrocyclic compounds that inhibit the PD-1 protein-protein interactions, thereby modulating the immune response and potentially treating cancer and infectious diseases.

Benefits of technology

The macrocyclic compounds effectively inhibit the PD-1/PD-L1 pathway, enhancing immune responses against chronic antigens and increasing the efficacy of immunotherapy in treating various diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544009000001
    Figure 2024544009000001
  • Figure 2024544009000002
    Figure 2024544009000002
  • Figure 2024544009000003
    Figure 2024544009000003
Patent Text Reader

Abstract

In accordance with the present invention, macrocycles have been discovered that are capable of binding to PD-1 and inhibiting the interaction between PD-1 and PD-L1, and that these macrocycles have in vitro immunomodulatory efficacy, making them therapeutic candidates for the treatment of a variety of diseases, including cancer and infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 285,826, filed December 3, 2021, the contents of which are incorporated herein by reference in their entirety.

[0002] Reference to electronically submitted sequence listings The electronically provided sequence listing (Name: 3338_221PC01_Seqlisting_ST26.xml; Size: 2,577 bytes; and Data Creation Date: December 1, 2022) is incorporated herein by reference in its entirety.

[0003] Field The present application provides macrocycle compounds that can bind to PD-1 and inhibit the interaction between PD-1 and PD-L1. These macrocycle compounds exhibit in vitro immunomodulatory efficacy and are therefore potential therapeutic agents for the treatment of various diseases, including cancer and infectious diseases. [Background technology]

[0004] background Human cancers carry numerous genetic and epigenetic alterations, producing potential neoantigens that can be recognized by the immune system (Sjoblom et al., 2006). The adaptive immune system, consisting of T and B lymphocytes, has potent anticancer potential, a broad ability to respond to diverse tumor antigens, and exquisite specificity. Furthermore, the immune system exhibits considerable plasticity and memory components. The successful exploitation of all these properties of the adaptive immune system makes immunotherapy unique among all cancer treatment modalities.

[0005] The protein programmed death 1 (PD-1) is an inhibitory member of the CD28 family of receptors, which also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata et al., supra; Okazaki et al., Curr. Opin. Immunol., 14: 779-782 (2002); Bennett et al., J. Immunol., 170: 711-718 (2003)).

[0006] The PD-1 protein is a 55 kDa type I transmembrane protein that is part of the Ig gene superfamily (Agata et al., Int. Immunol., 8: 765-772 (1996)). PD-1 contains a membrane-proximal immunoreceptor tyrosine-based inhibitory motif (ITIM) and a membrane-distal tyrosine-based switch motif (ITSM) (Thomas, ML, J. Exp. Med., 181: 1953-1956 (1995); Vivier, E. et al., Immunol. Today, 18: 286-291 (1997)). Although structurally similar to CTLA-4, PD-1 lacks the MYPPY motif, which is essential for CD80 to bind to CD86 (B7-2). Two ligands for PD-1 have been identified: PD-L1 (B7-H1) and PD-L2 (b7-DC). It has been shown that the activation of PD-1-expressing T cells is downregulated by interaction with cells expressing PD-L1 or PD-L2 (Freeman et al., J. Exp. Med., 192: 1027-1034 (2000); Latchman et al., Nat. Immunol., 2: 261-268 (2001); Carter et al., Eur. J. Immunol., 32: 634-643 (2002)). Both PD-L1 and PD-L2 are B7 protein family members that bind to PD-1 but not other CD28 family members. PD-L1 ligands are abundant in a variety of human cancers (Dong et al., Nat. Med., 8: 787-789 (2002)). Interaction between PD-1 and PD-L1 leads to a reduction in tumor-infiltrating lymphocytes, a decrease in T cell receptor-mediated proliferation, and immune evasion by cancer cells (Dong et al., J. Mol. Med., 81: 281-287 (2003); Blank et al., Cancer Immunol. Immunother., 54: 307-314 (2005); Konishi et al., Clin. Cancer Res., 10: 5094-5100 (2004)).Immune suppression can be reversed by inhibiting the local interaction of PD-1 and PD-L1, and the effect is additive when PD-1 and PD-L2 interactions are blocked simultaneously (Iwai et al., Proc. Natl. Acad. Sci. USA, 99: 12293-12297 (2002); Brown et al., J. Immunol., 170: 1257-1266 (2003)).

[0007] When PD-1-expressing T cells contact cells expressing its ligand, their functional activities in response to antigenic stimulation, including proliferation, cytokine secretion, and cytotoxicity, are reduced. PD-1 / PD-L1 or PD-L2 interactions downregulate immune responses during infection or tumor resolution or the development of self-tolerance (Keir, ME et al., Annu. Rev. Immunol., 26: Epub (2008)). Chronic antigen stimulation, such as that occurring during tumor disease or chronic infection, results in T cells with elevated levels of PD-1 expression that are dysfunctional with respect to activity against chronic antigens (reviewed in Kim et al., Curr. Opin. Imm. (2010)). This is called "T cell exhaustion." B cells also exhibit PD-1 / PD-ligand suppression and "exhaustion."

[0008] In addition to enhancing immunological responses to chronic antigens, blockade of the PD-1 / PD-L1 pathway has also been shown to increase responses to vaccinations, including therapeutic vaccinations in the setting of chronic infection (Ha, SJ et al., "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection," J. Exp. Med., 205(3): 543-555 (2008); Finnefrock, AC et al., "PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination," J. Immunol., 182(2): 980-987 (2009); Song, M.-Y. et al., "Enhancement of vaccine-induced primary and memory CD8+ T-cell responses by soluble PD-1," J. Immunother., 34(3): 297-306 (2011)).

[0009] The PD-1 pathway is a key inhibitory molecule in T cell exhaustion caused by chronic antigen stimulation during chronic infection and tumor disease. Summary of the Invention [Problem to be solved by the invention]

[0010] Therefore, drugs that block the interaction between PD-1 and PD-L1 are desirable. [Means for solving the problem]

[0011] overview The present invention provides macrocyclic compounds that inhibit PD-1 protein / protein interaction and are therefore effective in ameliorating various diseases, including cancer and infectious diseases.

[0012] In a first aspect, the present invention provides a compound of formula (I): [ka] [During the ceremony,

[0013] R 1 is C1-C6 alkoxyC1-C6 alkyl; C1-C6 alkyl; C1-C6 alkylaminoC1-C6 alkyl; C1-C6 alkylcarbonylaminoC1-C6 alkyl; aminoC1-C6 alkyl; aminocarbonylC1-C6 alkyl; arylC1-C6 alkyl; arylcarbonylaminoC1-C6 alkyl; carboxyC1-C6 alkyl; cyanoC1-C6 alkyl; heteroarylC1-C6 alkyl; heterocyclylC1-C6 alkyl; hydroxyC1-C6 alkyl; NHC(X)NHC1-C6 alkyl (where X is O or NH); and [ka] (where, [ka] is an azetidine, piperidine, or pyrrolidine ring); wherein the aryl portion of the aryl C1-C6 alkyl and arylcarbonylaminoC1-C6 alkyl and the heteroaryl portion of the heteroaryl C1-C6 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C6 alkoxy, C1-C6 alkylcarbonylamino, C2-C6 alkynyloxy, aminocarbonyl, aryl optionally substituted with 1 or 2 carboxy groups, aryl C1-C6 alkoxy, carboxy, carboxyC1-C6 alkoxy, halo, and trifluoromethyl;

[0014] R 1’ is hydrogen or C1-C6 alkyl;

[0015] R 2is selected from C1-C6 alkoxyC1-C6 alkyl; arylC1-C6 alkyl; azidoC1-C6 alkyl; biscarboxyCHC1-C6 alkyl; carboxyC1-C6 alkyl; and heteroarylC1-C6 alkyl;

[0016] the aryl portion of the arylC1-C6 alkyl and the heteroaryl portion of the heteroarylC1-C6 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkylcarbonylamino, C2-C6 alkynyloxy, amino, aminoC1-C6 alkyl, aminocarbonyl, aryl optionally substituted with 1 or 2 carboxy groups, arylC1-C6 alkoxy, arylcarbonyl, azido, carboxy, carboxyC1-C6 alkoxy, carboxyC1-C6 alkyl, cyano, halo, haloC1-C6 alkoxy, hydroxy, nitro, and trifluoromethyl;

[0017] R 2’ is hydrogen or C1-C6 alkyl;

[0018] R 3 is selected from C1-C6 alkoxyC1-C6 alkyl; aminocarbonylC1-C6 alkyl, arylC1-C6 alkoxyC1-C6 alkyl, arylC1-C3 alkyl, carboxyC1-C6 alkyl, furylC1-C3 alkyl, hydroxyC1-C6 alkyl, HOS(O)2C1-C3 alkyl, CH3S(O)2NHC(O)(C1-C3 alkyl), and tetrazolylC1-C3 alkyl; wherein the aryl portion of the arylC1-C3 alkyl is optionally substituted with one, two, or three aminoC1-C3 alkyl groups;

[0019] R 4is selected from aryl C1-C6 alkyl and heteroaryl C1-C6 alkyl, wherein the aryl portion of the aryl C1-C6 alkyl and the heteroaryl portion of the heteroaryl C1-C6 alkyl are optionally substituted with one or more groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, amino, cyano, C1-C6 fluoroalkyl, halo, and hydroxy;

[0020] R 5 is selected from C1-C6 alkoxyC1-C6 alkyl; C1-C6 alkyl; aryl; arylC1-C6 alkyl; cyanoC1-C6 alkyl; C3-C8 cycloalkyl; (C3-C8 cycloalkyl)C1-C6 alkyl; fluoroC1-C6 alkyl; heteroarylC1-C6 alkyl; and hydroxyC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl and the heteroaryl portion of the heteroarylC1-C6 alkyl are optionally selected from C2-C6 alkynyloxy, amino, aminoC substituted with 1, 2, 3, 4, or 5 groups independently selected from 1-C6 alkyl, aminocarbonyl, aryl, arylC1-C6 alkoxy, aryloxy, carboxyC1-C6 alkoxy, cyano, (C3-C6 cycloalkyl)oxy, carboxy, halo, heteroaryl, and hydroxy, wherein the aryl is optionally further substituted with 1, 2, or 3 groups independently selected from C1-C3 alkyl, C1-C3 alkylcarbonylamino, carboxy, and hydroxy;

[0021] R 6 is selected from aryl-aryl C1-C3 alkyl, aryl-heteroaryl C1-C3 alkyl, heteroaryl-aryl C1-C3 alkyl, and heteroaryl-heteroaryl C1-C3 alkyl; wherein each aryl and each heteroaryl is optionally substituted with one or more groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, amino, cyano, C1-C6 fluoroalkyl, halo, and hydroxyl;

[0022] R7 is hydrogen;C1-C6 alkyl;C1-C6 alkylcarbonylaminoC1-C6 alkyl;C2-C6 alkynyl;AminoC1-C6 alkyl;AminocarbonylC1-C6 alkyl;Aryl;ArylC1-C6 alkyl;CarboxyC1-C6 alkyl;C3-C8 cycloalkyl;(C3-C8 cycloalkyl)C1-C6 alkyl;HaloarylcarbonylaminoC1-C6 alkyl;HeteroarylC1-C6 alkyl;HydroxyC1-C6 alkyl;and and NHC(X)NHC(X)NHC(X) alkyl, where X is O or NH; wherein the aryl portion of the arylC(X) alkyl and the heteroaryl portion of the heteroarylC(X) alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C(X)-C alkynyloxy, arylC(X)-C alkoxy, carboxy, carboxyC(X)-C alkoxy, haloC(X)-C alkoxy, and hydroxy;

[0023] R 8 is C1-C6 alkyl; C1-C6 alkylcarbonylaminoC1-C6 alkyl; aminoC1-C6 alkyl; (C7H 15 O6) selected from amino C1-C6 alkyl; aminocarbonyl C1-C6 alkyl; aryl C1-C6 alkyl; carboxy C1-C6 alkyl; heterocyclyl; heteroaryl C1-C6 alkyl; and hydroxy C1-C6 alkyl; wherein the aryl portion of the aryl C1-C6 alkyl and the arylcarbonylamino C1-C6 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino C1-C6 alkyl, halo, and hydroxy;

[0024] R 8’ is hydrogen or R 8 and R 8’ together with the atoms to which they are attached form a C3-C8 cycloalkyl ring;

[0025] R 9is selected from C1-C6 alkyl; arylC1-C6 alkyl; and C3-C8 cycloalkylC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from halo and hydroxy;

[0026] R 10 is C1-C6 alkyl; C2-C6 alkynyl; amino C1-C6 alkyl; aminocarbonyl C1-C6 alkyl; aryl C1-C6 alkyl; carboxy C1-C6 alkyl; hydroxy C1-C6 alkyl; (C7H 15 O6)aminoC1-C6 alkyl; C1-C6 alkylcarbonylaminoC1-C6 alkyl; heteroarylC1-C6 alkyl; and NHC(X)NHC1-C6 alkyl (wherein X is O or NH); wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C2-C6 alkynyloxy and arylC1-C6 alkoxy;

[0027] R 11 is selected from C1-C8 alkyl; arylC1-C6 alkyl; C3-C8 cycloalkylC1-C6 alkyl; and heteroarylC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, amino, aminoC1-C6 alkoxy, aminoC1-C6 alkylcyano, halo, hydroxy, and trifluoromethyl;

[0028] R 12is selected from C1-C6 alkyl, C2-C6 alkynyl, arylC1-C6 alkyl, carboxyC1-C6 alkyl, and hydroxyC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C2-C6 alkynyloxy and arylC1-C6 alkoxy;

[0029] R 13 is selected from C1-C6 alkyl, C1-C6 alkylcarbonylaminoC1-C6 alkyl, aminoC1-C6 alkyl, aminocarbonylC1-C6 alkyl, arylC1-C6 alkyl, carboxyC1-C6 alkyl, haloarylcarbonylaminoC1-C6 alkyl, heteroarylC1-C6 alkyl, hydroxyC1-C6 alkyl, and NHC(X)NHC1-C6 alkyl (where X is O or NH); wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C2-C6 alkynyloxy and arylC1-C6 alkoxy;

[0030] R 14 is aminocarbonyl; carboxy; or -C(O)NR 14’ CR 15 R 15’ R 15’’ where

[0031] R 14’ is hydrogen or C1-C6 alkyl, or R 15 and R 14’ together with the atoms to which they are attached form an azetidine, morpholine, piperazine, piperidine, or pyrrolidine ring, wherein each ring is optionally substituted with an amino or hydroxy group;

[0032] R 15is selected from hydrogen, C-C alkyl, C-C alkylcarbonylaminoC-C alkyl, C-C alkynyl, aminoC-C alkyl, aminocarbonylC-C alkyl, arylC-C alkyl, azidoC-C alkyl, carboxy, carboxyC-C alkyl, heteroarylC-C alkyl, hydroxyC-C alkyl, and NHC(X)NHC-C alkyl (where X is O or NH); wherein the aryl portion of the arylC-C alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from arylC-C alkoxy and hydroxy;

[0033] R 15’ is hydrogen or C1-C6 alkyl; or R 15 and R 15’ together with the atoms to which they are attached form a C3-C8 cycloalkyl ring; and

[0034] R 15’’ is hydrogen; amine, carbonyl, carboxy or -(CH2) n C(O)NHCHR 16 R 16’ where

[0035] n is 0, 1 or 2;

[0036] R 16 is selected from hydrogen, C-C alkoxyC-C alkyl, C-C alkylC-C alkynyl, C-C alkynyl, aminoC-C alkyl, arylC-C alkyl, carboxy, carboxyC-C alkyl, heteroaryl, heteroarylC-C alkyl, hydroxyC-C alkyl, and NHC(X)NHC-C alkyl (where X is O or NH); wherein the aryl portion of the arylC-C alkyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C-C alkyl, arylC-C alkoxy, and hydroxy; and

[0037] R 16’ is hydrogen, C1-C6 alkyl, aminocarbonyl, carboxy or -(CH2) m C(O)NHCHR 17 R 17’ where

[0038] m is 0, 1 or 2;

[0039] R 17 is C2-C6 alkynyl; and

[0040] R 17’ is aminocarbonyl or carboxy; and

[0041] R a is hydrogen or C1-C6 alkyl; or R 1 and R a together with the atoms to which they are attached form an azetidine, morpholine, piperidine, piperazine, or pyrrolidine ring, wherein each ring is optionally substituted with an amino or hydroxy group. or a pharmaceutically acceptable salt thereof.

[0042] In some embodiments, R 1 is selected from C1-C6 alkyl, aminoC1-C6 alkyl, aminocarbonylC1-C6 alkyl, arylC1-C6 alkyl, heteroarylC1-C6 alkyl, heterocyclylC1-C6 alkyl, and hydroxyC1-C6 alkyl, wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo and carboxyC1-C6 alkoxy; and

[0043] R 1’ is hydrogen.

[0044] In some embodiments, R 2is selected from aryl C1-C6 alkyl and heteroaryl C1-C6 alkyl, wherein the aryl portion of the aryl C1-C6 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from carboxy, carboxy C1-C6 alkoxy, cyano, halo, hydroxy, and nitro; and R 2’ is hydrogen.

[0045] In some embodiments, R 3 is aminocarbonyl C1-C6 alkyl or carboxy C1-C6 alkyl.

[0046] In some embodiments, R 4 is arylC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from C1-C6 alkyl, halo, and trifluoromethyl.

[0047] In some embodiments, R 5 is C1-C6 alkyl or arylC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from carboxy, carboxyC1-C6 alkoxy, and hydroxy.

[0048] In some embodiments, R 6 is biphenyl C1-C6 alkyl.

[0049] In some embodiments, R 7 is selected from C1-C6 alkyl, arylC1-C6 alkyl, carboxyC1-C6 alkyl, and NHC(X)NHC1-C6 alkyl (where X is O or NH); wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from carboxy, carboxyC1-C6 alkoxy, and hydroxy.

[0050] In some embodiments, R 8is C1-C6 alkyl or aminoC1-C6 alkyl; and R 8’ is hydrogen.

[0051] In some embodiments, R 9 is C1-C6 alkyl.

[0052] In some embodiments, R 10 is amino C1-C6 alkyl or aminocarbonyl C1-C6 alkyl.

[0053] In some embodiments, R 11 is C1-C6 alkyl or C3-C6 cycloalkylC1-C3 alkyl.

[0054] In some embodiments, R 12 is C1-C4 alkyl or hydroxyC1-C4 alkyl.

[0055] In some embodiments, R 13 is amino C1-C6 alkyl, aminocarbonyl C1-C2 alkyl, carboxy C1-C6 alkyl or hydroxy C1-C4 alkyl.

[0056] In some embodiments, R 14 is aminocarbonyl or -C(O)NHCHR 15 C(O)NH2, where R 15 is hydrogen, C1-C6 alkyl, aminoC1-C6 alkyl.

[0057] In some embodiments, R 15 is hydrogen or C1-C6 alkyl.

[0058] In some embodiments, R 16 is hydrogen or C2-C4 alkynyl.

[0059] In some embodiments, R a is methyl.

[0060] In some embodiments, R 1’, R 2’ and R 8’ One, two or all of the are methyl.

[0061] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein:

[0062] R 1 is selected from C1-C4 alkyl, C1-C4 alkylcarbonylaminoC2-C4 alkyl, aminoC1-C3 alkyl, aminocarbonylC1-C2 alkyl, arylC1-C2 alkyl, arylcarbonylaminoC1-C2 alkyl, carboxypropyl, cyanomethyl; heteroarylmethyl, heterocyclylmethyl, hydroxyC2-C3 alkyl, methoxyC1-C2 alkyl, methylaminoC1-C2 alkyl, NHC(X)NHpropyl (where X is O or NH), and HNC(X)piperidinyl, wherein the aryl portion of the arylC1-C2 alkyl and arylcarbonylaminoC1-C6 alkyl is optionally substituted with one, two, or three groups independently selected from aminocarbonyl, arylmethoxy, carboxy, carboxymethoxy, carboxyphenyl, halo, methoxy, methylcarbonylamino, propynyloxy, and trifluoromethyl;

[0063] R 1’ is hydrogen or methyl;

[0064] R 2is selected from aryl C1-C2 alkyl, azido C1-C2 alkyl, biscarboxyethyl, carboxy C1-C3 alkyl, methoxy C1-C2 alkyl, and heteroaryl C1-C2 alkyl; wherein the aryl portion of the aryl C1-C2 alkyl and the heteroaryl portion of the heteroaryl C1-C2 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C4 alkyl, amino, aminocarbonyl, aminomethyl, arylcarbonyl, arylmethoxy, azido, carboxy, carboxymethoxy, carboxymethyl, carboxyphenyl, cyano, halo, hydroxy, methoxy, methylcarbonylamino, nitro, propynyloxy, trifluoromethoxy, and trifluoromethyl;

[0065] R 2’ is hydrogen or methyl;

[0066] R 3 is selected from aminocarbonylmethyl, arylC1-C3 alkyl, arylmethoxymethyl, carboxyC1-C2 alkyl, furylC1-C3 alkyl, hydroxyC1-C2 alkyl, methoxymethyl and tetrazolylmethyl, HOS(O)2C1-C3 alkyl and CH3S(O)2NHC(O)(C1-C3 alkyl); wherein the aryl portion of the arylC1-C3 alkyl is optionally substituted with one, two or three aminoC1-C3 alkyl groups;

[0067] R 4 is selected from aryl C1-C2 alkyl and heteroarylmethyl; wherein the aryl portion of the aryl C1-C2 alkyl and the heteroaryl portion of the heteroarylmethyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, cyano, halo, hydroxy, methoxy, methyl, and trifluoromethyl;

[0068] R 5is selected from C1-C5 alkyl, arylmethyl, cyanomethyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)methyl, heteroarylmethyl, hydroxyC1-C2 alkyl, methoxymethyl, and phenyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, aminomethyl, aminocarbonyl, aryl, arylmethoxy, aryloxy, carboxymethoxy, carboxy, cyano, (C3-C6 cycloalkyl)oxy, halo, heteroaryl, hydroxy, and propynyloxy; and wherein the aryl is optionally further substituted with 1, 2, or 3 groups independently selected from C1-C3 alkyl, C1-C3 alkylcarbonylamino, carboxy, and hydroxy;

[0069] R 6 is biphenylmethyl;

[0070] R 7 is selected from hydrogen, C1-C5 alkyl, aminoC1-C4 alkyl, aminocarbonylethyl, aminocarbonylmethyl, arylmethyl, butynyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)methyl, carboxyethyl, haloarylcarbonylaminopropyl, heteroarylpropyl, hydroxyC2 alkyl, methylcarbonylaminoC2-C4 alkyl, phenyl, and NHC(X)NHC2-C4 alkyl, where X is O or NH; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy, carboxy, carboxymethoxy, hydroxy, propynyloxy, and trifluoromethoxy;

[0071] R 8 is C1-C4 alkyl, C1-C4 alkylcarbonylaminoC1-C4 alkyl, aminoC1-C4 alkyl, aminocarbonylC1-C2 alkyl, (C7H 15O6) selected from aminomethyl, arylmethyl, carboxyC1-C3 alkyl, haloarylcarbonylaminopropyl, heterocyclyl or heteroarylmethyl, and hydroxymethyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from hydroxy and aminomethyl;

[0072] R 8’ is hydrogen or R 8 and R 8’ together with the atoms to which they are attached form a cyclopropyl ring;

[0073] R 9 is selected from C1-C4 alkyl, arylmethyl, and cyclohexylmethyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three hydroxy groups;

[0074] R 10 is C1-C4 alkyl, amino C1-C4 alkyl, aminocarbonyl C1-C2 alkyl, (C7H 15 O6) selected from aminomethyl, arylmethyl, butylcarbonylaminoethyl, butynyl, carboxyC1-C3 alkyl, heteroarylmethyl, hydroxyC1-C2 alkyl, NHC(NH)NHmethyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from arylmethoxy and propynyloxy;

[0075] R 11 is selected from C4-C8 alkyl, arylC1-C2 alkyl, C3-C6 cycloalkylC1-C2 alkyl, and heteroarylmethyl; wherein the aryl portion of the arylC1-C2 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from amino, aminoethoxy, aminomethyl, cyano, halo, hydroxy, methoxy, methyl, and trifluoromethyl;

[0076] R 12is selected from C3-C4 alkyl, arylmethyl, carboxybutyl, hydroxyC1-C3 alkyl, and propynyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from arylmethoxy and propynyloxy;

[0077] R 13 is selected from C3-C4 alkyl, C1-C4 alkylcarbonylaminoC2-C4 alkyl, aminoC1-C4 alkyl, aminocarbonylC1-C2 alkyl, arylmethyl, carboxyC1-C3 alkyl, haloarylcarbonylaminopropyl, heteroarylmethyl, hydroxyC1-C3 alkyl, and NHC(X)NHpropyl, where X is O or NH; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from arylmethoxy and propynyloxy;

[0078] R 14 is aminocarbonyl; carboxy; or -C(O)NR 14’ CR 15 R 15’ R 15’’ where

[0079] R 14’ is hydrogen or methyl; or R 15 and R 14’ together with the atoms to which they are attached to form a pyrrolidine ring;

[0080] R 15 is selected from hydrogen, C1-C2 alkyl, C1-C4 alkylcarbonylaminoC1-C3 alkyl, aminoC1-C4 alkyl, aminocarbonylC1-C2 alkyl, arylmethyl, azidoC2-C4 alkyl, carboxy, carboxyC1-C3 alkyl, heteroarylmethyl, hydroxymethyl, NHC(NH)NHpropyl, and propynyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy and hydroxy;

[0081] R 15’ is hydrogen or methyl; or R 15 and R 15’ together with the atoms to which they are attached form a cyclopropyl ring; and

[0082] R 15’’ is hydrogen, aminocarbonyl or carboxy; or -(CH2) n C(O)NHCHR 16 R 16’ where

[0083] n is 0, 1 or 2;

[0084] R 16 is selected from hydrogen, amino C1-C4 alkyl, arylmethyl, carboxy, carboxyethyl, heteroaryl, heteroarylethyl, hydroxymethyl, methoxymethyl, NHC(NH)NHpropyl, and propynyl; wherein the aryl portion of the aryl C1-C6 alkyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from arylmethoxy, hydroxy, and methyl; and

[0085] R 16’ is hydrogen, aminocarbonyl, carboxy, methyl or -(CH2) m C(O)NHCHR 17 R 17’ where

[0086] m is 0, 1 or 2;

[0087] R 17 is propynyl; and

[0088] R 17’ is aminocarbonyl or carboxy; and

[0089] R a is hydrogen or methyl; or R1 and R a together with the atoms to which they are attached form a piperazine or pyrrolidine ring, wherein each ring is optionally substituted with an amino or hydroxy group. Provide something.

[0090] In some embodiments, R 1 is selected from C1-C6 alkyl, aminoC1-C3 alkyl, aminocarbonylC1-C2 alkyl, arylC1-C2 alkyl, heteroarylmethyl, heterocyclylC1-C6 alkyl, and hydroxyC2-C3 alkyl, wherein the aryl portion of the arylC1-C2 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from carboxymethoxy and halo; and R 1’ is hydrogen.

[0091] In some embodiments, R a is hydrogen.

[0092] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein:

[0093] R 1 is selected from C1-C4 alkyl, C1-C4 alkylcarbonylaminoC2-C4 alkyl, aminoC1-C3 alkyl, aminocarbonylC1-C2 alkyl, arylC1-C2 alkyl, arylcarbonylaminoC1-C2 alkyl, carboxypropyl, cyanomethyl, heteroarylmethyl, heterocyclomethyl, hydroxyC2-C3 alkyl, methoxyC1-C2 alkyl, methylaminoC1-C2 alkyl, NHC(NH)NHpropyl, and HNC(NH)piperidinyl; wherein the aryl portion of the arylC1-C2 alkyl and the arylcarbonylaminoC1-C2 alkyl are optionally substituted with one, two, or three groups independently selected from aminocarbonyl, carboxy, carboxymethoxy, halo, methoxy, methylcarbonylamino, propynyloxy, and trifluoromethyl;

[0094] R 1’ is hydrogen;

[0095] R 2 is selected from aryl C1-C2 alkyl, azido C1-C2 alkyl, carboxypropyl, heteroaryl C1-C2 alkyl, and methoxy C1-C2 alkyl; wherein the aryl portion of the aryl C1-C2 alkyl and the heteroaryl portion of the heteroaryl C1-C2 alkyl are optionally substituted with one or more groups independently selected from C1-C4 alkyl, amino, aminocarbonyl, aminomethyl, arylcarbonyl, arylmethoxy, carboxy, carboxymethoxy, carboxymethyl, cyano, halo, hydroxy, methoxy, methylcarbonylamino, nitro, propynyloxy, trifluoromethoxy, and trifluoromethyl;

[0096] R 2’ is hydrogen or methyl;

[0097] R 3 is selected from aminocarbonylmethyl; arylC1-C3 alkyl, carboxymethyl, furylC1-C3 alkyl, hydroxyC1-C3 alkyl, HOS(O)2C1-C3 alkyl, CH3S(O)2NHC(O)(C1-C3 alkyl), and tetrazolyl; wherein the aryl portion of the arylC1-C3 alkyl is optionally substituted with one, two, or three aminoC1-C3 alkyl groups;

[0098] R 4 is selected from aryl C1-C2 alkyl and heteroarylmethyl, and wherein the aryl portion of the aryl C1-C2 alkyl and the heteroaryl portion of the heteroarylmethyl are optionally substituted with one or more groups independently selected from amino, halo, hydroxy, methoxy, methyl, and trifluoromethyl;

[0099] R 5is selected from C1-C5 alkyl, arylmethyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)methyl, heteroarylmethyl, hydroxyC2 alkyl, methoxymethyl, and phenyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, aminocarbonyl, aminomethyl, aryl, arylmethoxy, aryloxy, carboxy, carboxymethoxy, (C3-C6 cycloalkyl)oxy, cyano, halo, heteroaryl, hydroxy, and propynyloxy; wherein the aryl is optionally further substituted with C1-C3 alkyl, C1-C3 alkylcarbonylamino, carboxy, and hydroxy;

[0100] R 6 is biphenylmethyl;

[0101] R 7 is selected from C1-C5 alkyl, aminoC1-C4 alkyl, aminocarbonylethyl, aminocarbonylmethyl, arylmethyl, butynyl, carboxyethyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)methyl, heteroarylmethyl, hydroxyC2 alkyl, methylcarbonylaminoC2-C4 alkyl, phenyl, and NHC(X)NHC2-C4 alkyl, where X is O or NH; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy, carboxy, carboxymethoxy, hydroxy, propynyloxy, and trifluoromethoxyl;

[0102] R 8 is C1-C4 alkyl, C1-C4 alkylcarbonylaminoC1-C4 alkyl, aminoC1-C4 alkyl, aminocarbonylC1-C2 alkyl, (C7H 15O6) selected from aminomethyl, arylmethyl, carboxyC1-C3 alkyl, heteroarylmethyl, and hydroxymethyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from aminomethyl and hydroxy;

[0103] R 8’ is hydrogen;

[0104] R 9 is selected from C1-C4 alkyl, cyclohexylmethyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one or two hydroxy groups;

[0105] R 10 is amino C1-C4 alkyl, aminocarbonyl C1-C2 alkyl, (C7H 15 O6) selected from aminomethyl, butynyl, butylcarbonylaminoethyl; carboxy C1-C3 alkyl, heteroarylmethyl, hydroxy C1-C2 alkyl, and NH2C(NH)NHmethyl;

[0106] R 11 is selected from C4-C8 alkyl, arylC1-C2 alkyl, C3-C6 cycloalkylC1-C2 alkyl, and heteroarylmethyl; wherein the aryl portion of the arylC1-C2 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from aminomethyl, chloro, fluoro, hydroxy, methoxy, methyl, and trifluoromethyl;

[0107] R 12 is selected from C3-C4 alkyl, carboxybutyl, hydroxyC1-C3 alkyl, phenylmethyl, and propynyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three propynyloxy;

[0108] R 13is selected from C3-C4 alkyl, C1-C4 alkylcarbonylaminoC2-C4 alkyl, aminoC1-C4 alkyl, aminocarbonylC1-C2 alkyl, arylmethyl, carboxyC1-C3 alkyl, haloarylcarbonylaminopropyl; hydroxyC1-C3 alkyl, heteroarylmethyl, and NHC(X)NHpropyl, where X is O or NH; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from arylmethoxy and propynyloxy;

[0109] R 14 is aminocarbonyl or -C(O)NR 14’ CR 15 R 15’ R 15’’ where

[0110] R 14’ is hydrogen or methyl;

[0111] R 15 is selected from hydrogen; C1-C2 alkyl, C1-C4 alkylcarbonylaminoC1-C3 alkyl, aminoC1-C4 alkyl, aminocarbonylC1-C2 alkyl, arylmethyl, azidoC2-C3 alkyl, carboxy; carboxyC1-C2 alkyl, heteroarylmethyl, hydroxymethyl, propynyl, and NHC(NH)NHpropyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy and hydroxy;

[0112] R 15’ is hydrogen or methyl; or R 15 and R 15’ together with the atoms to which they are attached form a cyclopropyl ring; and

[0113] R 15’’ is hydrogen, aminocarbonyl, carboxy or -(CH2) n C(O)NHCHR 16 R16’ where

[0114] n is 0, 1 or 2;

[0115] R 16 is selected from hydrogen, amino C1-C4 alkyl, arylmethyl, carboxy, carboxyethyl, heteroaryl, heteroarylethyl, hydroxymethyl, methoxymethyl, NHC(NH)NHpropyl, and propynyl; wherein the aryl portion of the arylmethyl and heteroaryl are optionally substituted with one or more groups independently selected from arylmethoxy and methyl; and

[0116] R 16’ is hydrogen, aminocarbonyl, carboxy, methyl or -(CH2) m C(O)NHCHR 17 R 17’ where

[0117] m is 0, 1 or 2;

[0118] R 17 is propynyl; and

[0119] R 17’ is aminocarbonyl or carboxy; and

[0120] R a is hydrogen or methyl; or R 1 and R a together with the atoms to which they are attached form a pyrrolidine or piperazine ring, wherein each ring is optionally substituted with an amino group. Provide something.

[0121] In one embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein

[0122] R 1is selected from C1-C4 alkyl, C1-C4 alkylcarbonylaminoC2-C4 alkyl, aminoC1-C3 alkyl, aminocarbonylC1-C2 alkyl, carboxypropyl, cyanomethyl, heteroarylmethyl, heterocyclylmethyl, hydroxyC2 alkyl; methoxyC1-C2 alkyl, methylaminoC1-C2 alkyl, NHC(NH)NHpropyl, and HNC(NH)piperidinyl; arylC1-C2 alkyl; wherein the aryl portion of the arylC1-C2 alkyl is optionally substituted with one, two, or three groups independently selected from aminocarbonyl, carboxy, carboxymethoxy, halo, methoxy, methylcarbonylamino, propynyloxy, and trifluoromethyl;

[0123] R 1’ is hydrogen;

[0124] R 2 is selected from aryl C1-C2 alkyl and heteroaryl C1-C2 alkyl, wherein the aryl portion of the aryl C1-C2 alkyl and the heteroaryl portion of the heteroaryl C1-C2 alkyl are optionally substituted with one or more groups independently selected from amino, aminocarbonyl, aminomethyl, carboxy, carboxymethyl, carboxymethoxy, cyano, halo, hydroxy, methoxy, methyl, nitro, and propynyloxy;

[0125] R 2’ is hydrogen or methyl;

[0126] R 3 is selected from aminocarbonylmethyl, carboxymethyl and tetrazolyl;

[0127] R 4is selected from arylmethyl and heteroarylmethyl; wherein the aryl portion of the arylmethyl and the heteroaryl portion of the heteroarylmethyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, halo, hydroxy, methoxy, methyl, and trifluoromethyl;

[0128] R 5 is selected from C1-C5 alkyl, arylmethyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)methyl, hydroxyC2 alkyl, methoxymethyl, and phenyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from aminomethyl, aminocarbonyl, carboxy, carboxymethoxy, hydroxy, and propynyloxy;

[0129] R 6 is biphenylmethyl;

[0130] R 7 is selected from C1-C4 alkyl, aminoC1-C4 alkyl, aminocarbonylethyl, aminocarbonylmethyl, arylmethyl, butynyl, carboxyethyl, C3-C6 cycloalkyl, heteroarylmethyl, hydroxyC2 alkyl, methylcarbonylaminobutyl, phenyl, and NHC(X)NHC2-C4 alkyl, where X is O or NH; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from carboxy, carboxymethoxy, hydroxy, propynyloxy, and trifluoromethoxyl;

[0131] R 8 is selected from C1-C4 alkyl, C1-C4 alkylcarbonylaminoC2-C4 alkyl, aminoC1-C4 alkyl, aminocarbonylethyl, carboxypropyl, hydroxymethyl and imidazolylmethyl;

[0132] R 8’ is hydrogen;

[0133] R 9 is selected from C1-C4 alkyl, cyclohexylmethyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one or two hydroxy groups;

[0134] R 10 is selected from amino C1-C4 alkyl, aminocarbonyl C1-C2 alkyl, butylcarbonylaminoethyl, butynyl, carboxy C1-C3 alkyl, hydroxy C1-C2 alkyl, imidazolylmethyl, and NHC(NH)NHmethyl;

[0135] R 11 is selected from butyl, cyclohexylmethyl, and phenylmethyl;

[0136] the phenyl moiety of the phenylmethyl is optionally substituted with 1, 2, or 3 groups independently selected from fluoro and methyl;

[0137] R 12 is selected from C3-C4 alkyl, carboxybutyl, hydroxyC1-C3 alkyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three propynyloxy groups;

[0138] R 13 provides amino C1-C4 alkyl, C1-C4 alkylcarbonylamino C2-C4 alkyl, aminocarbonyl C1-C2 alkyl, arylmethyl, butyl, carboxy C1-C2 alkyl, heteroarylmethyl, hydroxy C1-C3 alkyl, and NHC(X)NHpropyl (wherein X is O or NH); wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three propynyloxy groups;

[0139] R 14 is aminocarbonyl or -C(O)NR 14’ CR15 R 15’ R 15’’ where

[0140] R 14’ is hydrogen or methyl;

[0141] R 15 is selected from hydrogen, C1-C2 alkyl, aminoC1-C4 alkyl, aminocarbonylmethyl, butylcarbonylaminoethyl, carboxy, carboxyethyl, hydroxymethyl, NHC(NH)NHpropyl, and propynyl;

[0142] R 15’ is hydrogen; methyl; or R 15 and R 15’ together with the atoms to which they are attached form a cyclopropyl ring; and

[0143] R 15’’ is hydrogen, aminocarbonyl, carboxy or -(CH2) n C(O)NHCHR 16 R 16’ where

[0144] n is 0, 1 or 2;

[0145] R 16 is selected from hydrogen, amino C1-C4 alkyl, arylmethyl, carboxyethyl, heteroaryl, heteroarylethyl, hydroxymethyl, methoxymethyl, NHC(NH)NHpropyl, and propynyl; wherein the aryl portion of the arylmethyl and heteroaryl are optionally substituted with one or more groups independently selected from arylmethoxy and methyl;

[0146] R 16’ is hydrogen, aminocarbonyl, carboxy, methyl or -(CH2) m C(O)NHCHR 17 R 17’ where

[0147] m is 0, 1, or 2;

[0148] R 17 is propynyl; and

[0149] R 17’ is aminocarbonyl; and

[0150] R a is hydrogen or methyl; or R 1 and R a together with the atoms to which they are attached form a pyrrolidine ring, wherein the pyrrolidine ring is optionally substituted with an amino group.

[0151] In one embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein

[0152] R 1 is selected from C2-C4 alkyl, aminoC1-C2 alkyl, aminocarbonylmethyl, heteroarylmethyl, hydroxyC2 alkyl, morpholinylmethyl, NHC(NH)NHpropyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from carboxymethoxy and fluoro;

[0153] R 1’ is hydrogen;

[0154] R 2 is selected from phenylmethyl and pyridylmethyl,

[0155] the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from hydroxy, carboxy, and carboxymethoxy;

[0156] R 2’ is hydrogen;

[0157] R 3is carboxymethyl;

[0158] R 4 is selected from indolylmethyl and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from hydroxy and methyl;

[0159] R 5 is selected from phenylmethyl and propyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from carboxy, carboxymethoxy, hydroxy, and propynyloxy; and

[0160] R 6 is biphenylmethyl;

[0161] R 7 is selected from C3-C4 alkyl, NHC(O)NHpropyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from carboxy, carboxymethoxy, hydroxy, and propynyloxy;

[0162] R 8 is selected from aminopropyl and methyl;

[0163] R 8’ is hydrogen;

[0164] R 9 is isobutyl;

[0165] R 10 is aminoethyl;

[0166] R 11 is selected from butyl and cyclohexylmethyl;

[0167] R 12is selected from hydroxyisopropyl, hydroxypropyl, isopropyl and propyl;

[0168] R 13 is selected from aminopropyl, carboxyethyl, hydroxy C1-C2 alkyl, imidazolylmethyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three propynyloxy groups;

[0169] R 14 is aminocarbonyl or -C(O)NR 14’ CR 15 R 15’ R 15’’ where

[0170] R 14’ is hydrogen;

[0171] R 15 is selected from aminocarbonylmethyl, aminoethyl, and methyl;

[0172] R 15’ is hydrogen; and

[0173] R 15’’ is hydrogen, aminocarbonyl or -(CH2) n C(O)NHCHR 16 R 16’ where

[0174] n is 0 or 1;

[0175] R 16 is propynyl; and

[0176] R 16’ is hydrogen, aminocarbonyl, or carboxy; and

[0177] R a is hydrogen Provide something.

[0178] In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0179] In certain embodiments, the present invention provides a method of enhancing, stimulating and / or increasing an immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0180] In one aspect, the present invention provides a method of blocking the interaction of PD-1 and PD-L1 in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0181] Detailed Description definition Unless otherwise specified, any atom with unsatisfied valences is presumed to have enough hydrogen atoms to satisfy the valences.

[0182] Singular terms include plural referents unless the context dictates otherwise.

[0183] As used herein, the term "or" is a logical disjunction (i.e., and / or) and does not indicate an exclusive disjunction unless expressly indicated, such as by the terms "either," "unless," "or," and other terms of similar effect.

[0184] As used herein, the term "or a pharmaceutically acceptable salt thereof" refers to at least one compound or a salt of at least one compound, or a combination thereof. For example, "a compound of Formula (I) or a pharmaceutically acceptable salt thereof" includes, but is not limited to, a compound of Formula (I), two compounds of Formula (I), a pharmaceutically acceptable salt of a compound of Formula (I), a compound of Formula (I) and one or more pharmaceutically acceptable salts of a compound of Formula (I), and a pharmaceutically acceptable salt of two or more compounds of Formula (I).

[0185] The term "C1-C6 alkoxy," as used herein, refers to a C1-C6 alkyl group attached to the parent molecular moiety through an oxygen atom.

[0186] The term "C1-C6 alkoxy C1-C6 alkyl," as used herein, refers to a C1-C6 alkoxy group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0187] As used herein, the term "alkyl" refers to a group derived from a straight or branched chain saturated hydrocarbon containing carbon atoms. # -C # " where # is an integer and refers to the number of carbon atoms. For example, C1-C2 alkyl contains 1 to 2 carbon atoms, and C1-C3 alkyl contains 1 to 3 carbon atoms.

[0188] The term "C1-C6 alkyl C2-C6 alkynyl," as used herein, refers to a C1-C6 alkyl group attached to the parent molecular moiety through a C2-C6 alkynyl group.

[0189] As used herein, the term "C1-C6 alkylamino" refers to a group having the formula -NH, where R is a C1-C6 alkyl group.

[0190] The term "C1-C6 alkylamino C1-C6 alkyl," as used herein, refers to a C1-C6 alkylamino group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0191] The term "C1-C3 alkylcarbonyl," as used herein, refers to a C1-C3 alkyl group attached to the parent molecular moiety through a carbonyl group.

[0192] The term "C1-C6 alkylcarbonyl," as used herein, refers to a C1-C6 alkyl group attached to the parent molecular moiety through a carbonyl group.

[0193] As used herein, the term "C1-C6 alkylcarbonylamino" refers to -NHC(O)R a (where R ais a C1-C6 alkyl group).

[0194] The term "C1-C6 alkylcarbonylamino C1-C6 alkyl," as used herein, refers to a C1-C6 alkylcarbonylamino group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0195] The term "C1-C4 alkylcarbonylamino C1-C3 alkyl," as used herein, refers to a C1-C4 alkylcarbonylamino group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0196] The term "C1-C4 alkylcarbonylamino C1-C4 alkyl," as used herein, refers to a C1-C4 alkylcarbonylamino group attached to the parent molecular moiety through a C1-C4 alkyl group.

[0197] The term "C1-C4 alkylcarbonylamino C2-C4 alkyl," as used herein, refers to a C1-C4 alkylcarbonylamino group attached to the parent molecular moiety through a C2-C4 alkyl group.

[0198] The term "C2-C4 alkynyl" as used herein refers to a group derived from a straight or branched chain hydrocarbon containing from 2 to 4 carbon atoms and containing one or more carbon-carbon triple bonds.

[0199] The term "C2-C6 alkynyl" as used herein refers to a group derived from a straight or branched chain hydrocarbon containing from 2 to 6 carbon atoms and containing one or more carbon-carbon triple bonds.

[0200] The term "C2-C6 alkynyloxy," as used herein, refers to a C2-C6 alkynyl group attached to the parent molecular moiety through an oxygen atom.

[0201] As used herein, the term "amino" refers to -NH2.

[0202] The term "amino C1-C6 alkoxy," as used herein, refers to an amino group attached to the parent molecular moiety through a C1-C6 alkoxy group.

[0203] The term "amino C1-C2 alkyl," as used herein, refers to an amino group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0204] The term "amino C1-C3 alkyl," as used herein, refers to an amino group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0205] The term "amino C1-C4 alkyl," as used herein, refers to an amino group attached to the parent molecular moiety through a C1-C4 alkyl group.

[0206] The term "amino C1-C6 alkyl," as used herein, refers to an amino group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0207] The term "aminocarbonyl," as used herein, refers to an amino group attached to the parent molecular moiety through a carbonyl group.

[0208] The term "aminocarbonyl C1-C2 alkyl," as used herein, refers to an aminocarbonyl group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0209] The term "aminocarbonyl C1-C6 alkyl," as used herein, refers to an aminocarbonyl group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0210] The term "aminocarbonylethyl," as used herein, refers to an aminocarbonyl group attached to the parent molecular moiety through a -CH2CH2- group.

[0211] The term "aminocarbonylmethyl," as used herein, refers to an aminocarbonyl group attached to the parent molecular moiety through a -CH2- group.

[0212] The term "aminoethoxy," as used herein, refers to an amino group attached to the parent molecular moiety through an ethoxy group.

[0213] The term "aminoethyl," as used herein, refers to an amino group attached to the parent molecular moiety through an ethyl group.

[0214] The term "aminomethyl," as used herein, refers to an amino group attached to the parent molecular moiety through a -CH2- group.

[0215] The term "aminopropyl," as used herein, refers to an amino group attached to the parent molecular moiety through a propyl group.

[0216] The term "C3-C8 cycloalkyl" as used herein refers to a saturated monocyclic or bicyclic hydrocarbon ring system having 3 to 8 carbon atoms and 0 heteroatoms. Bicyclic rings may be fused, spirocyclic, or bridged. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, octahydropentalene, and bicyclo[3.1.1]heptyl.

[0217] The term "C3-C6 cycloalkyl" as used herein refers to a saturated monocyclic hydrocarbon ring system having 3 to 6 carbon atoms and 0 heteroatoms. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.

[0218] The term "C3-C6 cycloalkyl C1-C2 alkyl," as used herein, refers to a C3-C6 cycloalkyl group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0219] The term "C3-C6 cycloalkyl C1-C3 alkyl," as used herein, refers to a C3-C6 cycloalkyl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0220] The term "(C3-C8 cycloalkyl)C1-C6 alkyl," as used herein, refers to a C3-C8 cycloalkyl group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0221] The term "(C3-C6 cycloalkyl)methyl," as used herein, refers to a C3-C6 cycloalkyl group attached to the parent molecular moiety through a -CH2- group.

[0222] The term "(C3-C6 cycloalkyl)oxy," as used herein, refers to a C3-C6 cycloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0223] The term "(C7H 15 O6) Amino" means a carboxylic acid of the formula CH attached to the parent molecular moiety through an amino group. 15 A group having O6.

[0224] The term "(C7H 15 O6)amino C1-C6 alkyl" refers to an amino group attached to the parent molecular moiety through a C1-C6 alkyl group (C7H 15 O6) Refers to the amino group.

[0225] The term "(C7H 15 O6) aminomethyl” is the aryl group attached to the parent molecular moiety through a –CH2– group (C7H 15 O6) Refers to the amino group.

[0226] The term "aryl," as used herein, refers to a phenyl group or a bicyclic fused ring system in which one or both of the rings is a phenyl group. A bicyclic fused ring system consists of a phenyl group fused to a 4- to 6-membered aromatic or non-aromatic carbocyclic ring. The aryl groups of the present invention can be attached to the parent molecular moiety through any substitutable carbon atom of the group. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.

[0227] The term "aryl C1-C6 alkoxy," as used herein, refers to an aryl group attached to the parent molecular moiety through a C1-C6 alkoxy group.

[0228] The term "aryl C1-C6 alkoxy C1-C6 alkyl," as used herein, refers to an aryl C1-C6 alkoxy group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0229] The term "aryl C1-C6 alkyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0230] The term "aryl C1-C2 alkyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0231] The term "aryl C1-C3 alkyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0232] The term "aryl-aryl," as used herein, refers to an aryl group attached to the parent molecular moiety through a second aryl group.

[0233] The term "aryl-aryl C1-C3 alkyl," as used herein, refers to an aryl-aryl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0234] The term "arylcarbonyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a carbonyl group.

[0235] As used herein, the term "arylcarbonylamino" refers to a group of formula -NHC(O)R, where R is an aryl group.

[0236] The term "arylcarbonylamino C1-C6 alkyl," as used herein, refers to an arylcarbonylamino group attached to the parent molecular moiety through a C1-C6 alkyl.

[0237] The term "arylcarbonylamino C1-C2 alkyl," as used herein, refers to an arylcarbonylamino group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0238] The term "aryl-heteroaryl," as used herein, refers to an aryl group attached to the parent molecular moiety through a heteroaryl group.

[0239] The term "aryl-heteroaryl C1-C3 alkyl," as used herein, refers to an aryl-heteroaryl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0240] The term "arylmethoxy," as used herein, refers to an aryl group attached to the parent molecular moiety through a methoxy group.

[0241] The term "arylmethoxymethyl," as used herein, refers to an arylmethoxy group attached to the parent molecular moiety through a -CH2- group.

[0242] The term "arylmethyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a -CH2- group.

[0243] The term "aryloxy," as used herein, refers to an aryl group attached to the parent molecular moiety through an oxygen atom.

[0244] As used herein, the term "azido" refers to -N3.

[0245] The term "azido C1-C2 alkyl," as used herein, refers to an azido group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0246] The term "azido C1-C6 alkyl," as used herein, refers to an azido group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0247] The term "azido C2-C3 alkyl," as used herein, refers to an azido group attached to the parent molecular moiety through a C2-C3 alkyl group.

[0248] The term "azido C2-C4 alkyl," as used herein, refers to an azido group attached to the parent molecular moiety through a C2-C4 alkyl group.

[0249] The term "biphenyl C1-C6 alkyl," as used herein, refers to a biphenyl group attached to the parent molecular moiety through a C1-C6 alkyl group. The biphenyl group can be attached to the alkyl moiety through any substitutable atom of the group.

[0250] The term "biphenylmethyl," as used herein, refers to a biphenyl group attached to the parent molecular moiety through a -CH2- group.

[0251] As used herein, the term "biscarboxyCHC1-C6 alkyl" refers to (CO2H)2CH(C1-C6 alkyl)-.

[0252] As used herein, the term "biscarboxyethyl" refers to (CO2H)2CHCH2-.

[0253] As used herein, the term "butylcarbonylamino" refers to a group selected from the group consisting of -NHC(O)R a (where R a is butyl).

[0254] The term "butylcarbonylaminoethyl," as used herein, refers to a butylcarbonylamino group attached to the parent molecular moiety through a -CH2CH2- group.

[0255] As used herein, the term "carbonyl" refers to -C(O)-.

[0256] As used herein, the term "carboxy" refers to -CO2H.

[0257] The term "carboxy C1-C6 alkoxy," as used herein, refers to a carboxy group attached to the parent molecular moiety through a C1-C6 alkoxy group.

[0258] The term "carboxy C1-C2 alkyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0259] The term "carboxy C1-C3 alkyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0260] The term "carboxy C1-C6 alkyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0261] The term "carboxybutyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a butyl group.

[0262] The term "carboxyethyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a -CH2CH2- group.

[0263] The term "carboxymethoxy," as used herein, refers to a carboxy group attached to the parent molecular moiety through a methoxy group.

[0264] The term "carboxymethyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a -CH2- group.

[0265] The term "carboxyphenyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a phenyl group.

[0266] The term "carboxypropyl," as used herein, refers to a carboxy group attached to the parent molecular moiety through a propyl group.

[0267] As used herein, the term "cyano" refers to --CN.

[0268] The term "cyano C1-C6 alkyl," as used herein, refers to a cyano group attached to the parent molecular moiety through a C1-C6 alkyl.

[0269] The term "cyanomethyl," as used herein, refers to a cyano group attached to the parent molecular moiety through a -CH2- group.

[0270] The term "cyclohexylmethyl," as used herein, refers to a cyclohexyl group attached to the parent molecular moiety through a -CH2- group.

[0271] As used herein, the term "ethoxy" refers to -OCH2CH3.

[0272] As used herein, the term "fluoroC1-C6 alkyl" refers to a C1-C6 alkyl group substituted with 1, 2, 3, 4, 5, or 6 fluoro groups.

[0273] The term "furyl C1-C3 alkyl," as used herein, refers to a furyl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0274] The term "furylmethyl," as used herein, refers to a furyl group attached to the parent molecular moiety through a -CH2- group.

[0275] As used herein, the terms "halo" and "halogen" refer to F, Cl, Br, or I.

[0276] The term "haloC1-C6 alkoxy" as used herein refers to a C1-C6 alkoxy group substituted with 1, 2, 3, 4, 5, or 6 halogen atoms.

[0277] The term "haloaryl," as used herein, refers to an aryl group substituted with one, two, three, four, or five halo groups.

[0278] The term "haloarylcarbonyl," as used herein, refers to a haloaryl group attached to the parent molecular moiety through a carbonyl group.

[0279] The term "haloarylcarbonylamino," as used herein, refers to a haloarylcarbonyl group attached to the parent molecular moiety through an amino group.

[0280] The term "haloarylcarbonylamino C1-C6 alkyl," as used herein, refers to a haloarylcarbonylamino group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0281] The term "haloarylcarbonylaminopropyl," as used herein, refers to a haloarylcarbonylamino group attached to the parent molecular moiety through a propyl group.

[0282] The term "heteroaryl," as used herein, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of 5 to 14 ring members, wherein the ring system has one point of attachment to the rest of the molecule, at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from nitrogen, oxygen, sulfur, or phosphorus, and wherein each ring in the system contains 4 to 7 ring members. As used herein, the term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic."

[0283] The term "heteroaryl C1-C2 alkyl" refers to a heteroaryl group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0284] The term "heteroaryl C1-C6 alkyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0285] The term "heteroaryl-aryl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an aryl group.

[0286] The term "heteroaryl-aryl C1-C3 alkyl," as used herein, refers to a heteroaryl-aryl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0287] The term "heteroarylethyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a -CH2CH2- group.

[0288] The term "heteroaryl-heteroaryl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a heteroaryl group.

[0289] The term "heteroaryl-heteroaryl C1-C3 alkyl," as used herein, refers to a heteroaryl-heteroaryl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0290] The term "heteroarylmethyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a -CH2- group.

[0291] The term "heteroarylpropyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a propyl group.

[0292] As used herein, the term "heterocyclyl" refers to a 5-, 6-, or 7-membered ring containing one, two, or three heteroatoms independently selected from nitrogen, oxygen, and sulfur. Five-membered rings have zero to two double bonds, and six- and seven-membered rings have zero to three double bonds. The term "heterocyclyl" also includes bicyclic groups in which a heterocyclyl ring is fused to a four- to six-membered aromatic or non-aromatic carbocyclic ring or another monocyclic heterocyclyl group. The heterocyclyl groups of the present invention can be attached to the parent molecular moiety through any substitutable atom in the group. Examples of heterocyclyl groups include, but are not limited to, benzothienyl, furyl, imidazolyl, indolinyl, indolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrrolopyridinyl, pyrrolyl, thiazolyl, thienyl, and thiomorpholinyl.

[0293] The term "heterocyclylC1-C6 alkyl," as used herein, refers to a heterocyclyl attached to the parent molecular moiety through a C1-C6 alkyl group.

[0294] The term "heterocyclylmethyl," as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through a -CH2- group.

[0295] As used herein, the term "hydroxy" refers to --OH.

[0296] The term "hydroxy C1-C2 alkyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0297] The term "hydroxy C1-C3 alkyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a C1-C3 alkyl group.

[0298] The term "hydroxy C1-C4 alkyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a C1-C4 alkyl group.

[0299] The term "hydroxy C1-C6 alkyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a C1-C6 alkyl group.

[0300] The term "hydroxyC2 alkyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a -CH2CH2- group.

[0301] The term "hydroxy C2-C3 alkyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a C2-C3 alkyl group.

[0302] The term "hydroxyisopropyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through an isopropyl.

[0303] The term "hydroxymethyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a -CH2- group.

[0304] The term "hydroxypropyl," as used herein, refers to a hydroxyl group attached to the parent molecular moiety through a propyl.

[0305] The term "imidazolylmethyl," as used herein, refers to an imidazolyl group attached to the parent molecular moiety through a -CH2- group.

[0306] The term "indolylmethyl," as used herein, refers to an indolyl group attached to the parent molecular moiety through a -CH2- group.

[0307] As used herein, the term "methoxy" refers to -OCH3.

[0308] The term "methoxy C1-C2 alkyl," as used herein, refers to a methoxy group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0309] The term "methoxymethyl," as used herein, refers to a methoxy group attached to the parent molecular moiety through a methyl group.

[0310] The term "methylamino C1-C2 alkyl," as used herein, refers to a methylamino group attached to the parent molecular moiety through a C1-C2 alkyl group.

[0311] As used herein, the term "methylcarbonylamino" refers to CH3C(O)NH-.

[0312] The term "methylcarbonylamino," as used herein, refers to a methylcarbonyl group attached to the parent molecular moiety through an amino group.

[0313] The term "methylcarbonylaminobutyl," as used herein, refers to a methylcarbonylamino group attached to the parent molecular moiety through a butyl group.

[0314] The term "methylcarbonylamino C2-C4 alkyl," as used herein, refers to a methylcarbonylamino group attached to the parent molecular moiety through a C2-C4 alkyl group.

[0315] The term "morpholinylmethyl," as used herein, refers to a morpholinyl group attached to the parent molecular moiety through a -CH2- group.

[0316] As used herein, the term "nitro" refers to -NO2.

[0317] The term "phenylmethyl," as used herein, refers to a phenyl group attached to the parent molecular moiety through a -CH2- group.

[0318] As used herein, the term "propynyl" refers to -CCCH3.

[0319] As used herein, the term "propynyloxy" refers to -OC≡CCH3.

[0320] The term "pyridinylmethyl," as used herein, refers to a pyridinyl group attached to the parent molecular moiety through a -CH2- group.

[0321] The term "tetrazolylmethyl," as used herein, refers to a tetrazolyl group attached to the parent molecular moiety through a -CH2- group.

[0322] As used herein, "hyperproliferative disease" refers to a condition in which cell proliferation increases above normal levels. For example, hyperproliferative diseases or disorders include malignant diseases (e.g., esophageal cancer, colon cancer, biliary tract cancer) and non-malignant diseases (e.g., atherosclerosis, benign hyperplasia and benign prostatic hyperplasia).

[0323] The term "immune response" refers to the actions of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules that result in the selective damage, destruction, or elimination in the human body of invading pathogens, pathogen-infected cells or tissues, cancer cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.

[0324] The terms "programmed death-ligand 1," "programmed cell death-ligand 1," "PD-L1," "PDL1," "hPD-L1," "hPD-LI," and "B7-H1" are used interchangeably and include variants, isoforms, species homologs, and analogs of human PD-L1 that share at least one shared epitope with PD-L1. The complete PD-L1 sequence can be found under GENBANK® Accession No. NP_054862.

[0325] The terms "programmed death 1," "programmed cell death 1," "protein PD-1," "PD-1," "PD1," "hPD-1," and "hPD-I" are used interchangeably and include variants, isoforms, species homologs, and analogs of human PD-1 that share at least one epitope with PD-1. The complete PD-1 sequence can be found under GENBANK® Accession No. U64863.

[0326] The term "treating" refers to (iii) preventing the disease, disorder, or condition, i.e., preventing its progression; and (iv) alleviating the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and / or condition and / or symptoms associated with the disease, disorder, and / or condition.

[0327] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and 14 C. Isotopically labeled compounds of the present invention can be prepared by conventional techniques generally known to those skilled in the art, or by methods similar to those described herein, using an appropriate isotopically labeled reagent in place of an otherwise unlabeled reagent. Such compounds have a variety of potential uses, for example, as standards and reagents for determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

[0328] A further aspect of the presently described subject matter is the use of the disclosed compounds as radiolabeled ligands for the development of ligand binding assays or for monitoring in vivo adsorption, metabolism, distribution, receptor binding or occupancy, or compound disposition. For example, the macrocycle compounds described herein can be prepared using radioisotopes, and the resulting radiolabeled compounds can be used for the development of binding assays or metabolic studies. Alternatively, and for the same purpose, the macrocycle compounds described herein can be converted to radiolabeled forms by catalytic tritiation, using methods known to those skilled in the art.

[0329] The macrocycles of the present invention can also be used as PET imaging agents by addition of a radioactive tracer using methods known to those skilled in the art.

[0330] Various aspects of the invention are described in greater detail below. DETAILED DESCRIPTION OF THE INVENTION

[0331] Compounds of formula (I) In one embodiment, the present invention provides a compound of formula (I): [ka] [During the ceremony,

[0332] R 1 is C1-C6 alkoxyC1-C6 alkyl; C1-C6 alkyl; C1-C6 alkylaminoC1-C6 alkyl; C1-C6 alkylcarbonylaminoC1-C6 alkyl; aminoC1-C6 alkyl; aminocarbonylC1-C6 alkyl; arylC1-C6 alkyl; arylcarbonylaminoC1-C6 alkyl; carboxyC1-C6 alkyl; cyanoC1-C6 alkyl; heteroarylC1-C6 alkyl; heterocyclylC1-C6 alkyl; hydroxyC1-C6 alkyl; NHC(X)NHC1-C6 alkyl (where X is O or NH); and [ka] (where, [ka] is an azetidine, piperidine, or pyrrolidine ring); wherein the aryl portion of the aryl C1-C6 alkyl and arylcarbonylaminoC1-C6 alkyl and the heteroaryl portion of the heteroaryl C1-C6 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C6 alkoxy, C1-C6 alkylcarbonylamino, C2-C6 alkynyloxy, aminocarbonyl, aryl optionally substituted with 1 or 2 carboxy groups, aryl C1-C6 alkoxy, carboxy, carboxyC1-C6 alkoxy, halo, and trifluoromethyl;

[0333] R 1’ is hydrogen or C1-C6 alkyl;

[0334] R 2 is selected from C1-C6 alkoxyC1-C6 alkyl; arylC1-C6 alkyl; azidoC1-C6 alkyl; biscarboxyCHC1-C6 alkyl; carboxyC1-C6 alkyl; and heteroarylC1-C6 alkyl;

[0335] the aryl portion of the arylC1-C6 alkyl and the heteroaryl portion of the heteroarylC1-C6 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkylcarbonylamino, C2-C6 alkynyloxy, amino, aminoC1-C6 alkyl, aminocarbonyl, aryl optionally substituted with 1 or 2 carboxy groups, arylC1-C6 alkoxy, arylcarbonyl, azido, carboxy, carboxyC1-C6 alkoxy, carboxyC1-C6 alkyl, cyano, halo, haloC1-C6 alkoxy, hydroxy, nitro, and trifluoromethyl;

[0336] R2’ is hydrogen or C1-C6 alkyl;

[0337] R 3 is selected from C1-C6 alkoxyC1-C6 alkyl; aminocarbonylC1-C6 alkyl, arylC1-C6 alkoxyC1-C6 alkyl, arylC1-C3 alkyl, carboxyC1-C6 alkyl, furylC1-C3 alkyl, hydroxyC1-C6 alkyl, HOS(O)2C1-C3 alkyl, CH3S(O)2NHC(O)(C1-C3 alkyl), and tetrazolylC1-C3 alkyl; wherein the aryl portion of the arylC1-C3 alkyl is optionally substituted with one, two, or three aminoC1-C3 alkyl groups;

[0338] R 4 is selected from aryl C1-C6 alkyl and heteroaryl C1-C6 alkyl, wherein the aryl portion of the aryl C1-C6 alkyl and the heteroaryl portion of the heteroaryl C1-C6 alkyl are optionally substituted with one or more groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, amino, cyano, C1-C6 fluoroalkyl, halo, and hydroxy;

[0339] R 5is selected from C1-C6 alkoxyC1-C6 alkyl; C1-C6 alkyl; aryl; arylC1-C6 alkyl; cyanoC1-C6 alkyl; C3-C8 cycloalkyl; (C3-C8 cycloalkyl)C1-C6 alkyl; fluoroC1-C6 alkyl; heteroarylC1-C6 alkyl; and hydroxyC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl and the heteroaryl portion of the heteroarylC1-C6 alkyl are optionally selected from C2-C6 alkynyloxy, amino, aminoC substituted with 1, 2, 3, 4, or 5 groups independently selected from 1-C6 alkyl, aminocarbonyl, aryl, arylC1-C6 alkoxy, aryloxy, carboxyC1-C6 alkoxy, cyano, (C3-C6 cycloalkyl)oxy, carboxy, halo, heteroaryl, and hydroxy, wherein the aryl is optionally further substituted with 1, 2, or 3 groups independently selected from C1-C3 alkyl, C1-C3 alkylcarbonylamino, carboxy, and hydroxy;

[0340] R 6 is selected from aryl-aryl C1-C3 alkyl, aryl-heteroaryl C1-C3 alkyl, heteroaryl-aryl C1-C3 alkyl, and heteroaryl-heteroaryl C1-C3 alkyl, wherein each aryl and each heteroaryl is optionally substituted with one or more groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, amino, cyano, C1-C6 fluoroalkyl, halo, and hydroxyl;

[0341] R 7is hydrogen;C1-C6 alkyl;C1-C6 alkylcarbonylaminoC1-C6 alkyl;C2-C6 alkynyl;AminoC1-C6 alkyl;AminocarbonylC1-C6 alkyl;Aryl;ArylC1-C6 alkyl;CarboxyC1-C6 alkyl;C3-C8 cycloalkyl;(C3-C8 cycloalkyl)C1-C6 alkyl;HaloarylcarbonylaminoC1-C6 alkyl;HeteroarylC1-C6 alkyl;HydroxyC1-C6 alkyl;and and NHC(X)NHC(X)NHC(X) alkyl, where X is O or NH; wherein the aryl portion of the arylC(X) alkyl and the heteroaryl portion of the heteroarylC(X) alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C(X)-C alkynyloxy, arylC(X)-C alkoxy, carboxy, carboxyC(X)-C alkoxy, haloC(X)-C alkoxy, and hydroxy;

[0342] R 8 is C1-C6 alkyl; C1-C6 alkylcarbonylaminoC1-C6 alkyl; aminoC1-C6 alkyl; (C7H 15 O6) selected from amino C1-C6 alkyl; aminocarbonyl C1-C6 alkyl; aryl C1-C6 alkyl; carboxy C1-C6 alkyl; heterocyclyl; heteroaryl C1-C6 alkyl; and hydroxy C1-C6 alkyl; wherein the aryl portion of the aryl C1-C6 alkyl and the arylcarbonylamino C1-C6 alkyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino C1-C6 alkyl, halo, and hydroxy;

[0343] R 8’ is hydrogen or R 8 and R 8’ together with the atoms to which they are attached form a C3-C8 cycloalkyl ring;

[0344] R 9is selected from C1-C6 alkyl; arylC1-C6 alkyl; and C3-C8 cycloalkylC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from halo and hydroxy;

[0345] R 10 is C1-C6 alkyl; C2-C6 alkynyl; amino C1-C6 alkyl; aminocarbonyl C1-C6 alkyl; aryl C1-C6 alkyl; carboxy C1-C6 alkyl; hydroxy C1-C6 alkyl; (C7H 15 O6)aminoC1-C6 alkyl; C1-C6 alkylcarbonylaminoC1-C6 alkyl; heteroarylC1-C6 alkyl; and NHC(X)NHC1-C6 alkyl (wherein X is O or NH); wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C2-C6 alkynyloxy and arylC1-C6 alkoxy;

[0346] R 11 is selected from C1-C8 alkyl; arylC1-C6 alkyl; C3-C8 cycloalkylC1-C6 alkyl; and heteroarylC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C1-C6 alkoxy, C1-C6 alkyl, amino, aminoC1-C6 alkoxy, aminoC1-C6 alkylcyano, halo, hydroxy, and trifluoromethyl;

[0347] R 12is selected from C1-C6 alkyl, C2-C6 alkynyl, arylC1-C6 alkyl, carboxyC1-C6 alkyl, and hydroxyC1-C6 alkyl; wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C2-C6 alkynyloxy and arylC1-C6 alkoxy;

[0348] R 13 is selected from C1-C6 alkyl, C1-C6 alkylcarbonylaminoC1-C6 alkyl, aminoC1-C6 alkyl, aminocarbonylC1-C6 alkyl, arylC1-C6 alkyl, carboxyC1-C6 alkyl, haloarylcarbonylaminoC1-C6 alkyl, heteroarylC1-C6 alkyl, hydroxyC1-C6 alkyl, and NHC(X)NHC1-C6 alkyl (where X is O or NH); wherein the aryl portion of the arylC1-C6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C2-C6 alkynyloxy and arylC1-C6 alkoxy;

[0349] R 14 is aminocarbonyl; carboxy; or -C(O)NR 14’ CR 15 R 15’ R 15’’ where

[0350] R 14’ is hydrogen or C1-C6 alkyl, or R 15 and R 14’ together with the atoms to which they are attached form an azetidine, morpholine, piperazine, piperidine, or pyrrolidine ring, wherein each ring is optionally substituted with an amino or hydroxy group;

[0351] R 15is selected from hydrogen, C-C alkyl, C-C alkylcarbonylaminoC-C alkyl, C-C alkynyl, aminoC-C alkyl, aminocarbonylC-C alkyl, arylC-C alkyl, azidoC-C alkyl, carboxy, carboxyC-C alkyl, heteroarylC-C alkyl, hydroxyC-C alkyl, and NHC(X)NHC-C alkyl (where X is O or NH); wherein the aryl portion of the arylC-C alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from arylC-C alkoxy and hydroxy;

[0352] R 15’ is hydrogen or C1-C6 alkyl; or R 15 and R 15’ together with the atoms to which they are attached form a C3-C8 cycloalkyl ring; and

[0353] R 15’’ is hydrogen; amine, carbonyl, carboxy or -(CH2) n C(O)NHCHR 16 R 16’ where

[0354] n is 0, 1 or 2;

[0355] R 16 is selected from hydrogen, C-C alkoxyC-C alkyl, C-C alkylC-C alkynyl, C-C alkynyl, aminoC-C alkyl, arylC-C alkyl, carboxy, carboxyC-C alkyl, heteroaryl, heteroarylC-C alkyl, hydroxyC-C alkyl, and NHC(X)NHC-C alkyl (where X is O or NH); wherein the aryl portion of the arylC-C alkyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C-C alkyl, arylC-C alkoxy, and hydroxy; and

[0356] R 16’ is hydrogen, C1-C6 alkyl, aminocarbonyl, carboxy or -(CH2) m C(O)NHCHR 17 R 17’ where

[0357] m is 0, 1 or 2;

[0358] R 17 is C2-C6 alkynyl; and

[0359] R 17’ is aminocarbonyl or carboxy; and

[0360] R a is hydrogen or C1-C6 alkyl; or R 1 and R a together with the atoms to which they are attached form an azetidine, morpholine, piperidine, piperazine, or pyrrolidine ring, wherein each ring is optionally substituted with an amino or hydroxy group. or a pharmaceutically acceptable salt thereof.

[0361] Those skilled in the art will recognize that amino acids have the general structure: [ka] wherein R and R' are as defined herein. Unless otherwise specified, the term "amino acid," as used herein, alone or as part of another group, includes an amino group and a carboxyl group attached to the same carbon, referred to as the "α" carbon, where R and / or R' may be natural or unnatural side chains containing hydrogen. The absolute "S" configuration at the "α" carbon is commonly referred to as the "L" or "natural" configuration. When both the "R" and "R'" (prime) substituents are equal to hydrogen, the amino acid is glycine and is not chiral.

[0362] Unless otherwise specified, the amino acids described herein may be of D- or L-stereochemistry and may be substituted as described elsewhere herein. When stereochemistry is not specified, it should be understood that the invention encompasses all stereochemically isomeric forms, or mixtures thereof, that possess the ability to inhibit the interaction of PD-1 and PD-L1. Individual stereoisomers of the compounds can be prepared by synthesis from commercially available starting materials that contain chiral centers, or by preparation of a mixture of enantiomeric products followed by conversion to a diastereomeric mixture and subsequent separation or resolution, such as recrystallization, chromatographic techniques, or direct separation of enantiomers on a chiral chromatographic column. Starting compounds of particular stereochemistry are either commercially available or can be prepared and resolved by techniques known in the art.

[0363] Certain compounds of the present invention can exist in various stable conformational isomeric forms, which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example, due to steric hindrance or ring strain, allows for the separation of different conformers. The present invention includes each conformational isomer of these compounds and mixtures thereof.

[0364] The pharmaceutical compounds of the present invention may include one or more pharmaceutically acceptable salts. A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see, e.g., Berge, SM et al., J. Pharm. Sci., 66: 1-19 (1977)). Salts can be obtained during the final isolation and purification of the compounds described herein, or separately, by reacting a free base functional group of the compound with a suitable acid, or by reacting an acidic group of the compound with a suitable base. Acid addition salts include those derived from non-toxic inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, and the like, and non-toxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, and aliphatic and aromatic sulfonic acids. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and such non-toxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like.

[0365] method As demonstrated herein, compounds of the invention bind to PD-1, disrupt the interaction between PD-1 and PD-L1, and are able to compete for binding of anti-PD-1 monoclonal antibodies known to block the interaction of PD-1 with PD-L1 and enhance CMV-specific T cell IFNγ secretion. As a result, the compounds of the invention are useful for modifying immune responses, treating diseases such as cancer, stimulating protective autoimmune responses, or stimulating antigen-specific immune responses (e.g., by co-administration of a PD-L1-blocking compound with an antigen of interest).

[0366] In another aspect, the present invention provides a method for enhancing, stimulating, and / or increasing an immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) disclosed herein or a pharmaceutically acceptable salt thereof. In a first embodiment, the method comprises administering an additional agent before, after, or simultaneously with the compound of Formula (I) or a pharmaceutically acceptable salt thereof. In a second embodiment, the additional agent is selected from an antimicrobial agent, an antiviral agent, a cytotoxic agent, a TLR7 agonist, a TLR8 agonist, an HDAC inhibitor, a STING agonist, and an immune response modifier.

[0367] The present invention also provides a method of inhibiting the growth, proliferation, or metastasis of cancer cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In a first embodiment of this aspect, the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, head and neck squamous cell carcinoma, cancer of the esophagus, gastrointestinal tract, and breast, and hematological tumors.

[0368] In another aspect, the present invention provides a method of treating an infectious disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In a first embodiment of the fourth aspect, the infectious disease is caused by a virus. In a second embodiment, the virus is selected from HIV, hepatitis A, hepatitis B, hepatitis C, herpes virus, and influenza.

[0369] In another aspect, the present invention provides a method of treating septic shock in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0370] In another aspect, the present invention provides a method of blocking the interaction of PD-1 and PD-L1 in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) disclosed herein, or a pharmaceutically acceptable salt thereof.

[0371] Administration of a therapeutic agent described herein includes, but is not limited to, administration of a therapeutically effective amount of the therapeutic agent. As used herein, the term "therapeutically effective amount" refers to, but is not limited to, the amount of a therapeutic agent to treat a condition treatable by administration of a composition comprising a PD-1 / PD-L1 binding inhibitor described herein, which amount is sufficient to exhibit a detectable therapeutic or ameliorative effect. The effect includes, by way of example and without limitation, treatment of the conditions listed herein. The precise effective amount for a subject will depend on the subject's size and health, the nature and extent of the condition being treated, the recommendations of the treating physician, and the treatment or combination of treatments selected for administration.

[0372] For administration of the macrocyclic peptides described herein, the dosage ranges from about 0.0001 to 100 mg / kg, and more usually 0.01 to 5 mg / kg, of the host body weight. For example, dosages can be 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, or 10 mg / kg body weight or within the range of 1 to 10 mg / kg.

[0373] A further aspect of the presently described subject matter is the use of the disclosed compounds as radiolabeled ligands for the development of ligand binding assays or for monitoring in vivo adsorption, metabolism, distribution, receptor binding or occupancy, or compound disposition. For example, the macrocycle compounds described herein can be prepared using radioisotopes, and the resulting radiolabeled compounds can be used for the development of binding assays or metabolic studies. Alternatively, and for the same purpose, the macrocycle compounds described herein can be converted to radiolabeled forms by catalytic tritiation, using methods known to those skilled in the art.

[0374] The macrocycles of the present invention can also be used as PET imaging agents by addition of a radioactive tracer using methods known to those skilled in the art.

[0375] Pharmaceutical Composition In another aspect, the present invention provides compositions, e.g., pharmaceutical compositions, comprising a compound or combination of compounds described within this disclosure formulated with a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention can also be administered in combination therapy, i.e., in combination with other agents. For example, the combination therapy can include a macrocycle compound in combination with at least one other anti-inflammatory or immunosuppressant agent. Examples of therapeutic agents that can be used in combination therapy are described in detail below in the section on uses of the compounds of the present invention.

[0376] As used herein, "pharmaceutically acceptable carrier" includes any and all physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. In some embodiments, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., injection or infusion). Depending on the route of administration, the active compound may be coated with a material to protect the compound from acids and other natural conditions that may inactivate the compound.

[0377] The pharmaceutical compositions of the present invention may also contain a pharmaceutically acceptable antioxidant. Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, etc.; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.

[0378] The pharmaceutical compositions of the present invention can be administered via one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by those skilled in the art, the route and / or method of administration will vary depending on the desired results. In certain embodiments, the route of administration of the macrocycle compounds of the present invention includes intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral routes of administration, for example, by injection or infusion. As used herein, the term "parenteral administration" refers to methods of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal, epidural, and intrasternal injection and infusion.

[0379] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount into a suitable solvent with one or a combination of the above-mentioned ingredients, as needed, followed by sterilization and precision filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and the other required ingredients listed above. In the case of sterile powders for the preparation of sterile injectable solutions, one method of preparation is vacuum drying and freeze-drying (lyophilization), which produces a powder of the active ingredient and any additional desired ingredients from a previously sterile-filtered solution.

[0380] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0381] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the presence of microorganisms can be ensured both by the above-mentioned sterilization methods and by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the compositions. Furthermore, prolonged absorption of injectable pharmaceutical forms can be achieved by the inclusion of agents that delay absorption, such as aluminum monostearate and gelatin.

[0382] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the immediate preparation of sterile injectable solutions or dispersions.The use of such media and agents for pharmaceutically active substances is known in the art.Except when any conventional media or agent is incompatible with the active compound, its use in the pharmaceutical compositions of the present invention is intended.Auxiliary active compounds can also be incorporated into the composition.

[0383] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, microemulsions, liposomes, or other ordered structures suitable to high drug concentrations. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it is desirable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the compositions. Prolonged absorption of injectable pharmaceutical forms can be achieved by the inclusion of agents that delay absorption, such as aluminum monostearate and gelatin.

[0384] Alternatively, the compounds of the invention can be administered by non-parenteral routes such as topical, epithelial or mucosal routes of administration, for example, intranasal, oral, vaginal, rectal, sublingual or topical.

[0385] Any pharmaceutical composition contemplated herein can be orally delivered by any acceptable and suitable oral formulation. Examples of oral formulations include, but are not limited to, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration can be prepared by any method known in the art for the manufacture of pharmaceutical compositions intended for oral administration. To provide a pharmaceutically acceptable formulation, the pharmaceutical composition of the present invention may contain at least one agent selected from sweeteners, flavoring agents, coloring agents, demulcents, antioxidants, and preservatives.

[0386] Tablets can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one non-toxic pharmaceutically acceptable additive suitable for tablet manufacture. Examples of additives include, but are not limited to, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents such as microcrystalline cellulose, sodium croscarmellose, corn starch, and alginic acid; binders such as starch, gelatin, polyvinylpyrrolidone, and acacia; and lubricants such as magnesium stearate, stearic acid, and talc. Furthermore, tablets can be plain or coated using known techniques to mask the unpleasant taste of unpleasant-tasting drugs or delay the disintegration and absorption of active ingredients in the gastrointestinal tract, thereby maintaining the effectiveness of the active ingredients for a long time. Examples of water-soluble taste-masking substances include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-cellulose. Examples of time delay materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.

[0387] Hard gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one salt thereof with at least one inert solid diluent, such as, for example, calcium carbonate; calcium phosphate; and kaolin.

[0388] Soft gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one water-soluble carrier, such as, for example, polyethylene glycol; and at least one oil medium, such as, for example, peanut oil, liquid paraffin, and olive oil.

[0389] Aqueous suspensions can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one excipient suitable for the manufacture of aqueous suspensions, including, but not limited to, a suspending agent, such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, alginic acid, polyvinylpyrrolidone, gum tragacanth, and gum acacia; a dispersing or wetting agent, such as, for example, a naturally occurring phosphatide, e.g., lecithin; a condensation product of an alkylene oxide with a fatty acid, such as, for example, polyoxyethylene stearate; a condensation product of ethylene oxide with a long-chain aliphatic alcohol, such as, for example, heptadecatylene-oxycetanol; a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol, such as, for example, polyoxyethylene sorbitol monooleate; and a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, such as, for example, polyethylene sorbitan monooleate. The aqueous suspensions may also contain at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate; at least one coloring agent; at least one flavoring agent; and / or at least one sweetening agent, for example, but not limited to, sucrose, saccharin, and aspartame.

[0390] Oily suspensions can be prepared by suspending at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof in vegetable oils such as peanut oil, sesame oil and coconut oil; or in mineral oils such as liquid paraffin.Oily suspensions can also contain at least one thickening agent such as beeswax, hard paraffin and cetyl alcohol.To make oily suspensions easy to swallow, at least one of the sweeteners listed above can be added to the oily suspension.Oily suspensions can further contain at least one preservative, including but not limited to, for example, antioxidants, such as butylated hydroxyanisole and alpha-tocopherol.

[0391] Dispersible powders and granules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one dispersing and / or wetting agent, at least one suspending agent, and / or at least one preservative. Suitable dispersing agents, wetting agents, and suspending agents have already been described above. Examples of preservatives include, but are not limited to, antioxidants, such as ascorbic acid. Furthermore, dispersible powders and granules may also contain at least one additive, including, but not limited to, sweeteners, flavoring agents, and coloring agents.

[0392] Emulsions of at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof can be prepared, for example, as oil-in-water emulsions. The oily phase of emulsions containing a compound of formula (I) can be prepared using known methods and ingredients. The oily phase can be, for example, provided by vegetable oils such as olive oil and peanut oil; mineral oils such as liquid paraffin; and mixtures thereof. The phase can simply contain an emulsifier, but can also contain at least a mixture of a non-emulsifying agent and a fat or oil, or both a fat and an oil. Suitable emulsifiers include, but are not limited to, naturally occurring phosphatides, such as soybean lecithin, esters or partial ester anhydrides derived from fatty acids and hexitols, such as sorbitan monooleate, and condensation products of ethylene oxide with partial esters, such as polyoxyethylene sorbitan monooleate. In some embodiments, a hydrophilic emulsifier is included together with a lipophilic emulsifier, which acts as a stabilizer. It may be preferable to include both an oil and a fat. Collectively, emulsifiers, with or without stabilizers, form the so-called emulsifying wax, and waxes, together with oils and fats, form the so-called emulsifying ointment base, which forms the oily dispersed phase of cream formulations. Emulsions may also contain sweeteners, flavorings, preservatives, and / or antioxidants. Emulsifiers and emulsion stabilizers suitable for use in the formulations of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glycerol distearate, alone or together with waxes or other materials known in the art.

[0393] The active compounds can be prepared with carriers that protect the compounds against rapid release, such as controlled-release formulations, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Many methods for preparing such formulations are patented or generally known to those skilled in the art. See, for example, Robinson, JR, ed., Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, Inc., New York (1978).

[0394] Therapeutic compositions can be administered using medical devices known in the art. For example, in certain embodiments, therapeutic compositions of the present invention can be administered using a needleless hypodermic injection device, such as those disclosed in U.S. Patents 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; or 4,596,556. Examples of well-known implants and modules useful in the present invention include U.S. Patent 4,487,603, which discloses an implantable microinfusion pump that dispenses medication at a controlled rate; U.S. Patent 4,486,194, which discloses a therapeutic device for administering medication through the skin; U.S. Patent 4,447,233, which discloses an infusion pump that dispenses medication at a precise infusion rate; U.S. Patent 4,447,224, which discloses a variable-flow implantable medication infuser for continuous drug delivery; U.S. Patent 4,439,196, which discloses an osmotic drug delivery system with multiple chamber compartments; and U.S. Patent 4,475,196, which discloses an osmotic drug delivery system. These patents are incorporated herein by reference. Many other such implants, delivery systems, and modules are known to those skilled in the art.

[0395] In some embodiments, the compounds of the present invention can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) ​​excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the present invention can cross the BBB (if desired), they can be formulated, for example, into liposomes. For methods of producing liposomes, see, for example, U.S. Patents 4,522,811; 5,374,548; and 5,399,331. Liposomes can contain one or more moieties that are selectively transported to specific cells or organs, thereby enhancing targeted drug delivery (see, for example, Ranade, VV, J. Clin. Pharmacol., 29: 685 (1989)). Examples of targeting moieties include folate or biotin (e.g., U.S. Patent No. 5,416,016 to Low et al.); mannosides (Umezawa et al., Biochem. Biophys. Res. Commun., 153: 1038 (1988)); macrocycles (Bloeman, P.G. et al., FEBS Lett., 357: 140 (1995); Owais, M. et al., Antimicrob. Agents Chemother., 39: 180 (1995)); surfactant protein A receptor (Briscoe et al., Am. J. Physiol., 1233: 134 (1995)); p120 (Schreier et al., J. Biol. Chem., 269: 9090 (1994)); Keinanen, K. et al., FEBS Lett., 357: 140 (1995); Owais, M. et al., Antimicrob. Agents Chemother., 39: 180 (1995)); Lett., 346: 123 (1994); see also Killion, JJ et al., Immunomethods 4: 273 (1994).

[0396] In certain embodiments, the compounds of the invention can be administered parenterally, i.e., by injection, including but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal, epidural, and intrasternal injection and / or infusion.

[0397] In certain embodiments, the compounds of the present invention can be administered orally, i.e., via gelatin capsules, tablets, hard or soft capsules, or liquid capsules. The compounds can be prepared by methods known in the art, including those described below and including variations within the skill of the art. Some reagents and intermediates are known in the art. Other reagents and intermediates can be prepared by methods known in the art using readily available materials. Any variables used in describing the synthesis of the compounds (e.g., numbered "R" substituents) are intended only to illustrate how to prepare the compounds and should not be confused with variables used in the claims or elsewhere in this specification. The following methods are for illustrative purposes and are not intended to limit the scope of the invention. [Example]

[0398] The following examples are included to illustrate various aspects of the present invention. Those skilled in the art will recognize that the techniques disclosed in the following examples represent techniques discovered by the inventors to function well in the practice of the invention, and therefore can be considered to constitute preferred modes of practice. However, those skilled in the art will recognize in light of the present invention that many changes can be made in the specific examples disclosed and still obtain like or similar results without departing from the spirit and scope of the invention.

[0399] The compounds can be made by methods known in the art, including those described below and including variations within the skill of the art. Some reagents and intermediates are known in the art. Other reagents and intermediates can be made by methods known in the art using readily available materials. Any variables (e.g., numbered "R" substituents) used in describing the synthesis of the compounds are intended only to describe how to make the compounds and should not be confused with variables used in the claims or elsewhere in this specification. The following methods are for illustrative purposes and are not intended to limit the scope of the invention.

[0400] The abbreviations used in the schemes are generally in accordance with the conventions used in the art.The scientific abbreviations used in this specification and examples are defined as follows: Ph=phenyl; Bn=benzyl; i-Bu=iso-butyl; i-Pr=iso-propyl; Me=methyl; Et=ethyl; Pr=n-propyl; Bu=n-butyl; t-Bu=tert-butyl; Trt=trityl; TMS=trimethylsilyl; TIS=triisopropylsilane; EtO=diethyl ether; HOAc or AcOH=acetic acid; MeCN or AcCN=acetonitrile; DMF=N,N-dimethylformamide; EtOAc=ethyl acetate; THF=tetrahydrofuran; TFA=trifluoroacetic acid; TFE=α,α,α-trifluoroethanol; EtNH=diethylamine; NMM=N-methylmorpholine; NMP=N-methylpyrrolidone; DCM=dichloromethane; TEA=trimethylamine; min.= minute; h or hr = hour; L = liter; mL or ml = milliliter; μL = microliter; g = gram; mg = milligram; mol = mole; mmol = millimole; meq = milligram equivalent; rt or RT = room temperature; sat or sat'd = saturated; aq = aqueous; mp = melting point; BOP reagent = benzotriazol-1-yloxy-tris-dimethylamino-phosphonium hexafluorophosphate (Castro's reagent); PyBOP reagent = benzotriazol-1-yloxy-tripyrrolidinophosphonium hexafluorophosphate; HBTU = 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HATU = O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HCTU = 2-(6-chloro-1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; T3P = 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide; DMAP = 4-(dimethylamino)pyridine; DIEA = diisopropylethylamine; Fmoc or FMOC = fluorenylmethyloxycarbonyl; Boc or BOC = tert-butyloxycarbonyl; HOBT or HOBT·H2O = 1-hydroxybenzotriazole hydrate; Cl-HOBt = 6-chlorobenzotriazole; HOAT = 1-hydroxy-7-azabenzotriazole; HPLC = high-performance liquid chromatography; LC / MS = high-performance liquid chromatography / mass spectrometry; MS or Mass Spectrometry Spec = mass spectrometry; NMR = nuclear magnetic resonance; Sc or SC or SQ = subcutaneous; and IP or ip = intraperitoneal.

[0401] Example 1. General synthetic and analytical methods compound synthesis The macrocycles of the invention can be produced by methods known in the art, such as chemical synthesis, recombinantly in a cell-free system, recombinantly synthesized in a cell, or isolated from a biological source. Chemical synthesis of the macrocycles of the invention can be carried out using a variety of art-recognized methods, including stepwise solid-phase synthesis, conformationally assisted religation of chemical fragments, semisynthesis via enzymatic ligation of cloned or synthetic chemical segments, and chemical ligation. A preferred method for the synthesis of the macrocycles and analogs thereof described herein is chemical synthesis using various solid-phase techniques, such as those described in Chan, W C et al., eds., Fmoc Solid Phase Synthesis, Oxford University Press, Oxford (2000); Barany, G. et al., The Peptides: Analysis, Synthesis, Biology, Vol. 2: "Special Methods in Peptide Synthesis, Part A", pp. 3-284, Gross, E. et al., eds., Academic Press, New York (1980); in Atherton, E., Sheppard, R C Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford, England (1989); and Stewart, J M Young, J D Solid-Phase Peptide Synthesis, 2nd Edition, Pierce Chemical Co., Rockford, IL (1984).

[0402] Compounds can be synthesized in a stepwise manner on an insoluble polymer support (also called a "resin"), starting from the C-terminus of the peptide. Synthesis begins with the addition of an amino acid or the C-terminal amino acid of the peptide to the resin via the formation of an amide or ester bond. This allows for the eventual liberation of the resulting peptide as the C-terminal amide or carboxylic acid, respectively.

[0403] The C-terminal amino acid and all other amino acids used in the synthesis must have differently protected α-amino groups and side chain functional groups (if present) so that the α-amino protecting groups can be selectively removed during synthesis. Coupling of an amino acid is carried out by activating its carboxyl group as an active ester and reacting it with the unblocked α-amino group of the N-terminal amino acid attached to the resin. A series of α-amino group deprotection and coupling reactions are repeated until the entire compound is assembled. The compound is then released from the resin, usually in the presence of an appropriate scavenger to limit side reactions, while simultaneously deprotecting the side chain functional groups. The resulting compound is finally purified by reverse-phase HPLC.

[0404] Synthesis of the peptidyl-resins required as precursors to the final compounds utilizes commercially available cross-linked polystyrene polymer resins (Novabiochem, San Diego, CA; Applied Biosystems, Foster City, CA). Preferred solid supports include 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-p-methylbenzhydrylamine resin (Rink amide MBHA resin) for C-terminal carboxamides; 9-Fmoc-amino-xanthen-3-yloxy-Merrifield resin (Sieber amide resin); 4-(9-Fmoc)aminomethyl-3,5-dimethoxyphenoxy)valerylaminomethyl-Merrifield resin (PAL resin). Coupling of the first and subsequent amino acids can be achieved using HOBt, 6-Cl-HOBt, or HOAt active esters prepared from DIC / HOBt, HBTU / HOBt, BOP, PyBOP, or DIC / 6-Cl-HOBt, HCTU, DIC / HOAt, or HATU, respectively. Preferred solid supports include 2-chlorotrityl chloride resin and 9-Fmoc-amino-xanthen-3-yloxy-Merrifield resin (Sieber amide resin) for protected peptide fragments. Loading of the first amino acid onto the 2-chlorotrityl chloride resin is best accomplished by reaction of the resin with the Fmoc-protected amino acid in dichloromethane and DIEA. If necessary, a small amount of DMF can be added to solubilize the amino acid.

[0405] Synthesis of the compound analogs described herein can be performed using a single or multi-channel peptide synthesizer such as a CEM Liberty Microwave synthesizer or a Protein Technologies, Inc. Prelude (6 channel) or Symphony (12 channel) or Symphony X (24 channel) synthesizer.

[0406] Useful Fmoc amino acid derivatives are listed in Table 1. [Table 1]

[0407] The peptidyl-resin precursor for each peptide can be cleaved and deprotected using any standard method (for compounds, see King, DS et al., Int. J. Peptide Protein Res., 36: 255-266 (1990)). A preferred method is the use of TFA in the presence of TIS as a scavenger and DTT or TCEP as a disulfide reducing agent. Typically, the peptidyl-resin is stirred in TFA / TIS / DTT (95:5:1 to 97:3:1, v:v:w; 1-3 mL / 100 mg of peptidyl resin) for 1.5-3 hours at room temperature. The spent resin is then filtered, the TFA solution is cooled, and EtO solution is added. The precipitate is collected by centrifugation and decantation of the ether layer (3x). The resulting crude peptide is either dissolved directly in DMF or DMSO or CH3CN / H2O for purification by preparative HPLC or used directly in the next step.

[0408] Peptides of the desired purity can be purified by preparative HPLC on a Waters Model 4000 or Shimadzu Model LC-8A liquid chromatograph. The crude peptide solution is loaded onto a YMC S5 ODS (20 x 100 mm) column and eluted with a linear gradient of MeCN in water (both buffered with 0.1% TFA) at a flow rate of 14-20 mL / min. The effluent is monitored by UV absorbance at 217 nm or 220 nm. The structure of the purified peptide can be confirmed by electrospray MS analysis.

[0409] A list of the unnatural amino acids described herein is provided in Table 2: [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13]

[0410] Analysis data: Mass spectrometry: "ESI-MS(+)" indicates electrospray ionization mass spectrometry performed in positive ion mode; "ESI-MS(-)" indicates electrospray ionization mass spectrometry performed in negative ion mode; "ESI-HRMS(+)" indicates high-resolution electrospray ionization mass spectrometry performed in positive ion mode; "ESI-HRMS(-)" indicates high-resolution electrospray ionization mass spectrometry performed in negative ion mode. Detected masses are reported according to the "m / z" unit designation. Compounds with exact masses greater than 1000 were often detected as doubly or triply charged ions.

[0411] The crude material was purified via preparative LC / MS. Fractions containing the desired product were combined and dried by centrifugal evaporation.

[0412] Analytical LC / MS conditions A: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water and 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water and 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0 to 100% B over 3 min, then hold at 100% B for 0.75 min; Flow rate: 1.0 mL / min; Detection: UV at 220 nm.

[0413] Analytical LC / MS conditions B: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water and 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water and 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 0 to 100% B over 3 min, then hold at 100% B for 0.75 min; Flow rate: 1.0 mL / min; Detection: UV at 220 nm.

[0414] Analytical LC / MS conditions C: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water and 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water and 10 mM ammonium acetate; Temperature: 70 °C; Gradient: 0 to 100% B over 3 min, then hold at 100% B for 2.0 min; Flow rate: 0.75 mL / min; Detection: UV at 220 nm.

[0415] Analytical LC / MS conditions D: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water and 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water and 0.1% trifluoroacetic acid; Temperature: 70 °C; Gradient: 0 to 100% B over 3 min, then hold at 100% B for 2.0 min; Flow rate: 0.75 mL / min; Detection: UV at 220 nm.

[0416] Analytical LC / MS conditions E: Column: Kinetex XB C18, 3.0 × 75 mm, 2.6 μm particles; Mobile phase A: 10 mM aqueous ammonium formate:acetonitrile (98:2); Mobile phase B: 10 mM aqueous ammonium formate:acetonitrile (02:98); Gradient: 20 to 100% B over 4 min, then hold at 100% B for 0.6 min; Flow rate: 1.0 mL / min; Detection: UV at 254 nm.

[0417] Analytical LC / MS conditions F: Column: Ascentis Express C18, 2.1 x 50 mm, 2.7 μm particles; Mobile phase A: 10 mM aqueous ammonium acetate:acetonitrile (95:5); Mobile phase B: 10 mM aqueous ammonium acetate:acetonitrile (05:95); Temperature: 50 °C; Gradient: 0 to 100% B over 3 min; Flow rate: 1.0 mL / min; Detection: UV at 220 nm.

[0418] Analytical LC / MS conditions G: Column: X Bridge C18, 4.6 x 50 mm, 5 μm particles; Mobile phase A: 0.1% TFA in water; Mobile phase B: acetonitrile, Temperature: 35 °C; Gradient: 5 to 95% B over 4 min; Flow rate: 4.0 mL / min; Detection: UV at 220 nm.

[0419] Analytical LC / MS conditions H: Column: X Bridge C18, 4.6 x 50 mm, 5 μm particles; Mobile phase A: 10 mM NH4OAc; Mobile phase B: Methanol, Temperature: 35 °C; Gradient: 5 to 95% B over 4 min; Flow rate: 4.0 mL / min; Detection: UV at 220 nm.

[0420] Analytical LC / MS conditions I: Column: X Bridge C18, 4.6 x 50 mm, 5 μm particles; Mobile phase A: 10 mM NH4OAc; Mobile phase B: acetonitrile, Temperature: 35 °C; Gradient: 5 to 95% B over 4 min; Flow rate: 4.0 mL / min; Detection: UV at 220 nm.

[0421] Analytical LC / MS conditions J: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water with 0.05% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water with 0.05% trifluoroacetic acid; Temperature: 70 °C; Gradient: 0 to 100% B over 1.5 min, then hold at 100% B for 2.0 min; Flow rate: 0.75 mL / min; Detection: UV at 254 nm.

[0422] Analytical LC / MS conditions K: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Mobile phase A: 100% water and 0.05% trifluoroacetic acid; Mobile phase B: 100% acetonitrile and 0.05% trifluoroacetic acid; Temperature: 50 °C; Gradient: 2 to 98% B over 1.0 min, then hold at 100% B for 1.0 to 1.5 min; Flow rate: 0.80 mL / min; Detection: UV at 220 nm.

[0423] Analytical LC / MS conditions L: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 μm particles; Buffer: 10 mM ammonium acetate. Mobile phase A: Buffer CH3CN (95 / 5); Mobile phase B: Buffer ACN (5:95); Temperature: 50 °C; Gradient: 20 to 98% B over 2.0 min, then hold at 100% B for 0.2 min; Flow rate: 0.70 mL / min; Detection: UV at 220 nm.

[0424] Analytical LC / MS conditions M: Column: Waters Acquity UPLC BEH C18, 3.0 × 50 mm, 1.7 μm particles; Mobile phase A: 95% water and 5% water with 0.1% trifluoroacetic acid; Mobile phase B: 95% acetonitrile and 5% water with 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 20 to 100% B over 2.0 min, then hold at 100% B for 2.0 to 2.3 min; Flow rate: 0.7 mL / min; Detection: UV at 220 nm.

[0425] Preliminary method: All operations were performed under automation on a front-end peptide synthesizer (Protein Technologies). Unless otherwise noted, all procedures were performed in a 45 mL polypropylene reaction vessel equipped with a bottom frit. The reaction vessel was connected to the front-end peptide synthesizer via both the bottom and top of the vessel. DMF and DCM were added through the top of the vessel, which allowed them to flow evenly down the sides of the vessel. The remaining reagents were added through the bottom of the reaction vessel and allowed to rise through the frit to contact the resin. All solution was removed from the bottom of the reaction vessel. "Periodic agitation" refers to short pulses of N2 gas through the bottom frit; pulses lasted approximately 5 seconds and occurred every 30 seconds. Amino acid solutions were generally not used more than two weeks after preparation. HATU solutions were used within 7–14 days of preparation.

[0426] Sieber amide resin = 9-Fmoc-aminoxanthene-3-yloxy polystyrene resin, where "3-yloxy" refers to the position and type of attachment to the polystyrene resin. The resin used is polystyrene with a Sieber linker (Fmoc-protected on nitrogen); 100-200 mesh, 1% DVB, 0.71 mmol / g loading.

[0427] Rink = (2,4-dimethoxyphenyl)(4-alkoxyphenyl)methanamine, where "4-alkoxy" refers to the position and type of attachment to the polystyrene resin. The resin used is Merrifield polymer (polystyrene) with a Rink linker (Fmoc-protected on nitrogen); 100-200 mesh, 1% DVB, 0.56 mmol / g loading.

[0428] 2-Chlorotrityl chloride resin (2-chlorotriphenylmethyl chloride resin), 50-150 mesh, 1% DVB, 1.54 mmol / g load. Fmoc-glycine-2-chlorotrityl chloride resin, 200-400 mesh, 1% DVB, 0.63 mmol / g load.

[0429] PL-FMP resin: (4-formyl-3-methoxyphenoxymethyl) polystyrene.

[0430] Common amino acids used are listed below, with the side chain protecting groups indicated in parentheses: Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Asn(Trt)-OH; Fmoc-Asp(tBu)-OH; Fmoc-Bip-OH; Fmoc-Cys(Trt)-OH; Fmoc-Dab(Boc)-OH; Fmoc-Dap(Boc)-OH; Fmoc-Gln(Trt)-OH; Fmoc-Gly-OH; Fmoc-His(Trt)-OH; Fmoc-Hyp(tBu)-OH; Fmoc-Ile-OH; Fmoc-Leu-OH; Fmoc-Ly s(Boc)-OH; Fmoc-Nle-OH; Fmoc-Met-OH; Fmoc-[N-Me]Ala-OH; Fmoc-[N-Me]Nle-OH; Fmoc-Orn(Boc)-OH, Fmoc-Phe-OH; Fmoc-Pro-OH; Fmoc-Sar-OH; Fmoc-Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Trp(Boc)-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Val-OH and their corresponding D-amino acids.

[0431] The "Preliminary Method" procedure describes experiments performed on a 0.100 mmol scale, where the scale is determined by the amount of Sieber, Rink, 2-chlorotrityl, or PL-FMP resin. This scale corresponds to approximately 140 mg of the Sieber amide resin described above. All methods can be scaled down from the 0.100 mmol scale by adjusting the volumes described by multiples of the scale. Prior to amino acid coupling, the entire peptide synthesis series begins with the resin swelling method described below as the "Resin Swelling Method." Coupling of an amino acid to the first amine N-terminus was performed using the "Single Coupling Method" described below. Coupling of an amino acid to the second amine N-terminus or to the N-terminus of Arg(Pbf)- and D-Arg(Pbf)- was performed using the "Double Coupling Method" described below.

[0432] Resin swelling method: To a 45 mL polypropylene solid-phase reaction vessel was added Sieber amide resin (140 mg, 0.100 mmol). The resin was washed (swollen) twice as follows: DMF (5.0 mL) was added to the reaction vessel from the top of the vessel (DMF top wash), and the mixture was then periodically stirred for 10 minutes, after which the solvent was drained through the frit.

[0433] Single coupling method: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (6.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 1.0 minutes, after which the solution was drained through the frit. To the reaction vessel, amino acid (0.2 M in DMF, 5.0 mL, 10 equivalents) was added, followed by HATU (0.4 M in DMF, 2.5 mL, 10 equivalents), and finally NMM (0.8 M in DMF, 2.5 mL, 20 equivalents). The mixture was stirred periodically for 60-120 minutes, and then the reaction solution was drained through the frit. The resin was washed four times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, and the resulting mixture was stirred periodically for 1.0 minute, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0434] Double coupling method: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5.0 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (6.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 1.0 minutes, after which the solution was drained through the frit. To the reaction vessel, amino acid (0.2 M in DMF, 5.0 mL, 10 equivalents) was added, followed by HATU (0.4 M in DMF, 2.5 mL, 10 equivalents), and finally NMM (0.8 M in DMF, 2.5 mL, 20 equivalents). The mixture was stirred periodically for 1-1.5 hours, then the reaction solution was drained through the frit. The resin was washed two times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 1.0 minute, and then the solution was drained through the frit. To the reaction vessel, amino acid (0.2 M in DMF, 5.0 mL, 10 equiv.) was added, followed by HATU (0.4 M in DMF, 2.5 mL, 10 equiv.) and finally NMM (0.8 M in DMF, 2.5 mL, 20 equiv.). The mixture was stirred periodically for 1-1.5 hours, then the reaction solution was drained through the frit. The resin was washed four times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 1.0 minute, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0435] Single Coupling Manual Addition Method A: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six consecutive times as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. The reaction was interrupted. The reaction vessel was opened, and a solution of the unnatural amino acid (2–4 equiv.) in DMF (1–2 mL) was manually added through the top of the vessel using a pipette while the bottom of the vessel remained attached to the apparatus. The vessel was then closed. The automated program was resumed, and HATU (0.4 M in DMF, 1.3 mL, 4 equiv.) and NMM (1.3 M in DMF, 1.0 mL, 8 equiv.) were added sequentially. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0436] Single Coupling Manual Addition Method B: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. The reaction was interrupted. The reaction vessel was opened, and a solution of the unnatural amino acid (2–4 equivalents) in DMF (1–1.5 mL) was manually added through the top of the vessel using a pipette while the bottom of the vessel remained attached to the apparatus. HATU (2–4 equivalents, the same equivalent as the unnatural amino acid) was then manually added, and the vessel was then closed. The automated program was resumed, and NMM (1.3 M in DMF, 1.0 mL, 8 equiv.) was added continuously. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0437] Chloroacetic anhydride coupling: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 5.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (6.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 1 minute, after which the solution was drained through the frit. To the reaction vessel, chloroacetic anhydride solution (0.4 M in DMF, 5.0 mL, 20 equivalents) was added, followed by N-methylmorpholine (0.8 M in DMF, 5.0 mL, 40 equivalents). The mixture was stirred periodically for 15 minutes, and then the reaction solution was drained through the frit. The resin was washed twice as follows: for each wash, DMF (6.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 1 minute, and then the solution was drained through the frit. To the reaction vessel was added chloroacetic anhydride solution (0.4 M in DMF, 5.0 mL, 20 equivalents), followed by N-methylmorpholine (0.8 M in DMF, 5.0 mL, 40 equivalents). The mixture was periodically stirred for 15 minutes, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (6.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 1 minute, and then the solution was drained through the frit. The resin was washed four times consecutively as follows: for each wash, DCM (6.0 mL) was added through the top of the vessel, the resulting mixture was periodically stirred for 1 minute, and then the solution was drained through the frit. The resin was then dried under a stream of nitrogen for 10 minutes. The resulting resin was used directly in the next step.

[0438] Symphony method: All operations were performed under automation on a 12-channel Symphony peptide synthesizer (Protein Technologies). Unless otherwise noted, all procedures were performed in a 25 mL polypropylene reaction vessel equipped with a bottom frit. The reaction vessel was connected to the Symphony peptide synthesizer via both the bottom and top of the vessel. DMF and DCM were added through the top of the vessel, flushing evenly down the sides of the vessel. The remaining reagents were added through the bottom of the reaction vessel and allowed to rise through the frit to contact the resin. All solution was removed from the bottom of the reaction vessel. "Periodic agitation" refers to short pulses of N2 gas through the bottom frit; pulses lasted approximately 5 seconds and occurred every 30 seconds. Amino acid solutions were generally not used more than two weeks after preparation. HATU solutions were used within 7–14 days of preparation.

[0439] Sieber amide resin = 9-Fmoc-aminoxanthene-3-yloxy polystyrene resin, where "3-yloxy" refers to the position and type of attachment to the polystyrene resin. The resin used is polystyrene with a Sieber linker (Fmoc-protected on nitrogen); 100-200 mesh, 1% DVB, 0.71 mmol / g loading.

[0440] Rink = (2,4-dimethoxyphenyl)(4-alkoxyphenyl)methanamine, where "4-alkoxy" refers to the position and type of attachment to the polystyrene resin. The resin used is Merrifield polymer (polystyrene) with a Rink linker (Fmoc-protected on nitrogen); 100-200 mesh, 1% DVB, 0.56 mmol / g loading.

[0441] 2-Chlorotrityl chloride resin (2-chlorotriphenylmethyl chloride resin), 50–150 mesh, 1% DVB, 1.54 mmol / g loading.

[0442] PL-FMP resin: (4-formyl-3-methoxyphenoxymethyl) polystyrene.

[0443] Fmoc-glycine-2-chlorotrityl chloride resin, 200–400 mesh, 1% DVB, 0.63 mmol / g loading.

[0444] Common amino acids used are listed below with side chain protecting groups indicated in parentheses: Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Asn(Trt)-OH; Fmoc-Asp(tBu)-OH; Fmoc-Bip-OH; Fmoc-Cys(Trt)-OH; Fmoc-Dab(Boc)-OH; Fmoc-Dap(Boc)-OH; Fmoc-Gln(Trt)-OH; Fmoc-Gly-OH Fmoc-Gly-OH;Fmoc-His(Trt)-OH;Fmoc-Hyp(tBu)-OH;Fmoc-Ile-OH;Fmoc-Leu-OH;Fmoc-Lys(Boc)-OH;Fmoc-Nle-OH;Fmoc-Met-OH;Fmoc-[N-Me]Ala-OH;Fmoc-[N-Me]Nle-OH;F moc-Orn(Boc)-OH, Fmoc-Phe-OH;Fmoc-Pro-OH;Fmoc-Sar-OH;Fmoc-Ser(tBu)-OH;Fmoc-Thr(tBu)-OH;Fmoc-Trp(Boc)-OH;Fmoc-Tyr(tBu)-OH;Fmoc-Val-OH and their corresponding D-amino acids.

[0445] The "Symphony Method" procedure describes experiments performed on a 0.05 mmol scale, where the scale is determined by the amount of Sieber or Rink or chlorotrityl linker or PL-FMP attached to the resin. This scale corresponds to approximately 70 mg of the Sieber resin. All methods can be scaled up from the 0.05 mmol scale by adjusting the volumes listed by multiples of the scale.

[0446] Prior to amino acid coupling, the entire peptide synthesis sequence begins with the resin swelling method described below as the "resin swelling method." Coupling of the first amine of an amino acid to the N-terminus was performed using the "single coupling method" described below.

[0447] Resin swelling method: To a 25 mL polypropylene solid-phase reaction vessel was added Sieber resin (70 mg, 0.05 mmol). The resin was washed (swollen) as follows: DMF (2.0 mL) was added to the reaction vessel, and the mixture was then periodically stirred for 10 minutes, after which the solvent was drained through a frit.

[0448] Single coupling method: To the reaction vessel containing the resin from the previous step, DMF (2.5 mL) was added three times, and the mixture was agitated for 30 seconds, after which the solvent was drained through the frit each time. To the resin was added piperidine:DMF (20:80 v / v, 3.75 mL). The mixture was agitated periodically for 5.0 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was agitated periodically for 5.0 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (2.5 mL) was added to the vessel, and the resulting mixture was agitated periodically for 30 seconds, after which the solution was drained through the frit. To the reaction vessel, the amino acid (0.2 M in DMF, 2.5 mL, 10 equiv.) was added, followed by HATU (0.4 M in DMF, 1.25 mL, 10 equiv.), and finally NMM (0.8 M in DMF, 1.25 mL, 20 equiv.). The mixture was periodically stirred for 30-120 min, and then the reaction solution was drained through the frit. The resin was washed six successive times as follows: for each wash, DMF (2.5 mL) was added, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0449] Single pre-coupling activation method: To the reaction vessel containing the resin from the previous step, DMF (3.75 mL) was added three times, and the mixture was agitated for 30 seconds, after which the solvent was drained through the frit each time. To the resin, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was periodically agitated for 5.0 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.75 mL) was added. To the resin, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was periodically agitated for 5.0 minutes, and then the solution was drained through the frit. The mixture was periodically agitated for 5.0 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (3.75 mL) was added to the vessel, and the resulting mixture was periodically agitated for 30 seconds, and then the solution was drained through the frit. To the reaction vessel, premixed amino acid and HATU (0.1 M in DMF, 1.25 mL, 2.5 equivalents in a 1:1 ratio) were added, followed by NMM (0.8 M in DMF, 1.25 mL, 20 equivalents). The mixture was periodically stirred for 2-3 hours, and then the reaction solution was drained through a frit. The resin was washed four successive times as follows: for each wash, DMF (3.75 mL) was added, and the resulting mixture was periodically stirred for 30 seconds, after which the solution was drained through a frit. The resulting resin was used directly in the next step.

[0450] Double coupling method: To the reaction vessel containing the resin from the previous step, DMF (2.5 mL) was added three times, and the mixture was agitated for 30 seconds, after which the solvent was drained through the frit each time. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was periodically agitated for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was periodically agitated for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (3.75 mL) was added, and the resulting mixture was periodically agitated for 30 seconds, after which the solution was drained through the frit. To the reaction vessel, the amino acid (0.2 M in DMF, 2.5 mL, 10 equiv.) was added, followed by HATU (0.4 M in DMF, 1.25 mL, 10 equiv.) and finally NMM (0.8 M in DMF, 1.25 mL, 20 equiv.). The mixture was periodically stirred for 1 h, and then the reaction solution was drained through the frit. The resin was washed twice with DMF (3.75 mL), and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit each time. To the reaction vessel, the amino acid (0.2 M in DMF, 2.5 mL, 10 equiv.) was added, followed by HATU (0.4 M in DMF, 1.25 mL, 10 equiv.) and finally NMM (0.8 M in DMF, 1.25 mL, 20 equiv.). The mixture was periodically stirred for 1-2 h, and then the reaction solution was drained through the frit. The resin was washed six successive times as follows: for each wash, DMF (3.75 mL) was added, the resulting mixture was vortexed periodically for 30 seconds, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0451] Chloroacetic anhydride coupling: To the reaction vessel containing the resin from the previous step, DMF (3.75 mL) was added three times, and the mixture was stirred for 30 seconds, after which the solvent was drained through the frit each time. To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.75 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (3.75 mL) was added from the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, after which the solution was drained through the frit. To the reaction vessel was added a solution of chloroacetic anhydride (0.4 M in DMF, 3.75 mL, 30 equivalents), followed by NMM (0.8 M in DMF, 2.5 mL, 40 equivalents). The mixture was stirred periodically for 15 minutes, and then the reaction solution was drained through the frit. The resin was washed once as follows: DMF (6.25 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, after which the solution was drained through the frit. To the reaction vessel was added a solution of chloroacetic anhydride (0.4 M in DMF, 3.75 mL, 30 equivalents), followed by NMM (0.8 M in DMF, 2.5 mL, 40 equivalents). The mixture was stirred periodically for 15 minutes, and then the reaction solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (2.5 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, after which the solution was drained through the frit. The resin was washed four times successively as follows: for each wash, DCM (2.5 mL) was added from the top of the vessel, the resulting mixture was periodically agitated for 30 seconds, and then the solution was drained through the frit. The resulting resin was dried using a stream of nitrogen for 10 minutes and then used directly in the next step.

[0452] Symphony X method: All operations were performed under automation on a Symphony X peptide synthesizer (Protein Technologies). Unless otherwise noted, all procedures were performed in a 45 mL polypropylene reaction vessel equipped with a bottom frit. The reaction vessel was connected to the Symphony X peptide synthesizer via both the bottom and top of the vessel. DMF and DCM could be added from the top of the vessel, flushing evenly down the sides of the vessel. The remaining reagents were added through the bottom of the reaction vessel and allowed to rise through the frit to contact the resin. All solutions were removed from the bottom of the reaction vessel. "Periodic agitation" refers to short pulses of N2 gas passed through the bottom frit; pulses lasted approximately 5 seconds and occurred every 30 seconds. "Single" mode of addition refers to the description of all solutions contained in a single Falcon tube, typically of any volume less than 5 mL. Amino acid solutions were generally not used more than two weeks after preparation. HATU solutions were used within 14 days of preparation.

[0453] Sieber amide resin = 9-Fmoc-aminoxanthene-3-yloxy polystyrene resin, where "3-yloxy" refers to the position and type of attachment to the polystyrene resin. The resin used is polystyrene with a Sieber linker (Fmoc-protected on nitrogen); 100-200 mesh, 1% DVB, 0.71 mmol / g loading.

[0454] Rink = (2,4-dimethoxyphenyl)(4-alkoxyphenyl)methanamine, where "4-alkoxy" refers to the position and type of attachment to the polystyrene resin. The resin used is Merrifield polymer (polystyrene) with a Rink linker (Fmoc-protected on nitrogen); 100-200 mesh, 1% DVB, 0.56 mmol / g loading.

[0455] 2-Chlorotrityl chloride resin (2-chlorotriphenylmethyl chloride resin), 50-150 mesh, 1% DVB, 1.54 mmol / g load. Fmoc-glycine-2-chlorotrityl chloride resin, 200-400 mesh, 1% DVB, 0.63 mmol / g load.

[0456] PL-FMP resin: (4-formyl-3-methoxyphenoxymethyl) polystyrene.

[0457] Common amino acids used are listed below with side chain protecting groups indicated in brackets:

[0458] Fmoc-Ala-OH;Fmoc-Arg(Pbf)-OH;Fmoc-Asn(Trt)-OH;Fmoc-Asp(tBu)-OH;Fmoc-Bip-OH;Fmoc-Cys(Trt)-OH;Fmoc-Dab(Boc)-OH;F moc-Dap(Boc)-OH;Fmoc-Gln(Trt)-OH;Fmoc-Gly-OH;Fmoc-His(Trt)-OH;Fmoc-Hyp(tBu)-OH;Fmoc-Ile-OH;Fmoc-Leu-OH;Fmoc-Ly s(Boc)-OH; Fmoc-Nle-OH; Fmoc-Met-OH; Fmoc-[N-Me]Ala-OH; Fmoc-[N-Me]Nle-OH; Fmoc-Orn(Boc)-OH, Fmoc-Phe-OH; Fmoc-Pro-OH; Fmoc-Sar-OH; Fmoc-Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Trp(Boc)-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Val-OH and their corresponding D-amino acids.

[0459] The "Symphony X Method" procedure describes experiments performed on a 0.050 mmol scale, where the scale is determined by the amount of Sieber, Rink, 2-chlorotrityl, or PL-FMP bound to the resin. This scale corresponds to approximately 70 mg of the Sieber amide resin described above. All methods can be scaled up or down from the 0.050 mmol scale by adjusting the volumes described by multiples of the scale. Prior to amino acid coupling, the entire peptide synthesis series begins with the resin swelling method described below as the "Resin Swelling Method." Coupling of the first amine N-terminus of an amino acid was performed using the "Single Coupling Method" described below. Coupling of the second amine N-terminus of an amino acid or the N-terminus of Arg(Pbf)- and D-Arg(Pbf)- or D-Leu was performed using the "Double Coupling Method" or "Single Coupling 2-Hour Method" described below. Unless otherwise noted, the final step in the automated synthesis is acetyl group introduction, described as "Chloroacetyl Anhydride Introduction." The entire synthesis concludes with a final rinse and dry step described as "Standard Final Rinse and Dry Method."

[0460] Resin swelling method: To a 45 mL polypropylene solid-phase reaction vessel was added Sieber amide resin (70 mg, 0.050 mmol). The resin was washed (swollen) three times as follows: DMF (5.0 mL) was added to the reaction vessel from the top of the vessel (DMF top wash), and the mixture was then periodically stirred for 3 minutes, after which the solvent was drained through the frit.

[0461] Single coupling method: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, after which the solution was drained through the frit. To the reaction vessel, amino acid (0.2 M in DMF, 2.0 mL, 8 equiv.) was added, followed by HATU (0.4 M in DMF, 1.0 mL, 8 equiv.), and finally NMM (0.8 M in DMF, 1.0 mL, 16 equiv.). The mixture was stirred periodically for 1-2 hours, and then the reaction solution was drained through the frit. The resin was washed five times successively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was periodically agitated for 30 seconds, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0462] Double coupling method: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, after which the solution was drained through the frit. To the reaction vessel, amino acid (0.2 M in DMF, 2.0 mL, 8 eq.) was added, followed by HATU (0.4 M in DMF, 1.0 mL, 8 eq.), and finally NMM (0.8 M in DMF, 1.0 mL, 16 eq.). The mixture was stirred periodically for 1 hour, and then the reaction solution was drained through the frit. The resin was washed two times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was periodically agitated for 30 seconds, and then the solution was drained through the frit. To the reaction vessel, amino acid (0.2 M in DMF, 2.0 mL, 8 equiv.) was added, followed by HATU (0.4 M in DMF, 1.0 mL, 8 equiv.) and finally NMM (0.8 M in DMF, 1.0 mL, 16 equiv.). The mixture was periodically agitated for 1-2 hours, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, the resulting mixture was periodically agitated for 30 seconds, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0463] Single Coupling Manual Addition Method A: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. The reaction was interrupted. The reaction vessel was opened, and a solution of the unnatural amino acid (2–4 equiv.) in DMF (1–1.5 mL) was manually added through the top of the vessel using a pipette while the bottom of the vessel remained attached to the apparatus. The vessel was then closed. The automated program was resumed, and HATU (0.4 M in DMF, 1.0 mL, 8 equiv.) and NMM (0.8 M in DMF, 1.0 mL, 16 equiv.) were added sequentially. The mixture was periodically stirred for 2–3 h, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step.

[0464] Single Coupling Manual Addition Method B: To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 4.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (5.0 mL) was added through the top of the vessel, the resulting mixture was stirred periodically for 30 seconds, and then the solution was drained through the frit. The reaction was interrupted. The reaction vessel was opened, and a solution of the unnatural amino acid (2–4 equivalents) in DMF (1–1.5 mL) was manually added through the top of the vessel using a pipette while the bottom of the vessel remained attached to the apparatus. HATU (2–4 equivalents, the same amount as the unnatural amino acid) was then manually added, and the vessel was then closed. The automated program was resumed, and NMM (0.8 M in DMF, 1.0 mL, 16 equiv.) was added continuously. The mixture was periodically stirred for 2-3 h, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (5.0 mL) was added from the top of the vessel, and the resulting mixture was periodically stirred for 30 s, after which the solution was drained through the frit. The resulting resin was used directly in the next step. Chloroacetic anhydride coupling:

[0465] To the reaction vessel containing the resin from the previous step, piperidine:DMF (20:80 v / v, 3.0 mL) was added. The mixture was stirred periodically for 3.5 or 5 minutes, and then the solution was drained through the frit. To the reaction vessel, piperidine:DMF (20:80 v / v, 3.0 mL) was added. The mixture was stirred periodically for 5 minutes, and then the solution was drained through the frit. The resin was washed six times consecutively as follows: for each wash, DMF (3.0 mL) was added through the top of the vessel, and the resulting mixture was stirred periodically for 30 seconds, after which the solution was drained through the frit. To the reaction vessel, chloroacetic anhydride solution (0.4 M in DMF, 2.5 mL, 20 equivalents) was added, followed by N-methylmorpholine (0.8 M in DMF, 2.0 mL, 32 equivalents). The mixture was stirred periodically for 15 minutes, and then the reaction solution was drained through the frit. The resin was washed twice as follows: for each wash, DMF (3.0 mL) was added from the top of the vessel, the resulting mixture was stirred periodically for 1.0 min, and then the solution was drained through the frit. To the reaction vessel was added chloroacetic anhydride solution (0.4 M in DMF, 2.5 mL, 20 eq.) followed by N-methylmorpholine (0.8 M in DMF, 2.0 mL, 32 eq.). The mixture was stirred periodically for 15 min, and then the reaction solution was drained through the frit. The resin was washed five times consecutively as follows: for each wash, DMF (3.0 mL) was added from the top of the vessel, the resulting mixture was stirred periodically for 1.0 min, and then the solution was drained through the frit. The resulting resin was used directly in the next step.

[0466] Final Rinse and Dry: The resin from the previous step was washed six times consecutively as follows: for each wash, DCM (5.0 mL) was added from the top of the vessel, and the resulting mixture was periodically stirred for 30 seconds, after which the solution was drained through the frit. The resin was then dried using a stream of nitrogen for 10 minutes. The resulting resin was used directly in the next step.

[0467] Comprehensive deprotection method A: Unless otherwise noted, all operations were performed manually. The "Comprehensive Deprotection Method" procedure describes experiments performed on a 0.050 mmol scale, where the scale is determined by the amount of Sieber, Rink, Wang, chlorotrityl resin, or PL-FMP resin. All methods can be scaled up from the 0.05 mmol scale by adjusting the volumes listed in multiples of the scale. To a 50 mL Falcon tube, the resin and 2.0–5.0 mL of cleavage cocktail (TFA:TIS:DTT, v / v / w = 94:5:1) were added. The volume of cleavage cocktail used for each individual linear peptide can be varied. Generally, the greater the number of protecting groups present on the peptide side chains, the greater the volume of cleavage cocktail required. The mixture was shaken at room temperature for 1–2 hours, usually about 1.5 hours. To the suspension, 35–50 mL of cold diethyl ether was added. The mixture was mixed vigorously, which precipitated a substantial amount of white solid. The mixture was centrifuged for 3–5 min, then the solution was decanted off the solid and discarded. The solid was suspended in EtO (30–40 mL); the mixture was then centrifuged for 3–5 min; and the solution was decanted off the solid and discarded. Finally, the solid was suspended in EtO (30–40 mL); the mixture was centrifuged for 3–5 min; and the solution was decanted off the solid and discarded. After drying with a nitrogen stream and / or house vacuum, the crude peptide was obtained as an off-white solid, along with the cleaved resin. The crude material was used in the cyclization step the same day.

[0468] Comprehensive deprotection method B: Unless otherwise noted, all operations were performed manually. The "Comprehensive Deprotection Method" procedure describes experiments performed on a 0.050 mmol scale, where the scale is determined by the amount of Sieber, Rink, Wang, chlorotrityl resin, or PL-FMP resin. All methods can be scaled up from a 0.05 mmol scale by adjusting the volumes listed. A 30 mL Bio-Rad polyprep chromatography column was loaded with the resin and 2.0–5.0 mL of cleavage cocktail (TFA:TIS:DTT, v / v / w = 94:5:1). The volume of cleavage cocktail used for each individual linear peptide can be varied. Generally, the greater the number of protecting groups present on the peptide side chains, the greater the volume of cleavage cocktail required. The mixture was shaken at room temperature for 1–2 hours, typically approximately 1.5 hours. The acidic solution was drained into 40 mL of cold diethyl ether, and the resin was washed twice with 0.5 mL of TFA. The mixture was centrifuged for 3-5 minutes, then the solution was decanted off the solid and discarded. The solid was suspended in EtO (35 mL); the mixture was then centrifuged for 3-5 minutes; and the solution was decanted off the solid and discarded. Finally, the solid was suspended in EtO (35 mL); the mixture was centrifuged for 3-5 minutes; and the solution was decanted off the solid and discarded. After drying with a nitrogen stream and / or house vacuum, the crude peptide was obtained as a white to off-white solid. The crude material was used in the cyclization step the same day.

[0469] Cyclization method A: Unless otherwise noted, all operations were performed manually. The procedure for "Cyclization Method A" describes an experiment performed on a 0.05 mmol scale, where the scale is determined by the amount of Sieber, Rink, chlorotrityl, Wang, or PL-FMP resin used to produce the peptide. This scale is not based on direct determination of the peptide quantification used in the method. All methods can be scaled up from the 0.05 mmol scale by adjusting the volumes listed by multiples of the scale. The crude peptide solid from the global deprotection was dissolved in DMF (30-45 mL) in a 50 mL centrifuge tube at room temperature, and DIEA (1.0-2.0 mL) was added to the solution. The pH of the reaction mixture was adjusted to 8. The solution was then shaken at room temperature for several hours, overnight, or 2-3 days. The reaction solution was concentrated to dryness using a speedvac or genevac EZ-2, and the crude residue was then dissolved in DMF or DMF / DMSO (2 mL). After filtration, the solution was subjected to single compound reverse phase HPLC purification to give the desired cyclic peptide.

[0470] Cyclization method B: Unless otherwise noted, all operations were performed manually. The procedure for "Cyclization Method B" describes experiments performed on a 0.05 mmol scale, where the scale is determined by the amount of Sieber, Rink, chlorotrityl, Wang, or PL-FMP resin used to produce the peptide. This scale is not based on direct determination of the peptide quantitation used in the method. All methods can be scaled up from the 0.05 mmol scale by adjusting the volumes listed by multiples of the scale. The crude peptide solid in a 50 mL centrifuge tube was dissolved in CH3CN / 0.1 M aqueous ammonium bicarbonate (1:1, v / v, 30-45 mL). The solution was then shaken at room temperature for several hours. The reaction solution was checked by pH paper and LCMS, and the pH could be adjusted to above 8 by adding 0.1 M aqueous ammonium bicarbonate (5-10 mL). After completion of the reaction based on the disappearance of the linear peptide by LCMS, the reaction was concentrated to dryness using a speedvac or genevac EZ-2. The resulting residue was added with CHCN:HO (2:3, v / v, 30 mL) and concentrated to dryness using a speedvac or genevac EZ-2. This procedure was repeated (usually twice). The resulting crude solid was then dissolved in DMF, DMF / DMSO, or CHCN / HO / formic acid. After filtration, the solution was subjected to single-compound reverse-phase HPLC purification to yield the desired cyclic peptide.

[0471] On-resin N-methylation Method A. To the resin (50 μmol) in a Bio-Rad tube was added CHCl (2 mL) and shaken for 5 min at rt. 2-Nitrobenzene-1-sulfonyl chloride (44.3 mg, 200 μmol, 4 equiv.) was added, followed by 2,4,6-trimethylpyridine (0.040 mL, 300 μmol, 6 equiv.). The reaction was shaken at rt for 2 h. The solvent was drained, and the resin was rinsed with CHCl (5 mL × 3), DMF (5 mL × 3), and then THF (5 mL × 3). THF (1 mL) was added to the resin. Triphenylphosphine (65.6 mg, 250 μmol, 5 equiv.), methanol (0.020 mL, 500 μmol, 10 equiv.), and diethyl azodicarboxylate or DIAD (0.040 mL, 250 μmol, 5 equiv.) were added. The mixture was shaken at RT for 2-16 h and the reaction was repeated. Triphenylphosphine (65.6 mg, 250 μmol, 5 equiv.), methanol (0.020 mL, 500 μmol, 10 equiv.), and diethyl azodicarboxylate or DIAD (0.040 mL, 250 μmol, 5 equiv.) were added. The mixture was shaken at RT for 1-16 h, the solvent was drained, and the resin was washed with THF (5 mL × 3) and CHCl3 (5 mL × 3). The resin was air-dried and used directly in the next step. The resin was shaken in DMF (2 mL). 2-Mercaptoethanol (39.1 mg, 500 μmol) was added, followed by DBU (0.038 mL, 250 μmol, 5 equiv.). The reaction was shaken for 1.5 h. The solvent was drained. The resin was washed with DMF (4×). It was air dried and used directly in the next step.

[0472] On-resin N-methylation Method B (Turner, RA et al., Org. Lett., 15(19): 5012-5015 (2013)). All operations were performed manually unless otherwise noted. The procedure for "On-resin N-methylation Method A" describes an experiment performed on a 0.100 mmol scale, where the scale is determined by the Sieber or Rink linker attached to the resin used to produce the peptide. This scale is not based on direct determination by quantitation of the peptide used in the method. All methods can be scaled up from the 0.10 mmol scale by adjusting the volumes listed by multiples of the scale. The resin was transferred to a 25 mL fritted syringe. Piperidine:DMF (20:80 v / v, 5.0 mL) was added to the resin. The mixture was shaken for 3 minutes, and then the solution was drained through the frit. The resin was washed three times with DMF (4.0 mL). To the reaction vessel was added piperidine:DMF (20:80 v / v, 4.0 mL). The mixture was shaken for 3 minutes, and then the solution was drained through the frit. The resin was washed successively three times with DMF (4.0 mL) and three times with DCM (4.0 mL). The resin was suspended in DMF (2.0 mL), ethyl trifluoroacetate (0.119 mL, 1.00 mmol), and l,8-diazabicyclo[5.4.0]undec-7-ene (0.181 mL, 1.20 mmol). The mixture was placed on a shaker for 60 minutes. The solution was drained through the frit. The resin was washed successively three times with DMF (4.0 mL) and three times with DCM (4.0 mL). The resin was washed three times with dry THF (2.0 mL) to remove any residual water. To an oven-dried 4.0 mL vial was added THF (1.0 mL) and triphenylphosphine (131 mg, 0.500 mmol) on dry 4 Å molecular sieves (20 mg). The solution was transferred to the resin, and diisopropyl azodicarboxylate (0.097 mL, 0.5 mmol) was slowly added. The resin was agitated for 15 min. The solution was drained through the frit, and the resin was washed three times with dry THF (2.0 mL) to remove any residual water. To an oven-dried 4.0 mL vial was added THF (1.0 mL), triphenylphosphine (131 mg, 0.50 mmol) on dry 4 Å molecular sieves (20 mg).The solution was transferred to the resin, and diisopropyl azodicarboxylate (0.097 mL, 0.5 mmol) was added slowly. The resin was stirred for 15 min. The solution was drained through a frit. The resin was washed successively three times with DMF (4.0 mL) and three times with DCM (4.0 mL). The resin was suspended in ethanol (1.0 mL), and THF (1.0 mL) and sodium borohydride (37.8 mg, 1.000 mmol) were added. The mixture was stirred for 30 min and drained. The resin was washed successively three times with DMF (4.0 mL) and three times with DCM (4.0 mL).

[0473] On-resin N-alkylation method A: A 3 mL THF solution of the alcohol corresponding to the alkylating group (0.046 g, 1.000 mmol), triphenylphosphine (0.131 g, 0.500 mmol), and DIAD (0.097 mL, 0.500 mmol) was added to the nosylated resin (0.186 g, 0.100 mmol), and the reaction mixture was stirred for 16 h at room temperature. The resin was washed three times with THF (5 mL) and tetrahydrofuran, and the above procedure was repeated 1 to 3 times. Reaction progress was monitored by TFA microcleavage of a small resin sample treated with a solution of 50 μL of TIS in 1 mL of TFA for 1.5 h.

[0474] On-resin N-alkylation method B: The nosylated resin (0.100 mmol) was washed three times with 3 mL of N-methylpyrrolidone (NMP). A solution of 3 mL of NMP, alkyl bromide (20 equiv., 2.000 mmol), and DBU (20 equiv., 0.301 mL, 2.000 mmol) was added to the resin, and the reaction mixture was stirred for 16 h at room temperature. The resin was washed with 3 mL of NMP, and the above procedure was repeated once more. Reaction progress was monitored by TFA microcleavage of a small resin sample treated with a solution of 50 μL of TIS in 1 mL of TFA for 1.5 h.

[0475] N-Nosylate Formation Method: A solution of collidine (10 equiv.) in DCM (2 mL) was added to the resin, followed by a solution of Nos-Cl (8 equiv.) in DCM (1 mL). The reaction mixture was stirred for 16 h at room temperature. The resin was washed three times with DCM (4 mL) and three times with DMF (4 mL). The alternating DCM and DMF washes were repeated three times, followed by a final set of four DCM washes (4 mL).

[0476] N-Nosylate Removal Method: The resin (0.100 mmol) was swelled using three washes with DMF (3 mL) and three washes with NMP (3 mL). A solution of NMP (3 mL), DBU (0.075 mL, 0.500 mmol), and 2-mercaptoethanol (0.071 mL, 1.000 mmol) was added to the resin, and the reaction mixture was stirred for 5 min at room temperature. After filtration and washing with NMP (3 mL), the resin was re-treated with a solution of NMP (3 mL), DBU (0.075 mL, 0.500 mmol), and 2-mercaptoethanol (0.071 mL, 1.000 mmol) for 5 min at room temperature. The resin was washed three times with NMP (3 mL), four times with DMF (4 mL), and four times with DCM (4 mL) and returned to the Symphony reaction vessel to complete the sequence assembly on the Symphony peptide synthesizer.

[0477] General method for preloading amine on PL-FMP resin: PL-FMP resin (Novabiochem, 1.00 mmol / g substitution) was swollen in DMF (20 mL / mmol) at room temperature. The solvent was drained, and 10 mL of DMF was added, followed by the addition of the amine (2.5 mmol) and acetic acid (0.3 mL) to the reaction vessel. After stirring for 10 minutes, sodium triacetoxyhydroborate (2.5 mmol) was added. The reaction was stirred overnight. The resin was washed with DMF (1x), THF / HO / AcOH (6:3:1) (2x), DMF (2x), and DCM (3x) and then dried. The resulting amine-preloaded PL-FMP resin was confirmed as follows: 100 mg of the resin was reacted with benzoyl chloride (5 equiv.) and DIEA (10 equiv.) in DCM (2 mL) at room temperature for 0.5 hours. The resin was washed with DMF (2x), MeOH (1x), and DCM (3x). The sample was then cleaved with 40% TFA / DCM (1 h). The product was collected and analyzed by HPLC and MS. The collected sample was dried and weighed for calculation of resin loading.

[0478] On-resin click reaction method A: This procedure describes an experiment performed on the 0.050 mmol scale. The volumes listed can be scaled up or down from the 0.050 mmol scale by adjusting the scale factor. The alkyne-containing resins (50 μmol each) were transferred to Bio-Rad tubes and swollen with DCM (2 × 5 mL × 5 min) followed by DMF (2 × 5 mL × 5 min). The following was added to a 200 mL bottle in 30-fold: vitamin C (0.026 g, 0.150 mmol), bis(2,2,6,6-tetramethyl-3,5-heptanedionato)copper(II) (10.75 mg, 0.025 mmol), DMF (1.5 mL), 2,6-lutidine (0.058 mL, 0.50 mmol), and THF (1.5 mL), followed by DIPEA (0.087 mL, 0.50 mmol) and tert-butyl azide. (S)-1-Azido-40-(tert-butoxycarbonyl)-37,42-dioxo-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36,41-diazanonapentacontan-59-oate (0.028 g, 0.025 mmol). The mixture was stirred until completely dissolved. The DMF from the Bio-Rad tubes was drained, and the above click solution (3 mL each) was added to each Bio-Rad tube. The tubes were shaken overnight on an orbital shaker. The solution was drained through the frit. The resin was washed with DMF (3 × 2 mL) and DCM (3 × 2 mL).

[0479] On-resin click reaction method B: This procedure describes an experiment performed on a 0.050 mmol scale. The volumes listed can be scaled up or down from the 0.050 mmol scale by adjusting the scale factor. The alkyne-containing resins (50 μmol each) were transferred to Bio-Rad tubes and swollen with DCM (2 × 5 mL × 5 min) followed by DMF (2 × 5 mL × 5 min). In a separate bottle, nitrogen was bubbled through 4.0 mL of DMSO for 15 min. To the DMSO was added copper iodide (9.52 mg, 0.050 mmol, 1.0 equiv.) (sonicated), lutidine (58 μL, 0.500 mmol, 10.0 equiv.), and DIEA (87 μL, 0.050 mmol, 10.0 equiv.). The solution was again purged with nitrogen. The DCM was drained through the frit. In a separate vial, ascorbic acid (8.8 mg, 0.050 mmol, 1.0 equiv.) was dissolved in water (600 μL). Nitrogen was bubbled through the solution for 10 minutes. The coupling partner (0.050 mmol–0.10 mmol, 1.0–2.0 equiv.) was dispensed into the tube, followed by the DMSO copper and base solutions, and finally the aqueous ascorbic acid solution. The solution was covered with a nitrogen blanket and capped. The tube was placed on a rotary mixer for 16 hours. The solution was drained through the frit. The resin was washed with DMF (3 × 2 mL) and DCM (3 × 2 mL).

[0480] On-resin Suzuki reaction: A BioRad tube was loaded with 50 μmole of dried Rink resin, an N-terminal Fmoc-protected linear polypeptide containing a 4-bromophenylalanine side chain. The resin was swollen in DMF (2 × 5 mL). To this was added a DMF solution (2 mL) of p-tolylboronic acid (0.017 g, 0.125 mmol), potassium phosphate (0.2 mL, 0.400 mmol), followed by the catalyst [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) [PdCl2(dtbpf)] (3.26 mg, 5.00 μmol). The tube was shaken overnight at RT, the solution was drained, and the resin was washed with DMF (5 × 3 mL), followed by alternating DCM (2 × 3 mL), then DMF (2 × 3 mL), then DCM (5 × 3 mL). A small sample of the resin was microcleaved using 235 μL of TIS in 1 ml TFA for 1 h at rt. The remainder of the resin was used for the next step of peptide coupling or N-terminal chloroacetic acid capping.

[0481] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid Scheme: [ka] Step 1: To a solution of (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(1H-indol-3-yl)propanoate (25.0 g, 58.3 mmol) and cesium carbonate (20.9 g, 64.2 mmol) in DMF (200 mL) at 0° C., tert-butyl 2-bromoacetate (9.36 mL, 64.2 mmol) was added. The solution was stirred for 18 h while slowly warming to RT. The reaction mixture was poured into ice water: 1N aqueous HCl (1:1) and then extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO4, filtered, and concentrated under reduced pressure. The resulting solid was subjected to flash chromatography (330 g column, 0-50% EtOAc:Hex over 20 column volumes) to afford (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoate as a white solid (29.6 g, 93%).

[0482] Step 2: H2 was slowly bubbled through a mixture of (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoate (29.6 g, 54.5 mmol) and Pd—C (1.45 g, 1.36 mmol) in MeOH (200 mL) at RT for 10 min. The mixture was then stirred under a positive pressure of H2 while monitoring the conversion by LCMS. After 48 h, the reaction mixture was filtered through diatomaceous earth and evaporated to give crude (S)-2-amino-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid (17.0 g), which was used in Step 3 without further purification.

[0483] Step 3: To a solution of (S)-2-amino-3-(1-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid (5.17 g, 16.2 mmol) and sodium bicarbonate (6.8 g, 81 mmol) in acetone:water (50.0 mL:100 mL) was added (9H-fluoren-9-yl)methyl (2,5-dioxopyrrolidin-1-yl)carbonate (5.48 g, 16.2 mmol). The mixture was stirred overnight, at which point LCMS analysis indicated complete conversion. The vigorously stirring mixture was acidified by the slow addition of 1N aqueous HCl. Once acidified, the mixture was diluted with DCM (150 mL), and the isolated organic phase was then washed with water, followed by brine. The organic layer was collected, dried over sodium sulfate, and evaporated to dryness to give the crude product. The crude material was purified by silica gel chromatography (330 g column, 20-80% EtOAc:Hex over 20 column volumes) to afford (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-(2-(tertbutoxy)-2-oxoethyl)-1H-indol-3-yl)propanoic acid as a white foam (7.26 g, 83%). 1 H NMR (500 MHz, methanol-d4) δ 7.80 (d, J = 7.6 Hz, 2H), 7.67 - 7.60 (m, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.32 - 7.22 (m, 3H), 7.18 (td, J = 7.6, 0.9 Hz, 1H), 7.08 (td, J = 7.5, 0.9 Hz, 1H), 7.04 (s, 1H), 4.54 (dd, J = 8.4, 4.9 Hz, 1H), 4.36 - 4.23 (m, 2H), 4.23 - 4.14 (m, 1H), 30 3.43 - 3.35 (m, 2H), 3.25 - 3.09 (m, 1H), 1.55 - 1.38 (m, 9H). ESI-MS(+) m / z = 541.3 (M + H).

[0484] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoic acid Scheme: [ka] Step 1: To a cooled, stirred solution of (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (70 g, 173 mmol) and KCO (35.8 g, 259 mmol) in DMF (350 mL) was added tert-butyl-2-bromoacetate (30.6 mL, 207 mmol) dropwise, and the resulting mixture was stirred at RT overnight. The reaction mixture was diluted with 10% brine solution (1000 mL) and extracted with ethyl acetate (2 × 250 mL). The combined organic layers were washed with water (500 mL), saturated brine solution (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a colorless gum. The crude compound was purified by flash column chromatography using 20% ​​ethyl acetate in petroleum ether as eluent to give a white solid (78 g, 85%).

[0485] Step 2: (S)-Benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoate (73 g, 140 mmol) was dissolved in MeOH (3000 mL) and purged with nitrogen for 5 minutes. Pd / C (18 g, 16.91 mmol) was added to the above purged mixture and stirred under 3 kg of hydrogen pressure for 15 hours. The reaction mixture was then filtered and cooled to 100°C. (登録商標) The mixture was filtered through a bed of hexane and washed with methanol (1000 mL). The filtrate was dried under reduced pressure to give a white solid (36 g, 87%).

[0486] Step 3: To a stirring solution of (S)-2-amino-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoic acid (38 g, 129 mmol) and sodium bicarbonate (43.2 g, 515 mmol) in water (440 mL) was added Fmoc-OSu (43.4 g, 129 mmol) dissolved in dioxane (440 mL) dropwise, and the resulting mixture was stirred at RT overnight. The reaction mixture was diluted with 1.5 N HCl (200 mL) and water (500 mL) and extracted with ethyl acetate (2 × 250 mL). The combined organic layers were washed with water (250 mL), saturated brine solution (250 mL), dried over NaSO, filtered, and concentrated to give a pale yellow gum. The crude compound was purified by column chromatography using 6% MeOH in chloroform as eluent to give a pale green gum. The gum was further triturated with petroleum ether to give an off-white solid (45g, 67%). 1 H NMR (400 MHz, DMSO-d6) δ 12.86 - 12.58 (m, 1H), 7.88 (d, J = 7.5 Hz, 2H), 7.73 - 7.61 (m, 3H), 7.58 - 7.47 (m, 1H), 7.44 - 7.27 (m, 4H), 7.18 (d, J = 8.5 Hz, 2H), 6.79 (d, J = 8.5 Hz, 2H), 4.57 (s, 2H), 4.25 - 4.10 (m, 4H), 3.34 (br s, 3H), 3.02 (dd, J = 13.8, 4.3 Hz, 1H), 2.81 (dd, J = 14.1, 10.5 Hz, 1H), 1.41 (s, 9H).

[0487] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxycarbonyl)phenyl)propanoic acid Scheme: [ka] Step 1: (S)-Benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (10 g, 24.66 mmol) was dissolved in DCM (100 mL) in a 250 mL multi-necked round-bottom flask under magnetic stirring with N2 evacuation. The reaction mixture was cooled to -40 °C, pyridine (5.49 mL, 67.8 mmol) was added slowly, and then stirred at the same temperature for 20 min. Subsequently, triflic anhydride (11.46 mL, 67.8 mmol) was added slowly at -40 °C and stirred at -40 °C for 2 h. The reaction mixture was quenched with water at -10 °C, and then citric acid solution (50 mL) was added. The organic layer was extracted with DCM and the separated organic layer was dried over anhydrous NaSO, filtered and then evaporated to give (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)propanoate (11.93 g, 22.20 mmol, 90% yield) as a pale yellow solid.

[0488] Process 2. The DMF solution (1500 mL) was purged with nitrogen for 10 minutes. To this was added sodium formate (114 g, 1676 mmol) and acetic anhydride (106 mL, 1123 mmol). Purging was continued and the mixture was cooled to 0° C. DIPEA (194 mL, 1111 mmol) was added and the reaction mixture was stirred for 1 hour at RT under a nitrogen atmosphere.

[0489] DMF (3200 mL) was added to a 10-liter autoclave, and the system was purged with nitrogen. Under nitrogen purging conditions, (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)propanoate (300 g, 558 mmol), lithium chloride (71 g, 1675 mmol), 1,3-bis(diphenylphosphino)propane (24.17 g, 58.6 mmol) were added, followed by palladium(II) acetate (12.9 g, 57.5 mmol). The solution prepared above was added to this reaction mixture, which was then heated at 80° C. for 16 hours.

[0490] The reaction mass was diluted with ethyl acetate and water. The phases were separated, and the ethyl acetate layer was washed with water and brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude material was loaded onto a torrent column and eluted with petroleum ether and ethyl acetate. The fractions from 30% to 65% ethyl acetate in petroleum ether were concentrated to give a cream-colored solid (300 g), which was dissolved in ethyl acetate (700 mL), and petroleum ether was added slowly. At approximately 20% ethyl acetate in petroleum ether, a white solid precipitated, which was filtered and washed with 20% ethyl acetate in petroleum ether to give a white solid (180 g, 74% yield).

[0491] Process 3. A 2000 mL multi-neck round-bottom flask was charged with (S)-4-(3-(benzyloxy)-2-(((benzyloxy)carbonyl)amino)-3-oxopropyl)benzoic acid (130 g, 300 mmol), dichloromethane (260 mL), and cyclohexane (130 mL). To the slurry reaction mixture was added BF3.OEt2 (3.80 mL, 30.0 mmol) at room temperature, followed by the slow addition of tert-butyl 2,2,2-trichloroacetimidate (262 g, 1200 mmol) over 30 minutes at room temperature. Upon addition, the slurry slowly began to dissolve, and by the end of the addition, it was completely dissolved. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with DCM, and the remaining solids were removed by filtration. The filtrate was concentrated and purified by flash chromatography. The crude material was purified using a 1.5 Kg silicycle column on Torrent. The product spot was eluted with a 15% ethyl acetate / petroleum ether mixture. The collected fractions were concentrated to give a colorless liquid (120 g, 82% yield).

[0492] Step 4. (S)-tert-Butyl 4-(3-(benzyloxy)-2-(((benzyloxy)carbonyl)amino)-3-oxopropyl)benzoate (200 g, 409 mmol) was dissolved in MeOH (4000 mL) and purged with N for 10 minutes. Pd / C (27.4 g, 25.7 mmol) was added. The reaction was shaken under H for 16 hours at room temperature. The reaction mass was filtered through a bed of Celite and the bed was washed with methanol. The resulting filtrate was concentrated to give a pale yellow solid. The resulting solid was stirred with a 5% methanol:diethyl ether mixture for 15 minutes, then filtered and dried under reduced pressure to give a pale yellow solid. Slurrying with 5% methanol in diethyl ether, stirring for 15 minutes, filtering, and drying gave (S)-2-amino-3-(4-(tert-butoxycarbonyl)phenyl)propanoic acid as a white solid (105 g, 97% yield). Analytical Condition E: Retention time = 0.971 min; ESI-MS(+) m / z [M+H] + : 266.2.

[0493] Process 5. (S)-2-Amino-3-(4-(tert-butoxycarbonyl)phenyl)propanoic acid (122 g, 460 mmol) was dissolved in acetone (1000 mL), followed by the addition of water (260 mL) and sodium bicarbonate (116 g, 1380 mmol). After cooling to 0 °C, Fmoc-OSu (155 g, 460 mmol) was added portionwise to the reaction mixture. After the addition was complete, the mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with dichloromethane (2 L), followed by the addition of water (1.5 L). The organic layer was washed with saturated citric acid solution, extracted, and the aqueous layer was extracted again with DCM. The combined organic layers were washed with 10% citric acid solution, brine solution, dried over Na2SO4, and evaporated to dryness. The resulting white solid was slurried with diethyl ether, filtered, and dried to give the desired product as a white solid (80 g, 35% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.87 (d, J = 7.5 Hz, 2H), 7.83 - 7.73 (m, 3H), 7.60 (t, J = 8.5 Hz, 2H), 7.51 - 7.24 (m, 7H), 4.26 - 4.11 (m, 4H), 3.45 - 3.27 (m, 4H), 3.17 (br dd, J = 13.8, 4.3 Hz, 1H), 2.94 (dd, J = 13.5, 11.0 Hz, 1H), 2.52 - 2.48 (m, 4H), 1.51 (s, 9H).

[0494] Preparation of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate Scheme: [ka] Process 1. To a solution of (R)-2-amino-3-chloropropanoic acid hydrochloride (125 g, 781 mmol) in a 1:1 mixture of acetone (1 L) and water (1 L) was added NaCO (182 g, 1719 mmol), followed by Fmoc-OSu (250 g, 742 mmol). The reaction was stirred at RT overnight. Extraction was performed with ethyl acetate (2 × 500 mL), and the aqueous layer was acidified with 5 N HCl. The HCl solution was extracted with ethyl acetate (1500 mL, then 2 × 500 mL). The combined organic layers were dried over anhydrous MgSO, filtered, and concentrated to give the crude product (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-chloropropanoic acid. The product (220 g) was used directly in the next step.

[0495] Process 2. A solution of (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-chloropropanoic acid (220 g, 636 mmol) in DCM (2 L) was cooled to −20° C. 2-Methylpropene (200 mL, 636 mmol) was bubbled into the solution for 15 min, then HSO (57.7 mL, 1082 mmol) was added and the mixture was stirred at RT overnight. To the reaction mixture was added water (500 mL). The layers were separated and the aqueous layer was extracted with DCM (2×500 mL). The combined organic layers were dried over anhydrous MgSO, filtered and evaporated. The crude material was purified by flash chromatography using petroleum ether and ethyl acetate as eluents. The desired fractions were combined and concentrated to give the product (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-chloropropanoate (83 g, 182 mmol, 29% yield).

[0496] Process 3. To a solution of (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-chloropropanoate (80 g, 199 mmol) in acetone (1000 mL) was added sodium iodide (119 g, 796 mmol) and the reaction was heated at reflux for 40 h. The acetone was removed by rotary evaporation and the crude product was diluted with water (1000 mL) and DCM (1000 mL). The layers were separated and the organic layer was washed with saturated aqueous sodium sulfite (1000 mL) and brine (1000 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The crude material was purified by flash chromatography using 7-9% ethyl acetate in petroleum ether. The desired product fractions were combined and concentrated to give the product (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (83 g, 156 mmol, 79%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.45 - 7.30 (m, 4H), 5.67 (br d, J = 7.0 Hz, 1H), 4.54 - 4.32 (m, 3H), 4.30 - 4.21 (m, 1H), 3.71 - 3.50 (m, 2H), 1.56 - 1.48 (m, 9H).

[0497] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methyl-1H-indol-3-yl)propanoic acid [ka] Step 1: To a 100 mL three-neck, flame-dried, nitrogen-purged round-bottom flask, zinc (2.319 g, 35.5 mmol) was added under an argon atmosphere, and the flask was heated to 150 °C using a hot gun and purged with argon. DMF (50 mL) was added to the reaction flask, followed by 1,2-dibromoethane (0.017 mL, 0.20 mmol) and TMS-Cl (0.026 mL, 0.20 mmol) under an argon atmosphere, and then stirred for 10 minutes. To the reaction mixture, (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (5 g, 10.14 mmol) was added, and the reaction was stirred for 1 hour. The reaction progress was monitored by TLC and LCMS until complete conversion of the starting iodide to the Zn complex. The organozinc reagent solution was cooled to room temperature, followed by the addition of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) (0.23 g, 0.25 mmol), dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (SPhos) (0.21 g, 0.51 mmol), and tert-butyl 3-bromo-2-methyl-1H-indole-1-carboxylate (3.77 g, 12.16 mmol). The reaction mixture was stirred at RT under a positive pressure of nitrogen for 1 h and then heated at 50 °C for 6 h. The reaction progress was monitored by LCMS. The mixture was diluted with EtOAc (700 mL) and filtered through Celite. The organic phase was washed with saturated NH4Cl (250 mL), water (2 × 200 mL), and saturated NaCl(aq) (250 mL), dried over anhydrous Na2SO4, concentrated, and dried under reduced pressure to give the crude compound (19 g). Purification was performed by ISCO flash chromatography using a 330 g Redisep column, eluting the product with 7–9% ethyl acetate in petroleum ether. The above reaction and purification were repeated. Concentration of pure fractions gave tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-3-oxopropyl)-2-methyl-1H-indole-1-carboxylate as a brownish solid (10.2 g, 95% purity, approximately 80% yield).Analysis conditions G: retention time = 4.23 min; ESI-MS(+) m / z [M+2H][M-Boc-tBu+H]. + : 441.2.

[0498] Process 2. To a 25 ml multi-neck, round-bottom flask was added DCM (65 mL) followed by (S)-tert-butyl 3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-3-oxopropyl)-2-methyl-1H-indole-1-carboxylate (6.5 g, 10.89 mmol) at RT under a nitrogen atmosphere. The reaction mixture was cooled to 0° C. and triethylsilane (4.18 mL, 26.1 mmol) was added, followed by the dropwise addition of TFA (5.87 mL, 76 mmol) at 0° C. The reaction mixture was slowly allowed to reach RT and stirred at RT for 4 h. The reaction progress was monitored by TLC. To the reaction mixture was added TFA (5.87 mL, 76 mmol). The reaction mixture was stirred at RT overnight and concentrated under reduced pressure. The crude material was triturated with hexane and stored in a refrigerator to give a brown solid (crude weight: 6.5 g). Purification by reverse-phase flash chromatography and concentration of pure fractions gave the desired final product as an off-white powder (2.3 g, 46%). 1 H NMR(DMSO-d6): δ ppm: 10.65 (s, 1H), 7.84(d, J = 9.12 Hz, 2H),7.65 (d, J = 9.12 Hz, 2H), 7.42-7.49 (m, 1H), 7.30-7.38 (m, 2H), 7.26-7.29 (m, 2H), 7.17-7.19 (m, 2H), 6.91-6.95 (m, 1H), 6.85-6.88 (t, J = 7.85 Hz, 1H), 4-16-4.18(m, 2H), 4.01-4.06 (m, 1H), 3.09-3.14 (m, 1H), 2.96-2.99 (m, 1H), 2.50 (s, 3H). Analysis conditions F: Retention time = 1.37 minutes; ESI-MS(+) m / z [M+2H][M+H] + : 441.2.

[0499] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(7-methyl-1H-indol-3-yl)propanoic acid [ka] Step 1: A 50 ml round-bottom flask was charged with dry zinc (0.928 g, 14.19 mmol) and flushed with argon three times. The flask was then heated to 150 °C for 5 min, then cooled to room temperature and flushed with argon three times. DMF (20 mL) was added, followed by 1,2-dibromoethane (6.99 μL, 0.081 mmol) and TMS-Cl (0.013 mL, 0.10 mmol). Successful zinc insertion was accompanied by a noticeable exotherm. After 5 min, (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (2.0 g, 4.05 mmol) was added, and the reaction was stirred for 30 min. In a 50 mL round-bottom flask under argon, the above alkylzinc reagent, tert-butyl 3-bromo-7-methyl-1H-indole-1-carboxylate (1.26 g, 4.05 mmol), was added, followed by 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) (0.083 g, 0.20 mmol) and Pd2(dba)3 (0.093 g, 0.101 mmol). After the addition, the reaction mixture was heated at 50 °C overnight. Additional equivalents of SPhos and Pd2(dba)3 were added, and heating was continued for an additional 16 h. The reaction mixture was diluted with EtOAc (100 mL) and filtered through Celite. The organic phase was washed with saturated aqueous NH4Cl (100 mL), water (50 mL), and saturated NaCl (100 mL), dried over anhydrous Na2SO4, concentrated, and dried under reduced pressure. After purification by flash chromatography, the desired tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-3-oxopropyl)-2-methyl-1H-indole-1-carboxylate was obtained in 58% yield.

[0500] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methyl-1H-indol-3-yl)propanoic acid. TFA hydrolysis with triethylsilane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(7-methyl-1H-indol-3-yl)propanoic acid as an off-white solid in 64% yield after purification by reverse-phase flash chromatography. Analytical condition E: retention time = 2.16 min; ESI-MS(+) m / z [M+H] + : 441.1. 1 H NMR (300 MHz, DMSO-d6) Shift 12.70 (br s, 1H), 10.81 (br s, 1H), 7.88 (d, J = 7.6 Hz, 2H), 7.76 - 7.56 (m, 2H), 7.49 - 7.21 (m, 5H), 7.17 (d, J = 2.3 Hz, 1H), 6.94 - 6.84 (m, 2H), 4.29 - 4.13 (m, 3H), 4.07 (br s, 1H), 3.19 (br dd, J = 14.7, 4.5 Hz, 1H), 3.01 (br dd, J = 14.5, 9.6Hz, 1H), 2.47 - 2.40 (m, 3H), 0.02 - -0.06 (m, 1H).

[0501] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(quinolin-6-yl)propanoic acid [ka] Step 1: A 25 ml round-bottom flask was charged with dry zinc (2.32 g, 35.5 mmol) and flushed with argon three times. The flask was heated to 150 °C for 5 minutes, then cooled to room temperature and flushed with argon three times. DMF (50 mL) was added, followed by 1,2-dibromoethane (0.017 mL, 0.20 mmol) and TMS-Cl (0.032 mL, 0.25 mmol). Successful zinc insertion was accompanied by a noticeable exotherm. After 5 minutes, (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (5.0 g, 10.14 mmol) was added, and the reaction was stirred for 30 minutes.

[0502] To an argon-purged 250 mL round-bottom flask was added DMF (50 mL), 6-bromoquinoline (2.53 g, 12.16 mmol), the previously prepared alkylzinc reagent solution, (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (5.0 g, 10.14 mmol), followed by 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (RuPhos) (0.24 g, 0.51 mmol) and Pd2(dba)3 (0.23 g, 0.25 mmol). The reaction mixture was stirred at rt for 5 h and then heated at 50 °C for 16 h. It was cooled to rt, filtered through Celite, and rinsed with ethyl acetate. The solution was concentrated by rotary evaporation. Purification by flash chromatography afforded the desired compound as a thick brown liquid in quantitative yield. Analytical condition E: retention time = 3.47 min; ESI-MS(+) m / z [M+H] + : 495.2. Process 2.

[0503] The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methyl-1H-indol-3-yl)propanoic acid. TFA hydrolysis with triethylsilane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(quinolin-6-yl)propanoic acid as a beige solid in 40% yield after solid-liquid extraction with diethyl ether and water. 1 H NMR (300 MHz, DMSO-d6) δ 8.94 (br d, J = 4.5 Hz, 1H), 8.49 (d, J = 8.7 Hz, 1H), 8.01 - 7.92 (m, 2H), 7.85 - 7.79 (m, 3H), 7.65 (dd, J = 8.3, 4.5 Hz, 1H), 7.55 (dd, J = 7.2, 4.2 Hz, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.26 - 7.14 (m, 2H), 4.32 (dd, J = 10.6, 4.5 Hz, 1H), 4.18 - 4.08 (m, 3H), 3.38 - 3.29 (m, 2H), 3.11 (br d, J = 10.6 Hz, 1H), 2.72 (s, 1H), 1.07 (t, J = 7.0 Hz, 1H), -0.02 (s, 1H). Analysis condition E: retention time = 1.54 min; ESI-MS(+) m / z [M+H] + : 439.0.

[0504] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-6-yl)propanoic acid [ka] Step 1: Zinc (1.392 g, 21.28 mmol) was added to a 50 mL three-neck, flame-dried, round-bottom flask under an argon atmosphere, and the flask was heated to 150 °C using a hot gun and purged with argon. DMF (30 mL) was added to the reaction, followed by 1,2-dibromoethane (10.48 μL, 0.12 mmol) and TMS-Cl (0.016 mL, 0.12 mmol) under argon. The reaction was stirred for 10 min. (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (3.0 g, 6.08 mmol) was added to the reaction mixture, and the reaction was stirred for 1 h. To the reaction mixture was added 6-bromoisoquinoline (1.52 g, 7.30 mmol) and bis-(triphenylphosphino)-palladium chloride (0.20 g, 0.30 mmol), and the reaction was stirred for 16 hours. The reaction mixture was diluted with ethyl acetate (50 mL), filtered through Celite, and washed with ethyl acetate (50 mL). The filtrate was concentrated under reduced pressure to give the crude product as a thick red gum. The crude product was purified by flash chromatography using 40–42% EtOAc in petroleum ether. After concentration by rotary evaporation, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-6-yl)propanoate (2.0 g, 66%) was obtained as a yellow gum. Analysis condition B: retention time = 2.46 min; ESI-MS(+) m / z [M+H] + : 495.3. Process 2.

[0505] The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methyl-1H-indol-3-yl)propanoic acid. TFA hydrolysis with triethylsilane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-6-yl)propanoic acid as a gray solid in 90% yield after recrystallization with EtOAc and hexanes. 1H NMR (400 MHz, methanol-d4) δ 9.55 (s, 1H), 8.46 (d, J = 6.5 Hz, 1H), 8.33 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 6.0 Hz, 1H), 8.08 (s, 1H), 7.99 - 7.86 (m, 1H), 7.78 (dd, J = 7.5, 4.0 Hz, 2H), 7.66 - 7.48 (m, 2H), 7.43 - 7.30 (m, 2H), 7.30 - 7.17 (m, 2H), 4.68 (dd, J = 10.0, 4.5 Hz, 1H), 4.32 - 4.13 (m, 2H), 4.12 - 3.84 (m, 1H), 3.61 (dd, J = 13.8, 4.8 Hz, 1H), 3.32 - 3.26 (m, 1H), 1.46 (s, 1H). Analysis condition B: retention time = 2.77 min; ESI-MS(+) m / z [M+H] + : 439.2.

[0506] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-4-yl)propanoic acid [ka] Step 1: To a stirring mixture of zinc (2.319 g, 35.5 mmol) in DMF (50 mL) was added dibromomethane (0.071 mL, 1.014 mmol) and TMS-Cl (0.130 mL, 1.014 mmol). An exotherm was observed. The reaction mixture was stirred for 10 min. (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (5 g, 10.14 mmol) was added, and again an exotherm was observed. The reaction was stirred for 1 h at room temperature. 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.21 g, 0.51 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.23 g, 0.25 mmol), and 4-bromoisoquinoline (2.11 g, 10.14 mmol) were added sequentially, and the reaction was heated at 50 °C for 16 h. The reaction mixture was cooled to rt and treated with saturated ammonium chloride solution (200 mL). The crude product was diluted with ethyl acetate (300 mL). The layers were separated, and the organic layer was washed with brine and dried over anhydrous sodium sulfate. After filtration and concentration, the crude product was purified by flash chromatography eluting with 30% ethyl acetate in petroleum ether to give tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-4-yl)propanoate (2.5 g, 50%).

[0507] Analysis condition E: retention time = 3.44 min; ESI-MS(+) m / z [M+H] + : 495.2.

[0508] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methyl-1H-indol-3-yl)propanoic acid. TFA hydrolysis afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-4-yl)propanoic acid as an off-white solid in quantitative yield after purification by diethyl ether trituration. 1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 8.52 (s, 1H), 8.44 - 8.24 (m, 2H), 8.18 - 8.00 (m, 1H), 7.95 - 7.80 (m, 4H), 7.59 (br d, J = 7.5 Hz, 1H), 7.56 (br d, J = 7.5 Hz, 1H), 7.47 - 7.34 (m, 2H), 7.34 - 7.24 (m, 2H), 4.46 - 4.30 (m, 1H), 4.25 - 4.02 (m, 3H), 3.69 (dd, J = 14.1, 4.5 Hz, 1H), 3.37 (dd, J = 14.1, 10.5 Hz, 1H), 0.10 -0.11 (m, 1H). Analysis condition E: retention time = 1.57 min; ESI-MS(+) m / z [M+H] + : 441.2.

[0509] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3,5-difluorophenyl)propanoic acid [ka] Step 1: The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-4-yl)propanoate. First, Negishi coupling with methyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate at 50 °C gave the desired methyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-2,6-difluorophenyl)propanoate (5.5 g, 48.5% yield) after purification by flash chromatography.

[0510] Analysis condition E: retention time = 3.99 min; ESI-MS(+) m / z [M+NH4] + : 527.2.

[0511] Process 2. In a multi-necked round-bottom flask, methyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3,5-difluorophenyl)propanoate (11 g, 21.59 mmol) was added, followed by tetrahydrofuran (132 mL) at RT under a nitrogen atmosphere. The reaction mixture was cooled to 0 °C, and a solution of LiOH (1.09 g, 45.3 mmol) in water (132 mL) was added. The reaction was stirred for 3 h. The solvent was removed by concentration under reduced pressure below 38 °C. The crude compound was cooled to 0 °C, and saturated citric acid solution was added to adjust the pH to 4-5. It was extracted with ethyl acetate (3 × 250 mL). The combined organic layer was washed with water (200 mL), followed by brine (200 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product (12 g) as a thick, colorless mass. The crude compound was purified by ISCO using a 120 g redisep column, and the product was eluted with 20% ethyl acetate in petroleum ether. The reaction was concentrated to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3,5-difluorophenyl)propanoic acid (9.0 g, 82%, HPLC purity 97%) as a white fluffy solid. Analytical condition E: retention time = 3.62 min; ESI-MS(+) m / z [M+H] + : 513.2. 1 H NMR (CDCl3, 400 MHz) d 7.75 (d, J = 7.6 Hz, 2H), 7.60 (m, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.30 (m, 2H), 6.71 (d, J = 7.6 Hz, 2H), 5.26 (m, 1H), 4.65 (m, 1H), 4.48 - 4.38 (m, 2H), 4.20 (m, 1H), 3.14 - 2.99 (m, 1H), 1.35 (s, 9H).

[0512] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-8-yl)propanoic acid [ka] Step 1: Zinc (0.79 g, 12.00 mmol) was added to a flame-dried, nitrogen-purged round-bottom flask with a sidearm. DMF (5 mL) was added via syringe, followed by a catalytic amount of iodine (0.16 g, 0.63 mmol). A color change of DMF from colorless to yellow and back again was observed. Protected (R)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (1.97 g, 4.00 mmol) was added immediately, followed by a catalytic amount of iodine (0.16 g, 0.63 mmol). The solution was stirred at room temperature; successful zinc insertion was accompanied by a noticeable exotherm. The organozinc reagent solution was cooled to room temperature, followed by the sequential addition of Pd(dba) (0.088 g, 0.096 mmol), dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (0.082 g, 0.200 mmol), and 8-bromoisoquinoline (1.082 g, 5.20 mmol). The reaction mixture was stirred at 50 °C under a positive nitrogen pressure for 4 h. The reaction mixture was cooled to rt, diluted with EtOAc (200 mL), and passed through Celite. The organic solvent was washed with saturated aqueous NHCl (200 mL), water (150 mL), and saturated aqueous NaCl (200 mL), dried over NaSO, concentrated, and dried under reduced pressure to give the crude compound. Purification using ISCO combiflash column chromatography (24 g silica gel column, hexane / ethyl acetate as eluent) gave (S)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-8-yl)propanoate (380 mg, 0.768 mmol, 19.21% yield). Analytical condition G: retention time = 2.59 min; ESI-MS(+) m / z [M+H] + : 495.3.

[0513] Process 2. (S)-tert-Butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-8-yl)propanoate (380 mg, 0.768 mmol) was placed in a 50 ml round-bottom flask and dissolved in DCM (8 mL). Triethylsilane (0.31 mL, 1.92 mmol) was added, followed by trifluoroacetic acid (2.66 mL, 34.6 mmol). The reaction mixture was stirred at room temperature for 5 hours. The solvent was evaporated, and the residue was dissolved in diethyl ether. The product was precipitated by the addition of petroleum ether. The resulting powder was then triturated with petroleum ether to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-8-yl)propanoic acid (320 mg, 0.712 mmol, 93% yield) as an off-white solid. 1 H-NMR: (400 MHz, DMSO-d6) δ ppm: 12.98 (bs, 1H), 9.79 (s, 1H), 8.62 (d, J = 9.42 Hz, 1H), 8.22 (d, J = 9.42 Hz, 1H), 8.06 (d, J = 9.42 Hz, 1H), 7.84-7.93 (m, 4H), 7.74-7.76 (m, 1H), 7.56-7.58 (m, 1H), 7.38-7.42 (m, 2H), (m, 3H), 7.26-7.30 (m, 2H), 4.41 (m, 1H), 4.10-4.15 (m, 3H), 3.731-3.66 (m, 1H), 3.47-3.50 (m, 1H). Analysis condition G: retention time = 2.012 min; ESI-MS(+) m / z [M+H] + : 439.2 and 97.5% purity.

[0514] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(7-fluoro-1H-indol-3-yl)propanoic acid [ka] Step 1. Synthesis of tert-butyl 6-fluoro-3-iodo-1H-indole-1-carboxylate from 6-fluoro-1H-indole: A solution of iodine (3.76 g, 14.80 mmol) in DMF (15 mL) was added dropwise to a solution of 6-fluoro-1H-indole (2 g, 14.80 mmol) and potassium hydroxide (2.076 g, 37.0 mmol) in DMF (15 mL) at room temperature, and the mixture was stirred for 45 minutes. The reaction mixture was then poured into 200 mL of ice water containing 0.5% ammonia and 0.1% sodium disulfite. The mixture was placed in a refrigerator to ensure complete precipitation. The precipitate was filtered, washed with 100 mL of ice water, and dried under reduced pressure to yield 3.80 g. The solid was suspended in dichloromethane (25 mL). 4-Dimethylaminopyridine (160 mg, 10 mol%) and di-tert-butyl dicarbonate (4.84 g, 22.20 mmol) were dissolved in dichloromethane (15 mL) and added to the reaction. The resulting mixture was stirred for 30 minutes at room temperature, washed with 0.1 N HCl (25 mL), and the aqueous phase was extracted with dichloromethane (3 × 35 mL, monitored by TLC). The combined organic layer was dried over sodium sulfate, and the solvent was removed under reduced pressure to give tert-butyl 6-fluoro-3-iodo-1H-indole-1-carboxylate (4.16 g, 11.52 mmol, 78% yield) as an orange solid. 1 H-NMR(CDCl3) δ ppm: 7.82 (d, J = 8.23 ​​Hz, 1H), 7.68(s 1H), 7.30-7.34 (m, 1H), 7.03-7.08 (m, 1H), 1.66 (s, 9H)

[0515] Process 2. The compound was prepared following the same method as (S)-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-8-yl)propanoate. First, Negishi coupling at 50 °C gave the desired tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-3-oxopropyl)-7-fluoro-1H-indole-1-carboxylate (690 mg, 1.149 mmol, 57.4% yield) after purification by flash chromatography.

[0516] Analysis conditions H: retention time = 3.885 minutes; ESI-MS(+) m / z [M-Boc-tBu+H] + : 445.2

[0517] Process 3 The final product was obtained following the same method as (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(isoquinolin-8-yl)propanoic acid. TFA hydrolysis afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(7-fluoro-1H-indol-3-yl)propanoic acid as an off-white powder (96 mg, 0.191 mmol, 16.63% yield) after purification by reverse-phase preparative HPLC (column: 80 g size, Silisep C18, 19 x 150 mm, 5 μm; mobile phase: A = 10 mM aqueous ammonium acetate, B = MeOH; 15 mL / min flow gradient: 0-20 min, 5-30% B, 20-55 min, 30-80% B, 55-60 min, 80-100% B, 5 min hold at 100% B; compound eluted at 5% B) followed by lyophilization.

[0518] Analysis conditions F: retention time = 1.367 minutes; ESI-MS(+) m / z [M+H] + : 445.3. 1H-NMR (400 MHz, DMSO-d6) δ ppm: 11.22 (s, 1H), 7.86 (d, J = 8.72 Hz, 2H), 7.62-7.65 (m, 1H), 7.52-7.55 (m, 3H), 7.40-7.42 (m, 2H), 7.26-7.38 (m, 2H), 6.78-6.83 (m, 2H), 4.12-4.21 (m, 4H), 3.15-3.18 (m, 1H), 2.97-3.03(m, 1H).

[0519] Preparation of (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)butanoic acid [ka] The compound (2S,3S)-2-azido-3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)butanoic acid was prepared by the method described in Tetrahedron Letters 2001, 42, 4601-4603. The azide reduction step used different conditions, detailed below.

[0520] Step 1: To a solution of (2S,3S)-2-azido-3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)butanoic acid (1000 mg, 2.90 mmol) in THF (58 mL) was added platinum(IV) oxide (132 mg, 0.58 mmol). The reaction mixture was evacuated and filled with hydrogen. The reaction mixture was stirred at room temperature with a hydrogen balloon for 2 hours. The reaction mixture was evacuated and backfilled with nitrogen three times. The solution was filtered through a Celite pad. (登録商標) The solvent was removed under reduced pressure and the crude residue was redissolved in EtOH. This solution was passed through a pad of Celite. (登録商標) Filtration through filtration gave a clear solution which was concentrated under reduced pressure (0.89 g, 96% yield). 1H NMR (400 MHz, methanol-d4) δ 8.13 (br d, J = 8.0 Hz, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.61 (s, 1H), 7.46 - 7.18 (m, 2H), 4.89 (s, 2H), 3.80 (d, J = 6.5 Hz, 1H), 3.58 (t, J = 7.2 Hz, 1H), 1.68 (s, 9H), 1.53 (d, J = 7.3 Hz, 3H). Analysis condition B: retention time = 0.93 min; ESI-MS(+) m / z [M+H] + : 319.1.

[0521] Process 2. To a solution of (2S,3S)-2-amino-3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)butanoic acid (3.96 g, 12.44 mmol) in MeOH (25 mL) was added (9H-fluoren-9-yl)methyl 2,5-dioxopyrrolidine-1-carboxylate (888 mg, 2.76 mmol), followed by EtN (0.385 mL, 2.76 mmol). The reaction was stirred for 2 h at room temperature. The solvent was removed under reduced pressure, and the residue was redissolved in EtOAc and 1 N aqueous HCl, then washed with brine. The organic layer was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the desired product (1.3 g, 89% yield), which was not further purified. 1 H NMR (500 MHz, DMSO-d6) δ 12.78 (br s, 1H), 8.07 - 7.80 (m, 2H), 7.76 - 7.48 (m, 4H), 7.46 - 7.15 (m, 6H), 5.75 (s, 1H), 4.44 (t, J = 8.2 Hz, 1H), 4.33 - 4.22 (m, 1H), 4.19 - 4.07 (m, 2H), 1.56 (s, 9H), 1.39 - 1.27 (m, 3H). Analysis condition B: retention time = 1.27 min; ESI-MS(+) m / z [M+H] + : Not observed.

[0522] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-(o-tolyl)pyridin-3-yl)propanoic acid [ka] Step 1: To a stirring solution of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-bromopyridin-3-yl)propanoate (1750 mg, 3.35 mmol) in toluene / iPrOH (1:1, v:v, 50 mL) was added o-tolylboronic acid (911.6 mg, 6.7 mmol) and 2 M aqueous NaCO (25.0 mL). The mixture was purged with argon three times. Dichlorobis(tricyclohexylphosphine)palladium(II) (123.6 mg, 0.167 mmol) was added, and the reaction mixture was purged with argon twice. The reaction was heated at 80 °C for 20 h. The reaction was cooled to room temperature, and iPrOH was removed by rotary evaporation. The crude material was partitioned between water and EtOAc. The aqueous phase was extracted with EtOAc. The organic phases were combined and dried over anhydrous MgSO. After filtration and concentration, the crude product was obtained as a brown oil. Purification by flash chromatography using EtOAc:DCM (1:9) as the eluent afforded tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-(o-tolyl)pyridin-3-yl)propanoate (1.81 g, 3.39 mmol, 90%) as a colorless oil.

[0523] Process 2. (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-(o-tolyl)pyridin-3-yl)propanoate (1750 mg, 3.19 mmol) was dissolved in trifluoroacetic acid (5.00 mL) and the reaction was stirred at room temperature for 2 hours. The reaction was rotary evaporated to dryness and the crude product was dissolved in diethyl ether and 1 M HCl in diethyl ether. The mixture was sonicated for 2 hours to give a white solid. The product was isolated by filtration and washed with water to give (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-(o-tolyl)pyridin-3-yl)propanoic acid (1.91 g, 3.99 mmol, 100%) as a white solid. 1 H NMR (499 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.48 (br d, J = 8.0 Hz, 1H), 7.96 (t, J = 6.9 Hz, 2H), 7.89 (d, J = 7.5 Hz, 2H), 7.64 (dd, J = 7.2, 4.8 Hz, 2H), 7.52 - 7.45 (m, 1H), 7.43 - 7.29 (m, 7H), 4.46 (ddd, J = 10.7, 8.9, 4.5 Hz, 1H), 4.25 - 4.15 (m, 3H), 3.45 - 3.34 (m, 1H), 3.18 - 3.10 (m, 1H), 3.08 - 3.00 (m, 1H), 2.27 - 2.20 (m, 3H).

[0524] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-acetamido-[1,1'-biphenyl]-4-yl)propanoic acid [ka] Step 1: A 5.0 L multi-necked round-bottom flask was charged with (S)-2-amino-3-(4-bromophenyl)propanoic acid (150.0 g, 615 mmol), a solution of Fmoc-OSu (207 g, 615 mmol) in acetone (1500 mL), and a solution of sodium bicarbonate (258 g, 3073 mmol) in water (3000 mL) in one lot and stirred at room temperature for 16 hours. The reaction mixture was slowly acidified to pH 1 with 10 N HCl solution and stirred for 15 minutes. The slurry was filtered and dried under reduced pressure, and the cake was washed with water (3.0 L). The solid was dried for 16 hours. The desired product was obtained as a white solid (280 g, 98%) and used in the next step. Analysis condition E: retention time = 2.17 min; ESI-MS (+) m / z [M+H] + : 466.2.

[0525] Process 2. In a 150 ml pressure tube, a stirred solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-bromophenyl)propanoic acid (1.0 g, 2.144 mmol) and (4-acetamidophenyl)boronic acid (0.576 g, 3.22 mmol) in THF (50 mL) was purged with argon for 5 minutes. Potassium phosphate tripotassium (1.366 g, 6.43 mmol) was then added, and the purging continued for an additional 5 minutes. 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (0.140 g, 0.214 mmol) was then added, and the purging continued for an additional 5 minutes. The reaction mixture was heated at 65° C. for 26 hours. The reaction mass was diluted with EtOAc (25 mL) and washed with 10% aqueous citric acid (10 mL) followed by brine to give the crude product. Triturated with 20% DCM, stirred for 10 minutes, filtered through a Buchner funnel, and then dried for 10 minutes. The crude was purified by flash chromatography to give 0.7 g (57%) of the desired product as a brown solid. Analytical condition E: retention time = 1.79 minutes; ESI-MS (+) m / z [M+H] + : 519.0. 1H NMR (400 MHz, DMSO-d6) δ 12.75 (br s, 1H), 9.99 (s, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.77 - 7.49 (m, 9H), 7.47 - 7.22 (m, 7H), 4.26 - 4.13 (m, 4H), 3.11 (br dd, J = 13.8, 4.3 Hz, 1H), 2.91 (dd, J = 13.8, 10.8 Hz, 1H), 2.12 - 2.01 (m, 4H).

[0526] [ka] General method for Suzuki-Miyaura coupling (SMC) reaction in Scheme 1. To a N2-flushed 20 mL scintillation vial equipped with a magnetic stir bar was added Fmoc-halo-Phe-OH (0.5 mmol), boronic acid (1.5–2.5 equiv.), and anhydrous THF (6 mL). The suspension was degassed by bubbling N2 through the vial for several minutes. Palladium(II) acetate (4.5 mol%), DtBuPF (5 mol%), and then anhydrous K3PO4 (2.5 equiv.) were added. The suspension was degassed for several minutes, and then the vial was capped with a septum. The reaction mixture was stirred at 50 °C for 16 h. After cooling, 20% aqueous citric acid was added to acidify the reaction. The organic layer was separated, and the aqueous layer was extracted with EtOAc (2x). Silica gel was added to the combined organic layer, and the mixture was concentrated to dryness. The residue was dry-loaded onto a silica gel column (ISCO system) and eluted with hexane / EtOAc to give the desired product. For compounds that do not react in the hexane / EtOAc system, further elution with MeOH / CH2Cl2 may be necessary.

[0527] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-(tert-butoxycarbonyl)-[1,1'-biphenyl]-4-yl)propanoic acid [ka] (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-(tert-butoxycarbonyl)-[1,1'-biphenyl]-4-yl)propanoic acid was prepared according to the SMC general method. Yield: 78% (439 mg); colorless solid. 1 H NMR (400 MHz, methanol-d4) δ 7.94 (d, J = 8.3 Hz, 2H), 7.74 (d, J = 7.6 Hz, 2H), 7.56 (d, J = 8.4 Hz, 4H), 7.51 (d, J = 8.1 Hz, 2H), 7.38 - 7.28 (m, 4H), 7.28 - 7.17 (m, 2H), 4.56 - 4.38 (m, 1H), 4.29 (dd, J = 10.5, 7.0 Hz, 1H), 4.17 (dd, J = 10.5, 7.1 Hz, 1H), 4.08 (t, J = 7.0 Hz, 1H), 3.29 - 3.21 (m, 1H), 2.98 & 2.80 (dd, J = 13.8, 9.6 Hz, total 1H), 1.59 (s, 9H). ESI-HRMS: C 35 H 34 NO6[M + H] + The calculated value was 564.23806, found 564.23896, mass difference 1.588 ppm.

[0528] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3'-(tert-butoxycarbonyl)-[1,1'-biphenyl]-4-yl)propanoic acid [ka] (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-(tert-butoxycarbonyl)-[1,1'-biphenyl]-4-yl)propanoic acid was prepared according to the SMC general method. Yield: 85% (240 mg); off-white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.08 (t, J = 1.8 Hz, 1H), 7.86 (dd, J = 7.7, 1.4 Hz, 3H), 7.83 (d, J = 8.1 Hz, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.58 - 7.48 (m, 3H), 7.41 - 7.35 (m, 2H), 7.31 (d, J = 7.8 Hz, 2H), 7.30 - 7.23 (m, 2H), 4.31 - 4.10 (m, 4H), 4.05 (td, J = 8.2, 4.5 Hz, ESI-HRMS: C 35 H 37 N2O6[M + NH4] + The calculated value was 581.26461, the measured value was 581.26474, the mass difference was 0.218 ppm.

[0529] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-boronophenyl)propanoic acid (ELN: A0934-595-01) [ka] A 75 mL pressure bottle was charged with (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-bromophenyl)propanoic acid (6.0 g, 12.87 mmol) and 2-methyl-THF (250 mL), and the solution was purged with argon for 5 minutes. Tri-o-tolylphosphine (0.31 g, 1.03 mmol), tetrahydroxydiboron (2.31 g, 25.7 mmol), and potassium acetate (3.79 g, 38.6 mmol) were all added at 10 minute intervals, followed by MeOH (100 mL) and Pd(OAc) (0.12 g, 0.52 mmol), and the solution was purged with argon for 10 minutes. The reaction was heated at 50 °C overnight. The reaction mixture was transferred to a 1 L separatory funnel, diluted with 2-methyl-THF, and acidified to pH = 2 with 1.5 N HCl. The organic layer was washed with brine, dried (sodium sulfate), passed through Celite, and concentrated to give a black crude material. The crude material was treated with petroleum ether to give a solid (10 g), which was dissolved in 2-methyl-THF, and charcoal (2 g) was added. The mixture was heated at 50 °C without vacuum on a rotary evaporator. After filtration, the filtrate was passed through Celite and concentrated. The resulting solid was treated with 30% ethyl acetate in petroleum ether and filtered to give 8 g of crude material as an off-white solid, which was further purified by flash chromatography and then triturated with petroleum ether to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-boronophenyl)propanoic acid (4.0 g, 9.28 mmol, 72.1% yield) as a white solid. LCMS: 432.1 (M+H), tr = 0.82 min. 1 H NMR (500 MHz, DMSO-d6) δ 7.88 (d, J = 7.6 Hz, 2H), 7.85 - 7.77 (m, 1H), 7.71 (br d, J = 7.9 Hz, 3H), 7.68 - 7.60 (m, 2H), 7.41 (br d, J = 6.6 Hz, 2H), 7.35 - 7.20 (m, 4H), 4.30 - 4.11 (m, 5H), 3.16 - 3.03 (m, 1H), 2.95 - 2.83 (m, 1H).

[0530] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-fluoro-[1,1'-biphenyl]-4-yl)propanoic acid [ka] To a stirred solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-boronophenyl)propanoic acid (217.5 mg, 0.504 mmol), 1-bromo-4-fluorobenzene (0.083 mL, 0.757 mmol), and XPhos Pd G2 (9.7 mg, 0.012 mmol) in THF (1 mL) at rt was added 0.5 M aqueous K3PO4 (2 mL, 1.000 mmol). N2 was purged with vacuum three times, and the mixture was stirred at 80 °C for 16 h. The mixture was cooled to rt. To the reaction was added 10% citric acid until pH < 6. Partitioned between EtOAc and H2O, the organic phase was separated, washed with brine, and dried over sodium sulfate. The mixture was filtered, SiO2 (5 g) was added, and concentrated. The material was then purified by flash chromatography (Teledyne ISCO CombiFlash® f The mixture was purified on a RediSep SiO (40 g) gradient of 0% to 20% MeOH / CHCl over 15 column volumes. Fractions containing the desired product were pooled and concentrated to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-fluoro-[1,1'-biphenyl]-4-yl)propanoic acid (206.1 mg, 0.43 mmol, 85% yield) as a cream-colored solid: HPLC: RT = 1.04 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CHCN / H2O / 0.05% TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 482 [M+H] + . 1H NMR (499 MHz, DMSO-d6) δ 12.78 (br s, 1H), 7.88 (d, J = 7.5 Hz, 3H), 7.71 - 7.61 (m, 5H), 7.53 (d, J = 8.1 Hz, 2H), 7.39 (q, J = 7.3 Hz, 3H), 7.36 - 7.23 (m, 8H), 4.24 - 4.13 (m, 5H), 3.12 (dd, J = 14.0, 4.5 Hz, 1H), 2.91 (dd, J = 13.6, 10.3 Hz, 1H).

[0531] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3',5'-difluoro-[1,1'-biphenyl]-4-yl)propanoic acid [ka] The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-fluoro-[1,1'-biphenyl]-4-yl)propanoic acid. Suzuki coupling reaction afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3',5'-difluoro-[1,1'-biphenyl]-4-yl)propanoic acid (197.1 mg, 0.40 mmol, 78% yield) as a colorless solid after purification by flash chromatography. HPLC: RT = 1.06 min (Waters Acquity UPLC BEH C18 1.7 um 2.1×50mm, CH3CN / H2O / 0.05%TFA, 1 min gradient, wavelength = 254nm); MS (ES): m / z = 500 [M+H] + . 1H NMR (499 MHz, DMSO-d6) δ 12.90 - 12.67 (m, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.69 - 7.61 (m, 4H), 7.45 - 7.35 (m, 6H), 7.33 - 7.27 (m, 2H), 7.22 - 7.16 (m, 1H), 4.25 - 4.18 (m, 3H), 4.17 - 4.12 (m, 1H), 3.14 (dd, J = 13.8, 4.4 Hz, 1H), 2.92 (dd, J = 13.7, 10.6 Hz, 1H).

[0532] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)propanoic acid [ka] The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4'-fluoro-[1,1'-biphenyl]-4-yl)propanoic acid. Suzuki coupling reaction afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)propanoic acid (218.5 mg, 0.422 mmol, 84% yield) as a colorless solid after purification by flash chromatography. HPLC: RT = 1.466 min (Shimadzu UPLC with Waters Acquity BEH C18 1.7 um 2.1 x 50 mm column, CH3CN / H2O / 0.1% TFA, 3 min gradient, wavelength = 254 nm); MS (ES): m / z = 556. 1H NMR (499 MHz, DMSO-d6) δ 12.79 (br s, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 8.6 Hz, 1H), 7.69 - 7.58 (m, 6H), 7.44 - 7.35 (m, 4H), 7.33 - 7.25 (m, 2H), 4.27 - 4.17 (m, 3H), 4.17 - 4.10 (m, 1H), 3.14 (dd, J = 13.8, 4.4 Hz, 1H), 2.92 (dd, J = 13.7, 10.7 Hz, 1H).

[0533] スキーム:

change

[0534] Preparation of (2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-(2-methoxypyridin-4-yl)propanoic acid [ka] The mixture was rotary evaporated onto silica gel and purified on the isco using 10%-80% EtOAc / hexanes.

[0535] Fractions were pooled and concentrated to give the desired product as a clear oil (237 mg, 100%).

[0536] Analysis condition D: retention time 1.74 minutes; ES+ 475.1.

[0537] Preparation of ((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid [ka] Step 1: Four separate 40 mL vials were charged with a solution of Ir(dF(CF3)ppy)2(dtbbpy)PF6 (5.6 mg, 4.99 μmol) and Na2CO3 (249 mg, 2.35 mmol) in dioxane (18 mL) and equipped with Teflon screw caps and stir bars. 1-Iodo-4-(trifluoromethoxy)benzene (0.16 mL, 1.02 mmol) was added to the mixture, briefly stirred, and then tris(trimethylsilyl)silane (0.23 mL, 0.75 mmol) was added via syringe. The suspension was degassed with nitrogen for 5 min (capped). Another 40 mL vial was charged with nickel(II) chloride ethylene glycol dimethyl ether complex (22 mg, 0.10 mmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (33 mg, 0.12 mmol). Dioxane (10 mL) was added, and the solution was degassed with nitrogen gas (capped) for 10 minutes and stirred. To the Ir mixture, 2.5 mL of the Ni solution and 5 mL of a solution of iodoalanine, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (987 mg, 2.0 mmol) in dioxane (20 mL) were added, and the mixture was then degassed with nitrogen gas for an additional 5 minutes (capped). The vials were sealed with parafilm, placed in a circular photoredox reactor with the light and fan on, and stirred for 40 hours. The reactions were removed from the light / reactor. The dark reaction mixture from each vial was poured into a 500 mL Erlenmeyer flask, to which EtOAc (200 mL) was added. The mixture was filtered through Celite, washed with EtOAc, and concentrated. The residue was analyzed by flash chromatography (Teledyne ISCO CombiFlash R fThe resulting mixture was purified on RediSep SiO (80 g, loaded as a DCM solution) using a 0% gradient with solvent A / B = CHCl / EtOAc over 10 column volumes. Fractions containing the desired product were pooled and concentrated to give the product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate (865.2 mg, 1.64 mmol, 82% yield, only about 73% HPLC purity), as a colorless oil that was used directly in the deprotection step: HPLC: RT = 1.62 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CHCN / HO / 0.05% TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 550 [M+23]+.

[0538] Process 2. To a stirring solution of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate (865.2 mg, 1.64 mmol) in dichloromethane (8.2 mL) at rt was added HCl (4 M in dioxane, 8.20 mL, 32.8 mmol). The mixture was stirred at rt for 18 h. The mixture was concentrated under reduced pressure and then dried under vacuum. The residue was dissolved in DMF (4 mL) and purified on an ISCO ACCQ Prep in two injections. Fractions containing the desired product were combined and partially concentrated by rotary evaporation, then the mixture was air-dried over the weekend. The residue was dissolved in CH3CN, diluted with water, frozen, and lyophilized. The product, (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid (344.1 mg, 0.73 mmol, 44.5% yield), was obtained as a colorless solid. HPLC: RT = 1.38 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CH3CN / HO / 0.05% TFA, 1.5 min gradient, wavelength = 254 nm); MS (ES): m / z = 472 [M+1]+.

[0539] 1 H NMR (499 MHz, DMSO-d6) ppm δ 7.88 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 7.4 Hz, 2H), 7.44 - 7.37 (m, 2H), 7.35 - 7.25 (m, 4H), 7.19 (br d, J = 7.6 Hz, 3H), 4.30 - 4.20 (m, 1H), 4.21 - 4.13 (m, 2H), 4.04 (br d, J = 3.5 Hz, 1H), 3.11 (br dd, J = 13.6, 4.4 Hz, 1H), 2.91 (br dd, J = 13.6, 9.1 Hz, 1H).

[0540] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,5-dimethylphenyl)propanoic acid [ka] Step 1: The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,5-dimethylphenyl)propanoate (140.5 mg, 0.298 mmol, 61.1% yield), after purification by flash chromatography. Analytical condition J: retention time = 1.21 min; ESI-MS(+) m / z [M-tBu+H] + : 416. 1H NMR (499 MHz, chloroform-d) δ 7.78 (d, J = 7.5 Hz, 2H), 7.63 - 7.56 (m, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.37 - 7.30 (m, 2H), 7.07 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 7.7 Hz, 1H), 6.96 (s, 1H), 4.58 - 4.51 (m, 1H), 4.39 (dd, J = 10.5, 7.3 Hz, 1H), 4.34 (dd, J = 10.5, 7.2 Hz, 1H), 4.24 - 4.19 (m, 1H), 3.10 - 3.01 (m, 2H), 2.34 (s, 3H), 2.28 (s, 3H), 1.40 (s, 8H).

[0541] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,5-dimethylphenyl)propanoic acid (115.2 mg, 0.277 mmol, 93% yield) as a cream-colored solid after purification by reverse-phase flash chromatography. HPLC: RT = 1.03 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 x 50 mm, CH3CN / HO / 0.05%TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 416 [M+H] + . 1H NMR (499 MHz, chloroform-d) δ 7.88 (d, J = 7.4 Hz, 2H), 7.79 (br d, J = 8.6 Hz, 1H), 7.67 (d, J = 7.4 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.41 (td, J = 7.3, 4.2 Hz, 3H), 7.35 - 7.29 (m, 2H), 7.29 - 7.25 (m, 1H), 7.02 (br d, J = 8.9 Hz, 2H), 6.91 (br d, J = 7.4 Hz, 1H), 4.21 - 4.10 (m, 5H), 3.07 (dd, J = 14.1, 4.4 Hz, 1H), 2.80 (dd, J = 14.1, 10.3 Hz, 1H), 2.24 (s, 3H), 2.18 (s, 3H).

[0542] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-fluoro-3-methylphenyl)propanoic acid [ka] Step 1: The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-fluoro-3-(trifluoromethyl)phenyl)propanoate (66.3 mg, 0.13 mmol, 24.9% yield), as a colorless solid after purification by flash chromatography. HPLC: RT = 1.19 min (Waters Acquity UPLC BEH C18 1.7 um 2.1×50mm, CH3CN / H2O / 0.05%TFA, 1 min gradient, wavelength = 254nm); MS (ES): m / z = 474 [M-tBu] + . 1H NMR (499 MHz, chloroform-d) δ 7.80 (d, J = 7.5 Hz, 2H), 7.60 (dd, J = 7.6, 3.3 Hz, 2H), 7.47 - 7.39 (m, 3H), 7.38 - 7.32 (m, 2H), 7.16 - 7.09 (m, 1H), 5.34 (br d, J = 7.7 Hz, 1H), 4.57 - 4.47 (m, 2H), 4.40 (dd, J = 10.3, 6.9 Hz, 1H), 4.26 - 4.21 (m, 1H), 3.14 (br d, J = 4.9 Hz, 2H), 1.44 (s, 9H).

[0543] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-fluoro-3-methylphenyl)propanoic acid (58.3 mg, 0.139 mmol, 85% yield) as a cream-colored solid after purification by reverse-phase flash chromatography. HPLC: RT = 1.02 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 x 50 mm, CH3CN / HO / 0.05%TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 420 [M+H] + . 1H NMR (499 MHz, DMSO-d6) δ 12.86 - 12.66 (m, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.73 (d, J = 8.3 Hz, 1H), 7.65 (t, J = 7.5 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.35 - 7.26 (m, 2H), 7.17 (br d, J = 7.5 Hz, 1H), 7.14 - 7.08 (m, 1H), 7.06 - 6.99 (m, 1H), 4.24 - 4.11 (m, 4H), 3.03 (dd, J = 13.7, 4.3 Hz, 1H), 2.82 (dd, J = 13.6, 10.6 Hz, 1H), 2.17 (s, 3H).

[0544] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,4-difluoro-5-methoxyphenyl)propanoic acid [ka] Step 1: The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,4-difluoro-5-methoxyphenyl)propanoate (77.1 mg, 0.151 mmol, 29.1% yield) as a colorless solid after purification by flash chromatography. HPLC: RT = 1.15 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CHCN / HO / 0.05% TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 454 [Mt-Bu]. 1H NMR (499 MHz, chloroform-d) δ 7.79 (d, J = 7.4 Hz, 2H), 7.59 (t, J = 6.4 Hz, 2H), 7.43 (t, J = 7.3 Hz, 2H), 7.33 (td, J = 7.5, 1.1 Hz, 3H), 6.85 (dd, J = 10.8, 9.3 Hz, 1H), 6.83 - 6.79 (m, 1H), 5.40 (br d, J = 8.1 Hz, 1H), 4.58 - 4.51 (m, 1H), 4.38 (dd, J = 7.0, 4.5 Hz, 2H), 4.25 - 4.20 (m, 1H), 3.82 (s, 3H), 3.18 - 3.05 (m, 2H), 1.45 (s, 9H).

[0545] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,4-difluoro-5-methoxyphenyl)propanoic acid (45.9 mg, 0.101 mmol, 66.9% yield) as a cream-colored solid after purification by reverse-phase flash chromatography. HPLC: RT = 0.99 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CHCN / HO / 0.05% TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 454 [M+1]+. 1H NMR (499 MHz, DMSO-d6) δ 12.92 (br s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.71 - 7.65 (m, 1H), 7.63 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.34 - 7.25 (m, 2H), 7.24 - 7.15 (m, 2H), 4.24 - 4.12 (m, 4H), 3.77 (s, 3H), 3.16 (br dd, J = 13.8, 4.6 Hz, 1H), 2.82 (dd, J = 13.6, 10.7 Hz, 1H).

[0546] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,3-dimethylphenyl)propanoic acid [ka] Step 1: The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,3-dimethylphenyl)propanoate (107.5 mg, 0.228 mmol, 55.5% yield), as a tan viscous oil after purification by flash chromatography. HPLC: RT = 1.21 min (Waters Acquity UPLC BEH C18 1.7 um 2.1×50mm, CH3CN / H2O / 0.05%TFA, 1 min gradient, wavelength = 254nm); MS (ES): m / z = 416 [Mt-Bu]+. 1H NMR (499 MHz, chloroform-d) δ 7.79 (d, J = 7.5 Hz, 2H), 7.61 - 7.56 (m, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.35 - 7.31 (m, 2H), 7.09 - 7.06 (m, 1H), 7.02 (t, J = 7.5 Hz, 1H), 7.00 - 6.96 (m, 1H), 5.30 (br d, J = 8.3 Hz, 1H), 4.53 (q, J = 7.4 Hz, 1H), 4.39 (dd, J = 10.6, 7.3 Hz, 1H), 4.34 (dd, J = 10.4, 7.0 Hz, 1H), 4.21 (t, J = 7.2 Hz, 1H), 3.15 (dd, J = 14.2, 7.0 Hz, 1H), 3.08 (dd, J = 14.1, 7.3 Hz, 1H), 2.29 (s, 3H), 2.28 (s, 3H), 1.40 (s, 9H).

[0547] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2,3-dimethylphenyl)propanoic acid (72.9 mg, 0.175 mmol, 77% yield) as a cream-colored solid after purification by reverse-phase flash chromatography. HPLC: RT = 1.03 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CHCN / HO / 0.05% TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 416 [M+H]+. 1H NMR (499 MHz, DMSO-d6) δ 12.76 (br d, J = 1.8 Hz, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.79 - 7.71 (m, 1H), 7.66 (dd, J = 13.6, 7.6 Hz, 2H), 7.42 (td, J = 7.2, 4.1 Hz, 2H), 7.35 - 7.27 (m, 2H), 7.07 (d, J = 7.3 Hz, 1H), 7.04 - 6.99 (m, 1H), 6.99 - 6.94 (m, 1H), 4.24 - 4.14 (m, 3H), 4.13 - 4.05 (m, 1H), 3.15 (dd, J = 14.1, 4.1 Hz, 1H), 2.85 (dd, J = 13.9, 10.4 Hz, 1H), 2.22 (s, 3H), 2.19 (s, 3H).

[0548] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-3-methylphenyl)propanoic acid [ka] Process 1 The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-3-methylphenyl)propanoate (136.9 mg, LCMS showed 77% product and 23% impurity) as a viscous oil after purification by flash chromatography. It was used as is in the purity after tBu hydrolysis.

[0549] Process 2 The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-3-methylphenyl)propanoic acid (79.7 mg, 0.190 mmol, 66.0% yield) as a cream-colored solid after purification by reverse-phase flash chromatography. HPLC: RT = 1.02 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 x 50 mm, CHCN / HO / 0.05%TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 420 [M+1] + . 1 H NMR (499 MHz, DMSO-d6) δ 12.79 (br s, 1H), 7.89 (d, J = 7.7 Hz, 2H), 7.78 (d, J = 8.6 Hz, 1H), 7.65 (dd, J = 11.6, 7.5 Hz, 2H), 7.44 - 7.39 (m, 3H), 7.37 - 7.25 (m, 3H), 7.14 (br t, J = 7.4 Hz, 2H), 7.01 - 6.96 (m, 1H), 4.24 - 4.12 (m, 4H), 3.17 (dd, J = 13.8, 4.8 Hz, 1H), 2.86 (dd, J = 13.6, 10.8 Hz, 1H), 2.21 (s, 3H). 1 H NMR and LCMS showed a 14% purity.

[0550] Preparation of ((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-5-methylphenyl)propanoic acid [ka] The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-5-methylphenyl)propanoate (148.1 mg, 0.311 mmol, 65.4% yield), as a colorless gum after purification by flash chromatography. HPLC: RT = 1.19 min (Waters Acquity UPLC BEH C18 1.7 um 2.1×50mm, CH3CN / H2O / 0.05%TFA, 1 min gradient, wavelength = 254nm); MS (ES): m / z = 420 [Mt-Bu] + . 1 H NMR (499 MHz, chloroform-d) δ 7.79 (d, J = 7.6 Hz, 2H), 7.60 (t, J = 7.2 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.37 - 7.30 (m, 2H), 7.06 - 6.99 (m, 2H), 6.97 - 6.90 (m, 1H), 5.41 (br d, J = 8.1 Hz, 1H), 4.60 - 4.54 (m, 1H), 4.43 (dd, J = 10.4, 7.2 Hz, 1H), 4.30 (dd, J = 10.1, 7.5 Hz, 1H), 4.26 - 4.21 (m, 1H), 3.16 (dd, J = 13.9, 6.7 Hz, 1H), 3.10 (dd, J = 13.9, 6.4 Hz, 1H), 2.28 (s, 3H), 1.44 (s, 9H).

[0551] Process 2 The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-5-methylphenyl)propanoic acid (98.1 mg, 0.23 mmol, 75% yield) as a colorless solid after purification by reverse-phase flash chromatography. HPLC: RT = 1.01 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 x 50 mm, CH3CN / HO / 0.05%TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 420 [M+1] + . 1 H NMR (499 MHz, DMSO-d6) δ 12.82 (br s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.78 (d, J = 8.6 Hz, 1H), 7.67 (d, J = 7.4 Hz, 1H), 7.64 (d, J = 7.4 Hz, 1H), 7.42 (td, J = 7.4, 3.0 Hz, 2H), 7.34 - 7.27 (m, 2H), 7.16 - 7.11 (m, 1H), 7.08 - 6.97 (m, 2H), 4.26 - 4.12 (m, 5H), 3.15 (dd, J = 13.8, 4.9 Hz, 1H), 2.83 (dd, J = 13.8, 10.3 Hz, 1H), 2.20 (s, 3H).

[0552] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-5-methoxyphenyl)propanoic acid [ka] Process 1 The compound was prepared according to the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-5-methoxyphenyl)propanoate (117.7 mg, 0.24 mmol, 50.4% yield) and obtained as a colorless solid after purification by flash chromatography. HPLC: RT = 1.15 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 x 50 mm, CH3CN / HO / 0.05%TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 436 [Mt-Bu] + . 1 H NMR (499 MHz, chloroform-d) δ 7.78 (d, J = 7.5 Hz, 2H), 7.63 - 7.56 (m, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.37 - 7.30 (m, 2H), 7.01 - 6.93 (m, 1H), 6.79 - 6.72 (m, 2H), 5.41 (br d, J = 8.2 Hz, 1H), 4.62 - 4.55 (m, 1H), 4.41 (dd, J = 10.4, 7.3 Hz, 1H), 4.31 (dd, J = 10.5, 7.4 Hz, 1H), 4.26 - 4.20 (m, 1H), 3.75 (s, 3H), 3.17 (dd, J = 13.9, 6.7 Hz, 1H), 3.11 (dd, J = 14.4, 6.6 Hz, 1H), 1.45 (s, 9H).

[0553] Process 2 The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-fluoro-5-methoxyphenyl)propanoic acid (79.5 mg, 0.183 mmol, 76% yield) as a colorless solid after purification by flash chromatography. HPLC: RT = 0.98 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 x 50 mm, CH3CN / H2O / 0.05% TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 436 [M+1]+. A base peak at 214 = a fully deprotected amino acid fragment was also observed. 1 H NMR (499 MHz, DMSO-d6) δ 12.84 (br s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.79 (d, J = 8.6 Hz, 1H), 7.64 (t, J = 8.4 Hz, 2H), 7.45 - 7.38 (m, 2H), 7.34 - 7.25 (m, 2H), 7.07 (t, J = 9.2 Hz, 1H), 6.94 (dd, J = 6.1, 3.2 Hz, 1H), 6.80 (dt, J = 8.9, 3.6 Hz, 1H), 4.25 - 4.13 (m, 4H), 3.69 (s, 3H), 3.17 (dd, J = 13.9, 4.6 Hz, 1H), 2.83 (dd, J = 13.7, 10.7 Hz, 1H).

[0554] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methoxy-5-methylphenyl)propanoic acid [ka] Step 1: The compound was prepared following the same method as tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoate. Photoredox coupling afforded the desired product, tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methoxy-5-methylphenyl)propanoate (73.9 mg, 0.15 mmol, 31.3% yield), as a colorless film after purification by flash chromatography. HPLC: RT = 1.20 min (Waters Acquity UPLC BEH C18 1.7 um 2.1×50mm, CH3CN / H2O / 0.05%TFA, 1 min gradient, wavelength = 254nm); MS (ES): m / z = 488 [M-tBu+H] + . 1 H NMR (499 MHz, chloroform-d) δ 7.78 (d, J = 7.6 Hz, 2H), 7.61 - 7.54 (m, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.34 - 7.30 (m, 2H), 7.05 (dd, J = 8.1, 1.5 Hz, 1H), 6.98 (d, J = 1.4 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 5.70 (br d, J = 7.7 Hz, 1H), 4.49 (q, J = 7.4 Hz, 1H), 4.33 (d, J = 7.4 Hz, 2H), 4.25 - 4.18 (m, 1H), 3.82 (s, 3H), 3.10 - 3.02 (m, 2H), 2.26 (s, 3H), 1.43 (s, 9H).

[0555] Process 2. The final product was obtained following the same method as for (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. Removal of the tBu ester with HCl / dioxane afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-methoxy-5-methylphenyl)propanoic acid (44.7 mg, 0.104 mmol, 68.4% yield) as a colorless solid after purification by flash chromatography. HPLC: RT = 1.02 min (Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm, CHCN / HO / 0.05%TFA, 1 min gradient, wavelength = 254 nm); MS (ES): m / z = 432 [M+H] + . 1 H NMR (499 MHz, DMSO-d6) δ 12.61 (br s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.67 (d, J = 7.5 Hz, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.60 (br d, J = 8.1 Hz, 1H), 7.42 (td, J = 7.2, 3.5 Hz, 2H), 7.32 (td, J = 7.5, 1.0 Hz, 1H), 7.30 - 7.26 (m, 1H), 7.02 - 6.97 (m, 2H), 6.84 (d, J = 8.9 Hz, 1H), 4.26 - 4.10 (m, 4H), 3.75 (s, 3H), 3.12 (dd, J = 13.5, 4.8 Hz, 1H), 2.72 (dd, J = 13.4, 10.2 Hz, 1H), 2.16 (s, 3H).

[0556] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-hydroxy-3-methylbutanoic acid Scheme: [ka] Step 1: A 10 L multi-necked round-bottom flask was charged with methyl (tert-butoxycarbonyl)-D-serinate (50 g, 228 mmol) and diethyl ether (4200 mL). The mixture was cooled to -78 °C, and methylmagnesium bromide (456 mL, 1368 mmol) was added dropwise over 30 min. The reaction was stirred at RT for 1 h. The mixture was cooled to 0 °C, and saturated NH4Cl solution (1500 mL) was added dropwise and stirred for 10 min. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 × 2000 mL). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated at 40 °C to give a thick colorless liquid. The crude material was purified by I2PAC. The desired fractions were eluted with 50% EtOAc:petroleum ether mixture, collected and concentrated at 40° C. to give tert-butyl (S)-(1,3-dihydroxy-3-methylbutan-2-yl)carbamate (43.5 g, 87%) as a white solid. 1 H NMR (MeOD, 300 MHz) δ 3.70 (m, 1H), 3.48 (m, 1H), 3.21 (m, 1H), 1.35 (s, 9H), 1.13 (s, 3H), 1.05 (s, 3H).

[0557] Process 2. A 50 mL single-neck round-bottom flask was charged with tert-butyl (S)-(1,3-dihydroxy-3-methylbutan-2-yl)carbamate (43.0 g, 196 mmol) and acetonitrile (650 mL) and stirred until the solution became clear. Sodium phosphate buffer (460 mL, 196 mmol) (pH = 6.7, 0.67 M), (diacetoxyiodo)benzene (4.48 g, 13.92 mmol), and TEMPO (2.206 g, 14.12 mmol) were added sequentially. The reaction was then cooled to 0 °C and sodium chlorite (19.95 g, 221 mmol) was added. The reaction color turned black. The reaction was stirred at 0 °C for 2 h and then at RT overnight. The orange reaction was quenched with saturated ammonium chloride solution (1000 mL) and adjusted to pH = 2 using 1.5 N HCl (330 mL) using a pH meter. The aqueous solution was saturated with solid NaCl and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over NaSO, and concentrated to give crude (S)-2-((tert-butoxycarbonyl)amino)-3-hydroxy-3-methylbutanoic acid (34.0 g, 74.3% yield) as an off-white solid, which was used directly in the next step. 1 H NMR (MeOD, 300 MHz) δ 3.98 (s, 1H), 1.35 (s, 9H), 1.19 (s, 3H), 1.16 (9s, 3H).

[0558] Process 3. A 2000 mL single-neck flask was charged with a solution of (S)-2-((tert-butoxycarbonyl)amino)-3-hydroxy-3-methylbutanoic acid (90 g, 386 mmol) in dioxane (450 mL) and cooled to 0 °C. 4 N HCl in dioxane (450 mL, 1800 mmol) was added dropwise over 10 min. The reaction was stirred at RT for 3 h. It was concentrated, azeotroped with toluene (2x), and then stirred with ethyl acetate for 10 min. Filtration and drying under reduced pressure gave crude (S)-2-amino-3-hydroxy-3-methylbutanoic acid, HCl (70 g, 107% yield) as a white solid, which was used directly in the next step.

[0559] Step 4. A 3000 mL multi-neck round-bottom flask was charged with (S)-2-amino-3-hydroxy-3-methylbutanoic acid, HCl (70 g, 413 mmol), dioxane (1160 mL), and water (540 mL). The stirred solution became clear, and a solution of sodium bicarbonate (104 g, 1238 mmol) in water (1160 mL) was added in one portion at RT. The reaction mass was stirred at RT for 30 min. A solution of Fmoc-OSu (139 g, 413 mmol) in 1,4-dioxane (1460 mL) was added in one portion at RT. The reaction was stirred at RT for 16 h. The reaction was concentrated to remove dioxane. Water was added to the resulting solution and washed with ethyl acetate (3 x 1000 mL). The aqueous solution was acidified to pH 1-2 and extracted with ethyl acetate. The combined organic layers were washed with water, followed by brine, and finally dried over NaSO and concentrated to give an off-white solid (135.7 g). To remove the trapped dioxane and ethyl acetate, the following procedure was followed: the solid was dissolved in ethyl acetate (1200 mL) and taken up with n-hexane (3000 mL). The resulting slurry was stirred for 10 minutes, filtered, and dried under reduced pressure to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-hydroxy-3-methylbutanoic acid (112.0 g, 74.8% yield over two steps) as a white solid.

[0560] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4,5-trifluorophenyl)propanoic acid [ka] Step 1: To a stirred solution of 2-((diphenylmethylene)amino)acetonitrile (100 g, 454 mmol) in DCM (1000 mL) was added 5-(bromomethyl)-1,2,3-trifluorobenzene (66.5 mL, 499 mmol) and benzyltrimethylammonium chloride (16.86 g, 91 mmol). To this was added 10 M NaOH (136 mL, 1362 mmol) solution and stirred at rt overnight. After 26 h, the reaction mixture was diluted with water (500 mL) and the DCM layer was separated. The aqueous layer was further extracted with DCM (2 × 250 mL). The organic layers were combined, washed with water and brine solution, dried over NaSO, filtered, and concentrated under reduced pressure. The crude compound was purified by flash column chromatography (1.5 kg, silica gel, 0-10% ethyl acetate / petroleum ether mixture), and the desired fractions were collected and concentrated to give 2-((diphenylmethylene)amino)-3-(3,4,5-trifluorophenyl)propanenitrile (140 g, 384 mmol, 85% yield) as a yellow solid. Analytical condition E: Retention time = 3.78 min; ESI-MS(+) m / z [M+H] + : 365.2.

[0561] Process 2. To a stirred solution of 2-((diphenylmethylene)amino)-3-(3,4,5-trifluorophenyl)propanenitrile (80 g, 220 mmol) in 1,4-dioxane (240 mL) was added concentrated HCl (270 mL, 3293 mmol), and the mixture was stirred at 90° C. for 16 h. The reaction mixture was used directly in the next step.

[0562] Process 3. To the crude aqueous dioxane solution from above, 10 N NaOH solution was added until neutral. Na2CO3 (438 ml, 438 mmol) was then added, followed by Fmoc-OSu (81 g, 241 mmol). The mixture was stirred at rt overnight. The aqueous solution was acidified to pH = 2 with 1.5 N HCl, and the formed solid was filtered and dried to give the crude compound. It was first slurried in 5% EtOAc / petroleum ether for 30 minutes and filtered. The filtered compound was further slurried in ethyl acetate for 20 minutes and filtered to give crude racemic 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4,5-trifluorophenyl)propanoic acid (90 g, 204 mmol, 93% yield) as an off-white solid. This racemic compound was separated into two isomers by SFC purification to give the desired isomer. Concentration of the desired isomer followed by slurrying with 5% EtOAc / petroleum ether and filtration gave (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4,5-trifluorophenyl)propanoic acid (43 g, 95 mmol, 43.3% yield) as an off-white solid. 1 H NMR (MeOD, 400 MHz) δ 7.78 (d, J = 7.2 Hz, 2H), 7.60 (t, J = 8.0 Hz, 2H), 7.38 (t, J = 8.0 Hz, 2H), 7.28 (t, J = 7.6 Hz, 2H), 7.01 (t, J = 7.8 Hz, 2H), 4.48 - 4.26 (m, 3H), 4.18 (m, 1H), 3.18 (m, 1H), 2.91 (m, 1H). 19 F(MeOD, 376 MHz) δ -137.56 (d, J = 19.6 Hz, 2F), -166.67 (t, J = 19.6 Hz, 1F). Analysis conditions E: retention time = 3.15 min; ESI-MS(+) m / z [M+H] + : 442.2.

[0563] The other fractions were concentrated to give (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4,5-trifluorophenyl)propanoic acid (40 g, 91 mmol, 41.4% yield) as an off-white solid.

[0564] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-3,3-dimethyl-4-oxobutanoic acid [ka] Process 1. To a stirred solution of 4-(tert-butyl) 1-methyl L-aspartate, HCl salt (34 g, 142 mmol) in acetonitrile (550 mL) was added lead(II) nitrate (47.0 g, 142 mmol), potassium phosphate (66.2 g, 312 mmol), and triethanolamine (19.77 mL, 142 mmol) under a nitrogen atmosphere. The mixture was cooled to 0 °C, and then a solution of 9-bromo-9-phenylfluorene (43.3 g, 135 mmol) in acetonitrile (100 mL) was added. The reaction mixture was stirred at RT for 48 h, and the reaction progress was monitored by TLC (50% EA in PE) and LCMS. The reaction mixture was filtered through Celite, washed with chloroform, and evaporated to give a thick, pale yellow liquid, to which ethyl acetate (3500 mL) was added. The EtOAc layer was washed with 5% citric acid solution (500 mL) followed by brine solution. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give a light yellow thick liquid, which was scratched with petroleum ether and filtered to give 4-(tert-butyl)1-methyl(9-phenyl-9H-fluoren-9-yl)-L-aspartate (55 g, 124 mmol, 87% yield) as a white solid. Analytical conditions: Retention time = 1.73 min; ESI-MS(+) m / z [M+Na] + : 466.40.

[0565] Process 2. A solution of 4-(tert-butyl)1-methyl(9-phenyl-9H-fluoren-9-yl)-L-aspartate (22.5 g, 50.7 mmol) was cooled to −78 °C under Ar, and a solution of KHMDS (127 mL, 127 mmol, 1 M solution in THF) was added over 30 min with stirring. The reaction was warmed to −40 °C, and methyl iodide (9.52 mL, 152 mmol) was added dropwise. The reaction was stirred at −40 °C for 5 h. The reaction was monitored by TLC and LCMS. Saturated NH₄Cl (400 mL) was added, followed by HO (100 mL). The resulting mixture was extracted with EtOAc (3×), and the combined organic extracts were washed with 2% citric acid (200 mL), aqueous NaHCO₃ (200 mL), and brine. The organic layer was dried over anhydrous Na2SO4, evaporated under reduced pressure, and recrystallized from hexane to give 1-(tert-butyl)4-methyl (S)-2,2-dimethyl-3-((9-phenyl-9H-fluoren-9-yl)amino)succinate (18.5 g, 39.2 mmol, 77% yield), which was used in the next step. Analytical condition L: retention time = 2.04 min; ESI-MS(+) m / z [M+Na] + : 494.34.

[0566] Process 3. A stirred solution of 1-(tert-butyl)4-methyl (S)-2,2-dimethyl-3-((9-phenyl-9H-fluoren-9-yl)amino)succinate (24 g, 50.9 mmol) in methanol (270 mL) and ethyl acetate (100 mL) was degassed with nitrogen. Pd—C (2.71 g, 2.54 mmol) (10 wt %) was added, the mixture was flushed with hydrogen gas, and then stirred at RT in a 1-L autoclave at 50 psi overnight. The reaction mixture was filtered through a pad of Celite and washed with a mixture of methanol and ethyl acetate. The combined solvent was evaporated to dryness, and the precipitated white solid was removed by filtration to give a pale yellow liquid, 1-(tert-butyl)4-methyl (S)-3-amino-2,2-dimethylsuccinate (11.7 g), which was used directly in the next step.

[0567] Step 4. To a stirred solution of 1-(tert-butyl)4-methyl (S)-3-amino-2,2-dimethylsuccinate (11.0 g, 47.6 mmol) cooled in an ice bath, lithium hydroxide (428 mL, 86 mmol, 0.2 M aqueous solution) was added, and the reaction was allowed to warm slowly to RT. The reaction was monitored by TLC and LCMS. The reaction mixture was evaporated and used directly in the next step. To a stirred solution of (S)-2-amino-4-(tert-butoxy)-3,3-dimethyl-4-oxobutanoic acid (15 g, 69.0 mmol) (aqueous solution from a previous batch) in acetonitrile (200 mL) was cooled to 0 °C, and sodium bicarbonate (5.80 g, 69.0 mmol) and Fmoc-OSu (46.6 g, 138 mmol) were added. The reaction mixture was stirred at RT overnight. Acidification to pH=4 with 2N HCl followed by extraction with ethyl acetate (3×500 mL) gave an off-white solid that was washed with brine, dried over sodium sulfate, and evaporated to give an off-white solid that was purified by ISCO flash chromatography using 20% ​​EA in petroleum ether to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-3,3-dimethyl-4-oxobutanoic acid (12.2 g, 26.9 mmol, 39.0% yield) as a white solid. 1 HNMR (CDCl3, 400 MHz) δ 7.77 (d, J = 7.6 Hz, 2H), 7.60 (m, 2H), 7.42 (t, J = 8.0 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 4.65 (m, 2H), 4.34 (m, 1H), 4.25 (m, 1H), 3.18 (m, 1H), 1.40-1.27 (m, 6H). Analysis condition E: retention time = 1.90 min; ESI-MS(+) m / z [M+H] + : 440.2.

[0568] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-(tert-butoxycarbonyl)phenyl)propanoic acid [ka] Step 1: To a solution of (S)-2-(1,3-dioxoisoindolin-2-yl)propanoic acid (80 g, 365 mmol), O-methylhydroxylamine hydrochloride (36.6 g, 438 mmol) in CHCl (2000 mL) was added TEA (153 mL, 1095 mmol) at RT. The reaction was cooled to 0 °C, and 1-propanephosphonic anhydride (326 mL, 547 mmol) was added dropwise. The reaction was stirred at RT for 2 h. It was quenched with saturated ammonium chloride (500 mL) and extracted with EtOAc (3 × 300 mL). The combined organic layer was washed with saturated brine, dried over NaSO, and concentrated under reduced pressure. The crude product was purified by combiflash using a 120 g silica column with 38-45% EtOAc in petroleum ether to give (S)-2-(1,3-dioxoisoindolin-2-yl)-N-methoxypropanamide (80 g, 322 mmol, 88% yield). 1 H NMR(DMSO-d6, 400 MHz) δ 11.36 (s, 1H), 7.91-7.85 (m, 4H), 4.75 - 4.69 (m, 1H), 3.56 (s, 3H), 1.51 (d, J = 7.6 Hz, 3H).

[0569] Process 2. To a solution of (S)-2-(1,3-dioxoisoindolin-2-yl)-N-methoxypropanamide (20 g, 81 mmol), palladium(II) acetate (1.809 g, 8.06 mmol), and silver acetate (26.9 g, 161 mmol) in a 1000 mL sealed tube, tert-butyl 3-iodobenzoate (36.8 g, 121 mmol), 2,6-lutidine (2.395 mL, 24.17 mmol), and HFIP (300 mL) were added at 25 °C under a N atmosphere. The reaction was stirred for 15 minutes at 25 °C under N and then warmed to 80 °C for 24 hours with vigorous stirring. The reaction mixture was filtered through Celite and washed with DCM (200 mL). The combined organic layer was concentrated under reduced pressure. The crude product was purified by combiflash on a 220 g silica column eluting with 25-30% EtOAc:CHCl3 to give the desired product, tert-butyl (S)-3-(2-(1,3-dioxoisoindolin-2-yl)-3-(methoxyamino)-3-oxopropyl)benzoate (11 g, 25.9 mmol, 32.2% yield). Analytical condition E: retention time = 2.52 min; ESI-MS (+) m / z [M−H] + : 423.2. 1 H NMR(DMSO-d6, 400 MHz) δ 11.46 (s, 1H), 7.82 (m, 4H), 7.63 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 4.93 - 4.89 (m, 1H), 3.59 (s, 3H), 3.56 - 3.49 (m, 1H), 3.36 - 3.27 (m, 1H), 1.40 (s, 9H).

[0570] Process 3. To a solution of tert-butyl (S)-3-(2-(1,3-dioxoisoindolin-2-yl)-3-(methoxyamino)-3-oxopropyl)benzoate (15 g, 35.3 mmol) in methanol (200 mL) was added (diacetoxyiodo)benzene (12.52 g, 38.9 mmol) at RT. The temperature was slowly raised to 80 °C and stirred at 80 °C for 3 h. The reaction was concentrated under reduced pressure to give the crude product. Purification by silica gel chromatography (100-200 mesh eluted with 20% EA:hexane) gave the desired compound, tert-butyl (S)-3-(2-(1,3-dioxoisoindolin-2-yl)-3-methoxy-3-oxopropyl)benzoate (10 g, 24.42 mmol, 69.1% yield). 1 H NMR (CDCl3, 400 MHz) δ 7.80 - 7.76 (m, 4H), 7.72 - 7.68 (m, 2H), 7.34 - 7.26 (m, 1H), 7.25 - 7.23 (m, 1H), 5.14 (dd, J = 10.8, 5.6 Hz, 1H), 3.76 (s, 3H), 3.65 - 3.49 (m, 2H), 1.50 (s, 9H).

[0571] Step 4. To a solution of tert-butyl (S)-3-(2-(1,3-dioxoisoindolin-2-yl)-3-methoxy-3-oxopropyl)benzoate (15 g, 36.6 mmol) in methanol (25 mL) was added ethylenediamine (12.25 mL, 183 mmol) at RT. The reaction temperature was slowly raised to 40 °C and stirred at 40 °C for 3 h. The mixture was concentrated under reduced pressure to give the crude product. Purification by silica gel chromatography (100-200 mesh, eluted with 20% EA:hexane) gave the desired compound, tert-butyl (S)-3-(2-amino-3-methoxy-3-oxopropyl)benzoate (8.3 g, 29.7 mmol, 81% yield). 1H NMR(DMSO-d6, 400 MHz) δ 8.32 (s, 1H), 7.77 - 7.72 (m, 2H), 7.46 - 7.38 (m, 1H), 3.61 - 3.57 (m, 4H), 2.96 - 2.91 (m, 1H), 2.85 - 2.82 (m, 1H), 1.79 (br. s, 2H), 1.55 (s, 9H).

[0572] Process 5. To a solution of tert-butyl (S)-3-(2-amino-3-methoxy-3-oxopropyl)benzoate (10 g, 35.8 mmol) in dioxane (150 mL) was added sodium bicarbonate (6.01 g, 71.6 mmol), followed by 9-fluorenylmethyl chloroformate (13.89 g, 53.7 mmol) at RT. The reaction was stirred for 12 h at RT. It was diluted with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to give the crude product. Purification by silica gel chromatography (100-200 mesh, eluting with 20% EA:hexane) gave the desired compound, tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxy-3-oxopropyl)benzoate (15 g, 29.9 mmol, 84% yield).

[0573] Process 6. To a solution of tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxy-3-oxopropyl)benzoate (18.00 g, 35.9 mmol) in THF (150 mL) and HO (150 mL) at RT was added lithium hydroxide monohydrate (1.66 g, 39.5 mmol). The reaction was stirred for 2 h at RT. The reaction was concentrated under reduced pressure to remove the THF. In a basic medium, the mixture was extracted with diethyl ether to remove non-polar impurities. The aqueous layer was acidified with aqueous citric acid and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give the desired compound as a gummy solid, which was further lyophilized to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-(tert-butoxycarbonyl)phenyl)propanoic acid (16 g, 32.72 mmol, quantitative yield) as an off-white solid. 7.86 (t, J = 7.6 Hz, 2H), 7.75 (d, J = 7.6 Hz, 1H), 7.66-7.59 (m, 2H), 7.52 (m, 2H), 7.41-7.37 (m, 3H), 7.31-7.24 (m, 2H), 4.21 - 4.16 (m, 4H), 3.17 (m, 1H), 2.96 (m, 1H), 1.53 (br, s. 9H). Analysis condition E: retention time = 3.865 min; ESI-MS(+) m / z [MH] + : 486.2.

[0574] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(m-tolyl)propanoic acid [ka] The compound was synthesized following a similar method to (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-(tert-butoxycarbonyl)phenyl)propanoic acid. Analysis condition E: retention time = 3.147 min; ESI-MS(+) m / z [M+H] + : 402.0. 1H NMR(DMSO-d6, 300 MHz) δ 7.88 (d, J = 7.5 Hz, 2H), 7.64 (t, J = 6.8 Hz, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.36 - 7.28 (m, 2H), 7.18 (t, J = 7.5 Hz, 1H), 7.09 - 7.02 (m, 3H), 4.24 - 4.17 (m, 4H), 3.21 - 3.04 (m, 1H), 2.89 -2.81 (m, 1H), 2.26 (s, 3H) ppm.

[0575] Preparation of ethyl (S)-5-((tert-butoxycarbonyl)amino)-2-(((S)-mesitylsulfinyl)amino)-3,3-dimethylpentanoate [ka] Step 1: This compound was synthesized using a method similar to that described in reference 1. To a 1000 ml flask equipped with a septum inlet and a magnetic stir bar was added bismuth(III) chloride (5.25 g, 16.64 mmol). The flask was connected to an argon line, and thionyl chloride (501 mL, 6864 mmol) was connected via syringe. To the suspension was added mesitylene (100 g, 832 mmol). The flask was fitted with a condenser and connected to an oil bubbler, and the reaction mixture was heated in an oil bath at 60 °C for 5 h. During this time, the solution turned red-orange, and HCl was released from the solution. The reaction was monitored by LCMS. The flask was cooled in an ice bath, and excess thionyl chloride was removed under reduced pressure to give an orange liquid. To remove the catalyst, 2000 mL of pentane was added, stirred, and filtered through Celite, washing the bed with pentane (2 x 500 mL). The organic phase was collected and evaporated under reduced pressure to give 2,4,6-trimethylbenzenesulfine chloride (151 g, 745 mmol, 90% yield) as a pale yellow solid, which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.07 - 6.76 (m, 2H), 2.66 (s, 6H), 2.38 - 2.24 (m, 3H) ppm.

[0576] [ka] Step 2. This compound was synthesized using a method similar to that described in reference: A stirred solution of 2,4,6-trimethylbenzenesulfinyl chloride (155 g, 765 mmol) in diethyl ether (1500 mL) was cooled to -40 °C. In a separate setup (2 L multi-neck RBF), diethyl ether (900 mL) was dissolved and ammonia gas was bubbled through for 30 minutes at -40 °C. This purged solution was added to the above reaction mass at -40 °C. After warming to rt, the reaction mixture was stirred for 2 hours and monitored for the absence of starting material by open access LCMS. The reaction was stirred overnight at room temperature as described. The reaction was monitored by TLC and open access LCMS, and TLC indicated the absence of starting material. Workup: The reaction mixture was diluted with ethyl acetate (3000 mL) and washed with water (2000 ml). The organic layer was separated and the aqueous phase was extracted again with ethyl acetate (1 x 500 mL). The combined organic layer was washed with brine (1 x 800 mL). The combined organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to give (235 g) as a light brown solid. The product (235 g) was recrystallized from 10% ethyl acetate / petroleum ether (500 mL), stirred, filtered, and dried to give mesitylenesulfinamide (125 g) racemate as a white solid. The compound was subjected to SFC development. Two peaks were collected from SFC. The solvent was concentrated to give peak 1 (unwanted): (R)-2,4,6-trimethylbenzenesulfinamide (51.6 g, 265 mmol, 34.6% yield) as a white solid ( 1H NMR (400 MHz, DMSO-d) δ 7.01 - 6.68 (m, 2H), 6.23 - 5.77 (m, 2H), 2.52 - 2.50 (m, 6H), 2.32 - 1.93 (m, 3H)) and peak 2 (desired): (S)-2,4,6-trimethylbenzenesulfinamide (51.6 g, 267 mmol, 35.0% yield) was obtained as a white solid ( 1 H NMR (400 MHz, DMSO-d) δ 6.87 (s, 2H), 6.16 - 5.82 (m, 2H), 2.53 - 2.50 (m, 6H), 2.34 - 1.93 (m, 3H)).

[0577] [ka] Step 3. This compound was synthesized using a method similar to that described in reference 1. To a well-stirred solution of (S)-2,4,6-trimethylbenzenesulfinamide (15.5 g, 85 mmol) in dichloromethane (235 mL) and 4 Å molecular sieves (84.5 g) was added a solution of ethyl 2-oxoacetate in toluene (25.9 mL, 127 mmol) and pyrrolidine (0.699 mL, 8.46 mmol). The reaction mixture was stirred overnight at room temperature. The reaction was repeated, and the two batches were combined for workup. The reaction mass was filtered through Celite, and the bed was washed with DCM. The solvent was removed under reduced pressure to give the crude product (55 g) as a brownish mass. The crude compound was purified by ISCO (column size: 300 g silica column; adsorbent: 60-120 silica mesh; mobile phase: 40% EtOAc / petroleum ether), and the product was collected with 15-20% EtOAc. The fractions were concentrated to give ethyl (S,E)-2-((mesitylsulfinyl)imino)acetate (16.5 g, 57.4 mmol, 67.9% yield) as a colorless liquid, which slowly solidified as an off-white solid. 1H NMR (400 MHz, CDCl3) δ = 8.27 (s, 1H), 7.04 - 6.70 (m, 2H), 4.59 - 4.21 (m, 2H), 2.55 - 2.44 (m, 6H), 2.36 - 2.23 (m, 3H), 1.51 - 1.30 (m, 3H). 2.670 minutes. 268.2 (M+H).

[0578] Step 4. General Method for the Synthesis of TCNHPI Redox-Active Esters in Reference ACIE: TCNHPI esters were synthesized according to the general method previously reported (ACIE paper and references therein): To a round-bottom flask or culture tube was added carboxylic acid (1.0 equiv.), N-hydroxytetrachlorophthalimide (1.0-1.1 equiv.), and DMAP (0.1 equiv.). Dichloromethane (0.1-0.2 M) was added, and the mixture was stirred vigorously. Carboxylic acid (1.0 equiv.) was added. DIC (1.1 equiv.) was then added via syringe, and the mixture was stirred until the acid was consumed (as determined by TLC). Typical reaction times were 0.5-12 h. The mixture was filtered (through a thin Celite® pad, SiO2, or fritted funnel) and rinsed with CHCl2 / Et2O. The solvent was removed under reduced pressure, and the crude mixture was purified by column chromatography to afford the desired TCNHPI redox-active esters. If necessary, the TCNHPI redox-active ester can be recrystallized from CH2Cl2 / MeOH.

[0579] Step 5. 4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl-4-((tert-butoxycarbonyl)amino)-2,2-dimethylbutanoate was obtained as a white solid following the general method with TCNHPI redox-active ester on a 5.00 mmol scale. Column purification (silica gel, gradient CHCl to 10:1 CHCl:EtO) afforded 2.15 g (84%) of the title compound. 1H NMR (400 MHz, CDCl3): δ 4.89 (br s, 1H), 3.30 (q, J = 7.0 Hz, 2H), 1.98 (t, J = 7.6 Hz, 2H), 1.42 (s, 15H) ppm. 13 C NMR (151 MHz, CDCl3): δ 173.1, 157.7, 156.0, 141.1, 130.5, 124.8, 79.3, 40.8, 40.2, 36.8, 28.5, 25.2 ppm. HRMS (ESI-TOF): C 19 H 20 Cl4N2NaO6[M+Na] + Calculated value: 534.9968, Measured value: 534.9973.

[0580] Step 6. Ethyl (S)-5-((tert-butoxycarbonyl)amino)-2-(((S)-mesitylsulfinyl)amino)-3,3-dimethylpentanoate was synthesized using the general method for decarboxylative amino acid synthesis in the reference ACIE. To a culture tube containing TCNHPI redox-active ester A (1.0 mmol), sulfinimine B (2.0 mmol), Ni(OAc)2·4H2O (0.25 mmol, 25 mol%), and zinc (3 mmol, 3 equiv.) were added. The tube was then evacuated and backfilled with argon (three times). Anhydrous NMP (5.0 mL, 0.2 M) was added using a syringe. The mixture was stirred overnight at rt. The reaction mixture was then diluted with EtOAc, washed with water, brine, and dried over MgSO4. After filtration, the organic layer was concentrated under reduced pressure (30°C water bath) and purified by flash column chromatography (silica gel) to give the product. Purification on a column (2:1 hexane:EtOAc) afforded 327.6 mg (72%) of the title compound ethyl (S)-5-((tert-butoxycarbonyl)amino)-2-(((S)-mesitylsulfinyl)amino)-3,3-dimethylpentanoate as a colorless oil. 1H NMR (600 MHz, CDCl3): δ 6.86 (s, 2H), 5.04 (d, J = 10.1 Hz, 1H), 4.47 (s, 1H), 4.28 - 4.16 (m, 2H), 3.66 (d, J = 10.1 Hz, 1H), 3.27 - 3.05 (m, 2H), 2.56 (s, 6H), 2.28 (s, 3H), 1.54 - 1.46 (m, 2H), 1.43 (s, 9H), 1.30 (t, J = 7.2 Hz, 3H), 0.96 (s, 6H) ppm. 13 C NMR (151 MHz, CDCl3): δ 172.5, 155.9, 141.1, 137.9, 136.9, 131.0, 79.4, 65.5,61.7, 38.8, 37.1, 36.5, 28.5, 23.9, 23.6, 21.2, 19.4, 14.3 ppm. HRMS (ESI-TOF): C 23 H 39 N2O5S [M+H] + Calculated value: 455.2574, measured value: 455.2569.

[0581]

change

[0582] (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4,4-difluorocyclohexyl)propanoic acid [ka] The final product was synthesized in a manner similar to ethyl (S)-5-((tert-butoxycarbonyl)amino)-2-(((S)-mesitylsulfinyl)amino)-3,3-dimethylpentanoate. The synthesis afforded the desired (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4,4-difluorocyclohexyl)propanoic acid (60 mg, 0.14 mmol, 27.9% yield) as a white solid after purification by reverse-phase HPLC. 1 H NMR (500 MHz, CDCl3) δ 7.79 (br d, J = 7.5 Hz, 2H), 7.61 (br s, 2H), 7.43 (s, 2H), 7.36 - 7.31 (m, 2H), 5.24 - 5.06 (m, 1H), 4.57 - 4.36 (m, 3H), 4.29 - 4.16 (m, 1H), 2.19 - 1.99 (m, 2H), 1.97 - 1.18 (m, 9H).

[0583] (2S)-5-(tert-butoxy)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3,3-dimethyl-5-oxopentanoic acid [ka] Process 1 A solution of 4,4-dimethyldihydro-2H-pyran-2,6(3H)-dione (8.29 g, 58.3 mmol) in dry toluene (100 mL) was added to a solution of (R)-2-amino-2-phenylethan-1-ol in dry toluene (100 mL) and CHCl (20 mL) at room temperature. The reaction mixture was then heated to 60° C. and reacted for 12 hours. The mixture was cooled to room temperature until a white solid formed. The solid was filtered and washed with 1:1 EtOAc / CHCl to give the crude desired compound (R)-5-((2-hydroxy-1-phenylethyl)amino)-3,3-dimethyl-5-oxopentanoic acid (11.9 g, 41.0 mmol, 56.2% yield), which was not further purified. 1H NMR (300 MHz, DMSO-d6) δ 8.41 (br d, J = 7.9 Hz, 1H), 7.44-7.32 (m, 2H), 7.32-7.27 (m, 4H), 7.26-7.18 (m, 1H), 4.89-4.80 (m, 1H), 4.14-3.98 (m, 1H), 3.63-3.43 (m, 3H), 2.27-2.18 (m, 4H), 2.08 (s, 1H), 1.99 (s, 1H), 1.17 (t, J = 7.2 Hz, 1H), 1.00 (d, J = 4.5 Hz, 6H), 0.92 (s, 1H).

[0584] Process 2 (R)-5-((2-hydroxy-1-phenylethyl)amino)-3,3-dimethyl-5-oxopentanoic acid (12 g, 43.0 mmol) was dissolved in a solution of benzyltrimethylammonium chloride (8.93 g, 48.1 mmol) in DMA (250 mL). KCO (154 g, 1117 mmol) was added to the above solution, followed by 2-bromo-2-methylpropane (235 mL, 2091 mmol). The reaction mixture was stirred at 55 °C for 24 h. The reaction mixture was then diluted with EtOAc (100 mL) and washed with HO (50 mL × 3) and brine (50 mL). The organic phase was dried over NaSO, concentrated under reduced pressure, and purified by flash column silica gel chromatography (CHCl / MeOH, 15:1) to give tert-butyl (S)-5-((2-hydroxy-1-phenylethyl)amino)-3,3-dimethyl-5-oxopentanoate (6.0 g, 17.89 mmol, 41.6% yield). Analytical LC / MS conditions: M: 1.96 min, 336.3 [M+H] + . 1H NMR (300 MHz, DMSO-d6) d = 8.14 (br d, J = 8.3 Hz, 1H), 7.33 - 7.25 (m, 4H), 7.25 - 7.17 (m, 1H), 4.90 - 4.77 (m, 2H), 3.52 (br t, J = 5.7 Hz, 2H), 3.34 (s, 1H), 2.94 (s, 1H), 2.78 (s, 1H), 2.20 (d, J = 14.0 Hz, 4H), 1.97 (d, J = 9.8 Hz, 2H), 1.41 - 1.31 (m, 9H), 1.00 (d, J = 1.1 Hz, 6H).

[0585] [ka] Process 3 tert-Butyl (S)-5-((2-hydroxy-1-phenylethyl)amino)-3,3-dimethyl-5-oxopentanoate (6 g, 17.89 mmol) and 2,3-dichloro-5,6-dicyano-p-benzoquinone (6.09 g, 26.8 mmol) were dissolved in dry dichloromethane (70 mL) under Ar. Triphenylphosphine (7.04 g, 26.8 mmol) was added to the above solution. The reaction mixture was stirred at room temperature for 2 h. The crude product was then concentrated under reduced pressure and purified by flash column silica gel chromatography (EtOAc / hexane, 1:5) to give tert-butyl (S)-3,3-dimethyl-4-(4-phenyl-4,5-dihydrooxazol-2-yl)butanoate (5.6 g, 17.64 mmol, 99% yield). ESI-MS(+) m / z: 318.3 [M+H] + . 1H NMR (300MHz, DMSO-d6) d = 7.41 - 7.18 (m, 5H), 5.18 (t, J = 9.1 Hz, 1H), 4.59 (dd, J = 8.7, 10.2 Hz, 1H), 3.94 - 3.85 (m, 1H), 3.94 - 3.85 (m, 1H), 3.95 - 3.84 (m, 1H), 4.10 - 3.84 (m, 1H), 2.43 - 2.22 (m, 4H), 1.40 (s, 9H), 1.09 (d, J = 1.9 Hz, 6H).

[0586] Process 4 [ka] A solution of tert-butyl (S)-3,3-dimethyl-4-(4-phenyl-4,5-dihydrooxazol-2-yl)butanoate (5.6 g, 17.64 mmol) in EtOAc (250 mL) was added to selenium dioxide (4.89 g, 44.1 mmol) and refluxed for 2 hours. The reaction mixture was then cooled to room temperature and stirred for 12 hours. The crude product was then concentrated under reduced pressure and purified by flash column silica gel chromatography (EtOAc / hexane, 1:7) to give tert-butyl (S)-3-methyl-3-(2-oxo-5-phenyl-5,6-dihydro-2H-1,4-oxazin-3-yl)butanoate (1.3 g, 3.92 mmol, 22.23% yield) as a colorless liquid. ESI-MS(+) m / z: 332.2 [M+H] + . 1 H NMR (CDCl3) δ 1.37 (s, 3H), 1.42 (s, 9H), 1.44 (s, 3H), 2.59 (d, J = 15.5 Hz, 1H), 3.12 (d, J = 15.5 Hz, 1H), 4.32 (t, J = 11.1 Hz, 1H), 4.47 (dd, J = 4.3 Hz, J = 6.7 Hz, 1H), 4.80 (dd, J = 4.3 Hz, J = 6.7 Hz, 1H), 7.35-7.39 (m, 5H). 13C NMR (CD3Cl) δ 26.40, 27.29, 28.00, 40.84, 45.94, 59.72, 70.88, 80.63, 127.13, 127.92, 128.65, 137.58, 155.07, 167.46, 171.95.

[0587] Process 5 [ka] Platinum(IV) oxide monohydrate (130 mg, 0.530 mmol) was added to a solution of tert-butyl (S)-3-methyl-3-(2-oxo-5-phenyl-5,6-dihydro-2H-1,4-oxazin-3-yl)butanoate (1.3 g, 3.92 mmol) in methanol (50 mL). The reaction flask was purged with H2 (3x) and stirred under H2 for 24 h. After evacuating the vessel, the reaction mixture was filtered through Celite, and the filtrate was washed with EtOAc. The crude product was concentrated under reduced pressure and purified by flash column silica gel chromatography (EtOAc / hexane, 1:8) to give tert-butyl 3-methyl-3-((3S,5R)-2-oxo-5-phenylmorpholin-3-yl)butanoate (1.2 g, 3.33 mmol, 85% yield). 1 H NMR (300 MHz, DMSO-d6) δ 7.52-7.42 (m, 2H), 7.41-7.26 (m, 3H), 4.30-4.20 (m, 2H), 4.13 (d, J = 10.6 Hz, 1H), 3.80 (d, J = 7.6 Hz, 1H), 3.07-2.98 (m, 1H), 2.47 (br s, 1H), 2.27 (d, J = 13.6 Hz, 1H), 1.43-1.35 (m, 9H), 1.17-1.07 (m, 5H).

[0588] Process 6. [ka] Pearlman's catalyst on carbon, Pd(OH) (1.264 g, 1.799 mmol, 20% w / w), was added to a solution of tert-butyl 3-methyl-3-((3S,5R)-2-oxo-5-phenylmorpholin-3-yl)butanoate (1.2 g, 3.60 mmol) in methanol (50 mL) / water (3.13 mL) / TFA (0.625 mL) (40:2.5:0.5, v / v / v). The vessel was purged with H and stirred under H for 24 h. After evacuating the vessel, the reaction mixture was filtered through Celite, and the filtrate was washed with MeOH. The crude product ((S)-2-amino-5-(tert-butoxy)-3,3-dimethyl-5-oxopentanoic acid (0.83 g, 3.59 mmol, 100% yield)) was concentrated under reduced pressure. This crude material was used in the next step without further purification. Analytical LC / MS conditions M: 1.13 min, 232.2 [M+H] + .

[0589] Step 7. [ka] The crude product (S)-2-amino-5-(tert-butoxy)-3,3-dimethyl-5-oxopentanoic acid (1 g, 4.32 mmol) was dissolved in water (30 mL). Na2CO3 (0.916 g, 8.65 mmol) was then added to the above solution. To this solution, a solution of fmoc n-hydroxysuccinimide ester (1.458 g, 4.32 mmol) in dioxane (30 mL) was added dropwise at 0 °C and stirred at room temperature for 16 hours. The reaction mixture was acidified with 1N HCl to pH ∼2, extracted with EtOAc (50 mL × 3), dried over NaSO, concentrated under reduced pressure, and purified by flash column silica gel chromatography (EtOAc / petroleum ether, 35–39%) to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-3,3-dimethyl-5-oxopentanoic acid (0.73 g, 1.567 mmol, 36.2% yield) as a white solid. LCMS, analytical LC / MS conditions E, MS(ESI) t R = 2.135 min, m / z 452.2 [M−H] - .1 H NMR (400 MHz, DMSO-d6) δ 12.78-12.64 (m, 1H), 7.90 (d, J = 7.5 Hz, 2H), 7.77 (dd, J = 4.5, 7.0 Hz, 2H), 7.65 (br d, J = 9.5 Hz, 1H), 7.46-7.39 (m, 2H), 7.37-7.29 (m, 2H), 4.32-4.15 (m, 4H), 2.39-2.31 (m, 1H), 2.30-2.21 (m, 1H), 1.39 (s, 9H), 1.12-1.00 (m, 6H).

[0590] Preparation of (2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-(morpholin-4-yl)propanoic acid [ka] Process 1 To a 2 L multi-necked round-bottom flask equipped with a thermal pocket was added (S)-3-amino-2-((tert-butoxycarbonyl)amino)propanoic acid (50 g, 245 mmol), dioxane (500 mL), followed by 1-bromo-2-(2-bromoethoxy)ethane (30.8 mL, 245 mmol) at rt. NaOH (367 mL, 734 mmol) solution was added, and the resulting clear yellow solution was heated at 110 °C (external temperature, 85 °C internal temperature) for 12 h. An aliquot of the clear solution was subjected to LCMS (polar method), which indicated completion, and then the dioxane was evaporated to give a light red solution, which was acidified to pH 3. The resulting mixture was concentrated under high vacuum (approximately 4 mbar) at 60° C. to give (S)-2-((tert-butoxycarbonyl)amino)-3-morpholinopropanoic acid (67 g, 244 mmol, 100% yield) as a pale yellow solid. Analytical LC / MS conditions M: 0.56 min, 275.2 [M+H] + .

[0591] Process 2 To a stirring suspension of (S)-2-((tert-butoxycarbonyl)amino)-3-morpholinopropanoic acid (100 g, 365 mmol) in dioxane (400 mL) at 0-5°C, HCl in dioxane (911 mL, 3645 mmol) was added slowly over 20 min. The resulting mixture was stirred at rt for 12 h. Evaporation of the volatiles gave a pale yellow viscous crude (S)-2-amino-3-morpholinopropanoic acid (16 g), which was used in the next step without further purification. MS (ESI) m / z 175.2 [M+H] + .

[0592] Process 3 The crude product (S)-2-amino-3-morpholinopropanoic acid (11 g, 63.1 mmol) was dissolved in water (250 mL). Na2CO3 (13.39 g, 126 mmol) was then added to the above solution. Fmoc-N-hydroxysuccinimide ester (21.30 g, 63.1 mmol) was added dropwise to the solution at 0 °C and stirred at room temperature for 16 hours. The reaction mixture was acidified with 1N HCl to pH ∼2, extracted with EtOAc (500 mL × 3), dried over NaSO, concentrated under reduced pressure, and purified by flash column silica gel chromatography (petroleum ether / EtOAc, 0–100%, then MeOH / CHCl 3, 0–15%) to give (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-morpholinopropanoic acid (23 g, 55.9 mmol, 89% yield) as a brown solid. Analytical LC / MS conditions E: 1.43 min, 397.2 [M+H] + . 1H NMR (400 MHz, methanol-d4) δ 7.78 (br d, J = 7.5 Hz, 2H), 7.71-7.57 (m, 2H), 7.42-7.34 (m, 2H), 7.34-7.26 (m, 2H), 4.71 (br s, 1H), 4.54-4.32 (m, 2H), 4.29-4.17 (m, 1H), 3.90 (br s, 4H), 3.76-3.62 (m, 1H), 3.58-3.47 (m, 1H), 3.41 (br s, 2H), 3.36-3.32 (m, 2H), 3.31-3.26 (m, 1H).

[0593] Preparation of (2S,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)butanoic acid [ka] Process 1 [ka] To a solution of benzyl (tert-butoxycarbonyl)-L-threoninate (22 g, 71.1 mmol) in CHCl (600 mL) was added trifluoromethanesulfonic anhydride (24.08 g, 85 mmol) dropwise at −78°C, followed by the slow addition of 2,6-lutidine (10.77 mL, 92 mmol). After stirring at the same temperature for 1.5 hours and monitoring by TLC (Hex: EtOAc 8:2), tetrabutylammonium azide (50.6 g, 178 mmol) was added portionwise. After stirring at −78°C for 1 hour, the cooling bath was removed and the reaction mixture was allowed to reach 23°C over 1.5 hours. The reaction was repeated. Saturated aqueous NaHCO was added, and the aqueous phase was extracted with EtOAc. The crude product was purified by flash chromatography on silica gel (Hex: EtOAc 95:5 to 9:1) to give benzyl (2S,3S)-3-azido-2-((tert-butoxycarbonyl)amino)butanoate (20 g, 59.8 mmol, 84% yield) as a colorless liquid. Analytical LC / MS conditions E: 3.13 min, 333.2 [MH]- .

[0594] Process 2 [ka] A solution of benzyl (2S,3S)-3-azido-2-((tert-butoxycarbonyl)amino)butanoate (20 g, 59.8 mmol), dichloromethane (300 mL), and TFA (50 mL, 649 mmol) was stirred for 2 hours at 23 °C and then evaporated to dryness to give the corresponding amine. The amine was dissolved in water (200 mL) and tetrahydrofuran (200 mL). At 0 °C, DIPEA (11.49 mL, 65.8 mmol) was added, followed by Fmoc chloride (17.02 g, 65.8 mmol). The mixture was warmed to rt and stirred for 3 hours. Extraction with EtOAc and 0.5 M HCl solution followed by washing with brine solution was performed. Concentration gave a crude liquid. The crude product was purified by silica gel column chromatography. The product was eluted with 20% EtOAc in petroleum ether. The fractions were concentrated to give benzyl (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-azidobutanoate (23 g, 50.4 mmol, 84% yield) as a colorless liquid. Analytical LC / MS conditions E: 3.70 min, 479.3 [M+Na] + .

[0595] Process 3. A multi-necked round-bottom flask was charged with a solution of benzyl (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-azidobutanoate (40 g, 88 mmol) in tetrahydrofuran (1200 mL). Pd / C (9.32 g, 8.76 mmol) was added under nitrogen, and the reaction was stirred under hydrogen for 12 h. A solution of sodium bicarbonate (11.04 g, 131 mmol) in water (6 mL) was added, followed by Boc-anhydride (30.5 mL, 131 mmol). The mixture was stirred under nitrogen for 12 h. The reaction mass was filtered through a bed of Celite, and the bed was washed with a THF / water mixture. The mother liquor was concentrated and washed with EtOAc. The pH of the aqueous layer was then adjusted to 7-6 using 1.5 N HCl solution. The resulting white solid was extracted with ethyl acetate. The above reaction was repeated three more times. The combined organics were washed with water and brine, dried over sodium sulfate, and concentrated to give (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tert-butoxycarbonyl)amino)butanoic acid as a white solid (28 g). This was mixed with the previously obtained batch (8 g) in DCM (200 mL). n-Hexane (1 L) was added to the above solution and sonicated for 2 minutes. The solid was filtered, rinsed with hexane, and dried overnight to give (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tert-butoxycarbonyl)amino)butanoic acid (36 g, 81 mmol, 92% yield) as a white powder. Analytical LC / MS conditions E: 1.90 min, 439.2 [MH] - . 1H NMR (400 MHz, DMSO-d6) d 7.90 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 7.2 Hz, 2H), 7.43 (t, J = 7.2 Hz, 2H), 7.34 (t, J = Hz, 6.71 (br. d. J = 7.6Hz, 1H), 4.29-4.26 (m, 2H), 4.25-4.21 (m, 1H), 3.94-3.90 (m, 1H), 1.37 (s, 9H), 1.02 (d, J = 6.8 Hz, 3H). 13C NMR (101 Hz, DMSO-d6) δ 171.9, 156.3, 154.8, 143.7, 140.6, 127.6, 127.0, 125.3, 120.0, 77.7, 65.8, 57.8, 47.0, 46.6, 28.2, 16.2.

[0596] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(1-(((tert-butoxycarbonyl)amino)methyl)cyclopropyl)acetic acid [ka] The compound was obtained following a similar method to ethyl (S)-5-((tert-butoxycarbonyl)amino)-2-(((S)-mesitylsulfinyl)amino)-3,3-dimethylpentanoate. The synthesis afforded the desired product (0.65 g, 22% yield) as a white solid after purification by flash column chromatography (Red Sep, 40 g, SiO, 35-40% EtOAc:hexanes (compound ELSD active)). Analytical LC / MS conditions: E: 2.04 min, 465.2 [MH] - . 1H NMR (300 MHz, DMSO-d6) δ 7.90 (d, J = 7.6 Hz, 2H), 7.71 (m, 3H), 7.47-7.27 (m, 2H), 6.98-6.71 (m, 2H), 4.30 - 4.17 (m, 3H), 3.94-3.82 (m, 1H), 3.20-2.90 (m, 2H), 1.44-1.30 (m, 9H), 0.48 (br s, 4H).

[0597] Preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid [ka] The compound was obtained following a similar method to ethyl (S)-5-((tert-butoxycarbonyl)amino)-2-(((S)-mesitylsulfinyl)amino)-3,3-dimethylpentanoate. The synthesis afforded the desired product (2.66 g, 20% yield) as a slightly tan solid after purification by reverse-phase HPLC. Analytical LC / MS conditions E: 1.87 min, 467.2 [MH] - . 1 H NMR (400 MHz, DMSO-d6) δ 7.89 (d, J = 7.6 Hz, 2H), 7.69 (m, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.34-7.31 (m, 2H), 6.71 (br. d. J = 7.6Hz, 1H), 4.29 - 4.23 (m, 3H), 3.77-3.70 (m, 5H), 2.80 (m, 1H), 1.36 (s, 9H).

[0598] Example 2: Preparation of compounds of formula (I) Preparation of Compound 1000 [ka] A 45 mL polypropylene solid-phase reaction vessel was loaded with Siebber or Rink resin on a 50 μmol scale, and the reaction vessel was placed in a Symphony peptide synthesizer. The following procedures were then performed sequentially: the "Symphony resin swelling method" was followed; the "Symphony single coupling method" was followed with Fmoc-Gly-OH; the "Symphony single coupling method" was followed with Fmoc-Cys(Trt)-OH; the "Symphony single coupling method" was followed with Fmoc-Ser(tBu)-OH; the "Symphony single coupling method" was followed with Fmoc-Val-OH; the "Symphony single coupling method" was followed with Fmoc-Ahp-OH; the "Symphony single coupling method" was followed with Fmoc-Val-OH; the "Symphony single coupling method" was followed with Fmoc-D-Phe-OH; the "Symphony single coupling method" was followed with Fmoc-Asp-OH. "Symphony single coupling method" was followed with Fmoc-Arg(Pbf)-OH; "Symphony double coupling method" was followed with Fmoc-Bip-OH; "Symphony single coupling method" was followed with Fmoc-Val-OH; "Symphony single coupling method" was followed with Fmoc-Trp(Boc)-OH; "Symphony single coupling method" was followed with Fmoc-Asp(tBu)-OH; "Symphony single coupling method" was followed with Fmoc-Tyr(tBu)-OH; "Symphony single coupling method" was followed with Fmoc-Phe-OH; "Symphony chloroacetic anhydride coupling method" was followed; "Global deprotection method A" was followed; "Cyclization method" was followed.

[0599] The crude material was purified by preparative LC / MS using the following conditions: Column: Waters xbridge C-18, 30 x 150 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water and 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water and 10 mM ammonium acetate; Gradient: 20 to 60% B over 20 min, then hold at 100% B for 5 min; Flow rate: 20 mL / min. Fractions containing the desired product were combined and dried by centrifugal evaporation. The product yield was 6.3 mg, and its estimated purity by LCMS analysis was 97%.

[0600] Analysis conditions A: retention time = 1.72 minutes; ESI-MS(+) m / z [M+H] + : 1981.7.

[0601] Analysis condition B: retention time = 1.86 min; ESI-MS(+) m / z [M+H] + : 1981.9.

[0602] Preparation of Compound 1001 [ka] A 45 mL polypropylene solid phase reaction vessel was loaded on a 50 μmol scale using Siebber or Rink resin and the reaction vessel was placed in a Symphony X peptide synthesizer. The following procedures were then carried out successively: "Symphony X resin swelling method" was followed; "Symphony X single coupling method" was followed with Fmoc-Ala-OH; "Symphony X single coupling method" was followed with Fmoc-Cys(Trt)-OH; "Symphony X single coupling method" was followed with Fmoc-Thrr(tBu)-OH; "Symphony X single coupling method" was followed with Fmoc-Val-OH; "Symphony X single coupling method" was followed with Fmoc-Leu-OH; "Symphony X single coupling method" was followed with Fmoc-Dab(Boc)-OH; "Symphony X single coupling method" was followed with Fmoc-D-Leu-OH; "Symphony X single coupling method" was followed with Fmoc-Ala-OH; "Symphony X single coupling method" or "Symphony "Symphony X double coupling method" was followed with Fmoc-Arg(Pbf)-OH; "Symphony X single coupling method" was followed with Fmoc-Bip-OH; "Symphony X single coupling method" was followed with Fmoc-Val-OH; "Symphony X single coupling method" was followed with Fmoc-Trp(Boc)-OH; "Symphony X single coupling method" was followed with Fmoc-Asp(tBu)-OH; "Symphony X single coupling method" was followed with Fmoc-Tyr(tBu)-OH; "Symphony X single coupling method" was followed with Fmoc-Asn(Trt)-OH; "Symphony X chloroacetic anhydride coupling method" was followed; "Global deprotection method A" was followed; "Cyclization method" was followed.

[0603] The crude material was purified by preparative LC / MS using the following conditions: Column: XBridge C18, 30 x 200 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water and 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water and 10 mM ammonium acetate; Gradient: 10 to 60% B over 20 min, then a 2 min hold at 100% B; Flow rate: 45 mL / min. Fractions containing the desired product were combined and dried by centrifugal evaporation. The product yield was 2.9 mg, and its estimated purity by LCMS analysis was 92%.

[0604] Analysis conditions A: retention time = 1.66 min; ESI-MS(+) m / z [M+H] + : 1886.2.

[0605] Analysis condition B: retention time = 1.57 min; ESI-MS(+) m / z [M+2H] 2+ : 944.1.

[0606] Preparation of Compound 1002 [ka] To a 45 mL polypropylene solid-phase reaction vessel, Rink resin (470 mg, 0.25 mmol) was added, and the reaction vessel was placed in a pre-stage peptide synthesizer. The following procedures were then performed sequentially: the "Prelude Resin Swelling Method" was followed; the "Pre-stage Single Coupling Method" was followed using Fmoc-Ala-OH; the "Pre-stage Single Coupling Method" was followed using Fmoc-Cys(Trt)-OH; the "Pre-stage Single Coupling Method" was followed using Fmoc-Thr(tBu)-OH; the "Pre-stage Single Coupling Method" was followed using Fmoc-Val-OH; the "Pre-stage Single Coupling Method" was followed using Fmoc-Cha-OH; the "Pre-stage Single Coupling Method" was followed using Fmoc-Val-OH. was followed with Fmoc-Dab(Boc)-OH; "Pre-step single coupling method" was followed with Fmoc-D-Leu-OH; "Pre-step single coupling method" was followed with Fmoc-Orn(Boc)-OH; "Pre-step single coupling method" was followed with Fmoc-Cit-OH; "Pre-step single coupling method" was followed with Fmoc-Bip-OH; The resin was divided into 0.050 mmol portions and transferred to 45 mL polypropylene solid phase reaction vessels which were placed in a Symphony peptide synthesizer. The following procedures were then carried out successively: "Symphony single coupling method" was followed with Fmoc-Ser(Me)-OH; "Symphony single coupling method" was followed with Fmoc-Trp(Boc)-OH; "Symphony single coupling method" was followed with Fmoc-Asp(tBu)-OH; "Symphony single coupling method" was followed with Tyr(CH2COOtBu)-OH; "Symphony single coupling method" was followed with Fmoc-Dap(Boc)-OH; "Symphony chloroacetic anhydride coupling method" was followed; "Symphony final rinse and dry method" was followed; "Global deprotection method A" was followed; "Cyclization method A" was followed.

[0607] The crude material was purified by preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water and 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water and 10 mM ammonium acetate; Gradient: 16% B, hold 0 min, 16–56% B over 20 min, then 100% B, hold 4 min; Flow rate: 20 mL / min; Column temperature: 25°C. Fraction collection was triggered by the MS signal. Fractions containing the desired product were combined and dried by centrifugal evaporation. The material was further purified by preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Gradient: 33% B, hold for 0 min, 33–55% B over 25 min, then 100% B, hold for 2 min; Flow rate: 20 mL / min; Column temperature: 25 °C. Fraction collection was triggered by UV signal. Fractions containing the desired product were combined and dried by centrifugal evaporation. The product yield was 15.1 mg, and its estimated purity by LCMS analysis was 96%.

[0608] Analysis condition A: retention time = 1.43 min; ESI-MS(+) m / z [M+2H] 2+ : 1002.2.

[0609] Analysis condition B: retention time = 1.42 minutes; ESI-MS(+) m / z [M+2H] 2+ : 1002.0.

[0610] Following the general synthesis and purification methods and those described for compounds 1000-1002 and 2048, compounds 1003-1865, 2000-2330 and 2500-2707 were obtained.

[0611] Preparation of Compound 1003 [ka] Compound 1003 was prepared on a 50 μmol scale. The yield of the product was 2.4 mg, and its estimated purity by LCMS analysis was 100%. Analysis condition A: retention time = 1.84 min; ESI-MS(+) m / z [M+2H] 2+ : 992.

[0612] Preparation of Compound 1004 [ka] Compound 1004 was prepared on a 50 μmol scale. The yield of the product was 7 mg, and its estimated purity by LCMS analysis was 96.8%. Analysis condition A: retention time = 1.62 min; ESI-MS(+) m / z [M+2H] 2+ : 1915.2.

[0613] Preparation of Compound 1005 [ka] Compound 1005 was prepared on a 50 μmol scale. The yield of the product was 10.9 mg, and its estimated purity by LCMS analysis was 95.3%. Analysis condition B: retention time = 1.39 min; ESI-MS(+) m / z [M+3H] 3+ : 644.1.

[0614] Preparation of Compound 1006 [ka] Compound 1006 was prepared on a 50 μmol scale. The yield of the product was 18.5 mg, and its estimated purity by LCMS analysis was 98.5%. Analysis condition B: retention time = 1.44 min; ESI-MS(+) m / z [M+2H] 2+ : 972.1.

[0615] Preparation of Compound 1007 [ka] Compound 1007 was prepared on a 50 μmol scale. The yield of the product was 41 mg, and its estimated purity by LCMS analysis was 96.1%. Analysis condition B: retention time = 1.28, 1.31 min; ESI-MS(+) m / z [M+2H] 2+ : 1001.

[0616] Preparation of Compound 1008 [ka] Compound 1008 was prepared on a 50 μmol scale. The yield of the product was 32.3 mg, and its estimated purity by LCMS analysis was 96.6%. Analysis condition A: retention time = 1.33 min; ESI-MS(+) m / z [M+3H] 3+ : 648.8.

[0617] Preparation of Compound 1009 [ka] Compound 1009 was prepared on a 50 μmol scale. The yield of the product was 30.4 mg, and its estimated purity by LCMS analysis was 95.8%. Analysis condition B: retention time = 1.26 min; ESI-MS(+) m / z [M+3H] 3+ : 634.9.

[0618] Preparation of Compound 1010 [ka] Compound 1010 was prepared on a 50 μmol scale. The yield of the product was 17 mg, and its estimated purity by LCMS analysis was 92.7%. Analysis condition B: retention time = 1.27 min; ESI-MS(+) m / z [M+3H] 3+ : 653.3.

[0619] Preparation of Compound 1011 [ka] Compound 1011 was prepared on a 50 μmol scale. The yield of the product was 44.5 mg, and its estimated purity by LCMS analysis was 95.9%. Analysis condition B: retention time = 1.27 min; ESI-MS(+) m / z [M+3H] 3+ : 658.2.

[0620] Preparation of Compound 1012 [ka] Compound 1012 was prepared on a 50 μmol scale. The yield of the product was 20.1 mg, and its estimated purity by LCMS analysis was 98.2%. Analysis condition B: retention time = 1.4 min; ESI-MS(+) m / z [M+H] + : 1985.2.

[0621] Preparation of Compound 1013 [ka] Compound 1013 was prepared on a 50 μmol scale. The yield of the product was 31.7 mg, and its estimated purity by LCMS analysis was 92.3%. Analysis condition B: retention time = 1.25 min; ESI-MS(+) m / z [M+2H] 2+ : 1000.8.

[0622] Preparation of Compound 1014 [ka] Compound 1014 was prepared on a 50 μmol scale. The yield of the product was 3.9 mg, and its estimated purity by LCMS analysis was 98%. Analysis condition B: retention time = 1.55 min; ESI-MS(+) m / z [M+H] + : 1828.9.

[0623] Preparation of Compound 1015 [ka] Compound 1015 was prepared on a 50 μmol scale. The yield of the product was 23.4 mg, and its estimated purity by LCMS analysis was 93.2%. Analysis condition B: retention time = 1.36 min; ESI-MS(+) m / z [M+2H] 2+ : 937.

[0624] Preparation of Compound 1016 [ka] Compound 1016 was prepared on a 50 μmol scale. The yield of the product was 9.5 mg, and its estimated purity by LCMS analysis was 93.8%. Analysis condition B: retention time = 1.34 min; ESI-MS(+) m / z [M+2H] 2+ : 952.2.

[0625] Preparation of Compound 1017 [ka] Compound 1017 was prepared on a 50 μmol scale. The yield of the product was 13 mg, and its estimated purity by LCMS analysis was 92.2%. Analysis condition B: retention time = 1.33 min; ESI-MS(+) m / z [M+2H] 2+ : 966.

[0626] Preparation of Compound 1018 [ka] Compound 1018 was prepared on a 50 μmol scale. The yield of the product was 18.2 mg, and its estimated purity by LCMS analysis was 90.8%. Analysis condition B: retention time = 1.33 min; ESI-MS(+) m / z [M+2H] 2+ : 959.2.

[0627] Preparation of Compound 1019 [ka] Compound 1019 was prepared on a 50 μmol scale. The yield of the product was 11.9 mg, and its estimated purity by LCMS analysis was 96%. Analysis condition A: retention time = 1.35 min; ESI-MS(+) m / z [M+2H] 2+ : 973.3.

[0628] Preparation of Compound 1020 [ka] Compound 1020 was prepared on a 50 μmol scale. The yield of the product was 6 mg, and its estimated purity by LCMS analysis was 88.8%. Analysis condition B: retention time = 1.4 min; ESI-MS(+) m / z [M+2H] 2+ : 952.4.

[0629] Preparation of Compound 1021 [ka] Compound 1021 was prepared on a 50 μmol scale. The yield of the product was 11.8 mg, and its estimated purity by LCMS analysis was 97.5%. Analysis condition A: retention time = 1.38 min; ESI-MS(+) m / z [M+2H] 2+ : 937.

[0630] Preparation of Compound 1022 [ka] Compound 1022 was prepared on a 50 μmol scale. The yield of the product was 18.9 mg, and its estimated purity by LCMS analysis was 92%. Analysis condition B: retention time = 1.4 min; ESI-MS(+) m / z [M+2H] 2+ : 923.1.

[0631] Preparation of Compound 1023 [ka] Compound 1023 was prepared on a 50 μmol scale. The yield of the product was 15.1 mg, and its estimated purity by LCMS analysis was 96.6%. Analysis condition A: retention time = 1.39 min; ESI-MS(+) m / z [M+2H] 2+ : 930.

[0632] Preparation of Compound 1024 [ka] Compound 1024 was prepared on a 50 μmol scale. The yield of the product was 22.2 mg, and its estimated purity by LCMS analysis was 93.2%. Analysis condition B: retention time = 1.34 min; ESI-MS(+) m / z [M+2H] 2+ : 951.2.

[0633] Preparation of Compound 1025 [ka] Compound 1025 was prepared on a 50 μmol scale. The yield of the product was 5.5 mg, and its estimated purity by LCMS analysis was 96%. Analysis condition A: retention time = 1.45 min; ESI-MS(+) m / z [M+2H] 2+ : 944.1.

[0634] Preparation of Compound 1026 [ka] Compound 1026 was prepared on a 50 μmol scale. The yield of the product was 7.8 mg, and its estimated purity by LCMS analysis was 92.7%. Analysis condition A: retention time = 1.45 min; ESI-MS(+) m / z [M+2H] 2+ : 915.3.

[0635] Preparation of Compound 1027 [ka] Compound 1027 was prepared on a 50 μmol scale. The yield of the product was 18.4 mg, and its estimated purity by LCMS analysis was 84.4%. Analysis condition B: retention time = 1.32 min; ESI-MS(+) m / z [M+2H] 2+ : 937.1.

[0636] Preparation of Compound 1028 [ka] Compound 1028 was prepared on a 50 μmol scale. The yield of the product was 7.8 mg, and its estimated purity by LCMS analysis was 90.7%. Analysis condition B: retention time = 1.36 min; ESI-MS(+) m / z [M+2H] 2+ : 923.2.

[0637] Preparation of Compound 1029 [ka] Compound 1029 was prepared on a 50 μmol scale. The yield of the product was 10.4 mg, and its estimated purity by LCMS analysis was 91%. Analysis condition B: retention time = 1.36 min; ESI-MS(+) m / z [M+2H] 2+ : 930.3.

[0638] Preparation of Compound 1030 [ka] Compound 1030 was prepared on a 50 μmol scale. The yield of the product was 12 mg, and its estimated purity by LCMS analysis was 95.4%. Analysis condition B: retention time = 1.55 min; ESI-MS(+) m / z [M+H] + : 1956.9.

[0639] Preparation of Compound 1031 [ka] Compound 1031 was prepared on a 50 μmol scale. The yield of the product was 5.6 mg, and its estimated purity by LCMS analysis was 100%. Analysis condition A: retention time = 1.71 min; ESI-MS(+) m / z [M+H] + : 1922.

[0640] Preparat...

Claims

1. Formula (I) 【Chemistry 1】 [During the ceremony, R 1 is C 1 -C 6 Alkoxy C 1 -C 6 Alkyl; C 1 -C 6 Alkyl; C 1 -C 6 Alkylamino C 1 -C 6 Alkyl; C 1 -C 6 Alkylcarbonylamino C 1 -C 6 Alkyl; Amino C 1 -C 6 Alkyl; Aminocarbonyl C 1 -C 6 Alkyl; Aryl C 1 -C 6 Alkyl; Arylcarbonylamino C 1 -C 6 Alkyl; Carboxy C 1 -C 6 Alkyl; Cyano C 1 -C 6 Alkyl; Heteroaryl C 1 -C 6 Alkyl; Heterocyclyl C 1 -C 6 Alkyl; Hydroxy C 1 -C 6 Alkyl; NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); and 【Chemistry 2】 (where: 【Chemistry 3】 is an azetidine, piperidine or pyrrolidine ring; 1 -C 6 Alkyl and aryl carbonyl amino C 1 -C 6 The aryl portion of the alkyl and the heteroaryl C 1 -C 6 The heteroaryl portion of the alkyl is optionally C 1 -C 6 Alkoxy, C 1 -C 6 Alkylcarbonylamino, C 2 -C 6 Alkynyloxy, aminocarbonyl, aryl optionally substituted with one or two carboxy groups, aryl C 1 -C 6 Alkoxy, Carboxy, Carboxy C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy, halo, and trifluoromethyl; R 1’ is hydrogen or C 1 -C 6 is alkyl; R 2 is C 1 -C 6 Alkoxy C 1 -C 6 Alkyl; Aryl C 1 -C 6 Alkyl; Azide C 1 -C 6 Alkyl; biscarboxy CHC 1 -C 6 Alkyl; Carboxy C 1 -C 6 Alkyl; and heteroaryl C 1 -C 6 alkyl; Aryl C 1 -C 6 The aryl portion of the alkyl and the heteroaryl C 1 -C 6 The heteroaryl portion of the alkyl is optionally C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkylcarbonylamino, C 2 -C 6 Alkynyloxy, Amino, Amino C 1 -C 6 Alkyl, aminocarbonyl, aryl optionally substituted with one or two carboxy groups, aryl C 1 -C 6 Alkoxy, arylcarbonyl, azido, carboxy, carboxy C 1 -C 6 Alkoxy, Carboxy C 1 -C 6 Alkyl, cyano, halo, haloC 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy, hydroxy, nitro, and trifluoromethyl; R 2’ is hydrogen or C 1 -C 6 is alkyl; R 3 is C 1 -C 6 Alkoxy C 1 -C 6 Alkyl; Aminocarbonyl C 1 -C 6 Alkyl, aryl C 1 -C 6 Alkoxy C 1 -C 6 Alkyl, aryl C 1 -C 3 Alkyl, Carboxy C 1 -C 6 Alkyl, Furyl C 1 -C 3 Alkyl, Hydroxy C 1 -C 6 Alkyl, HOS(O) 2 C 1 -C 3 Alkyl, CH 3 S (O) 2 NHC(O)(C 1 -C 3 Alkyl) and tetrazolyl C 1 -C 3 alkyl; wherein aryl C 1 -C 3 The aryl portion of the alkyl optionally contains one, two or three amino C 1 -C 3 is substituted with an alkyl group; R 4 is aryl C 1 -C 6 Alkyl and Heteroaryl C 1 -C 6 alkyl, wherein aryl C 1 -C 6 The aryl portion of the alkyl and the heteroaryl C 1 -C 6 The heteroaryl portion of the alkyl is optionally C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, amino, cyano, C 1 -C 6 substituted with one or more groups independently selected from fluoroalkyl, halo, and hydroxy; R 5 is C 1 -C 6 Alkoxy C 1 -C 6 Alkyl; C 1 -C 6 Alkyl; Aryl; Aryl C 1 -C 6 Alkyl; Cyano C 1 -C 6 Alkyl; C 3 -C 8 Cycloalkyl; 3 -C 8 Cycloalkyl)C 1 -C 6 Alkyl; Fluoro C 1 -C 6 Alkyl; Heteroaryl C 1 -C 6 Alkyl; and Hydroxy C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of the alkyl and the heteroaryl C 1 -C 6 The heteroaryl portion of the alkyl is optionally C 2 -C 6 Alkynyloxy, Amino, Amino C 1 -C 6 Alkyl, aminocarbonyl, aryl, aryl C 1 -C 6 Alkoxy, aryloxy, carboxy C 1 -C 6 Alkoxy, cyano, (C 3 -C 6 cycloalkyl)oxy, carboxy, halo, heteroaryl, and hydroxy, wherein the aryl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C 1 -C 3 Alkyl, C 1 -C 3 further substituted with 1, 2, or 3 groups independently selected from alkylcarbonylamino, carboxy, and hydroxy; R 6 is aryl-aryl C 1 -C 3 Alkyl, aryl-heteroaryl C 1 -C 3 Alkyl, Heteroaryl-Aryl C 1 -C 3 Alkyl and Heteroaryl-Heteroaryl C 1 -C 3 alkyl, where each aryl and each heteroaryl is optionally selected from C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, amino, cyano, C 1 -C 6 substituted with one or more groups independently selected from fluoroalkyl, halo, and hydroxyl; R 7 is hydrogen; C 1 -C 6 Alkyl; C 1 -C 6 Alkylcarbonylamino C 1 -C 6 Alkyl; C 2 -C 6 Alkynyl; Amino C 1 -C 6 Alkyl; Aminocarbonyl C 1 -C 6 Alkyl; Aryl; Aryl C 1 -C 6 Alkyl; Carboxy C 1 -C 6 Alkyl; C 3 -C 8 Cycloalkyl; 3 -C 8 Cycloalkyl)C 1 -C 6 Alkyl; haloarylcarbonylamino C 1 -C 6 Alkyl; Heteroaryl C 1 -C 6 Alkyl; Hydroxy C 1 -C 6 Alkyl; and NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); aryl C 1 -C 6 The aryl portion of the alkyl and the heteroaryl C 1 -C 6 The heteroaryl portion of the alkyl is optionally C 2 -C 6 Alkynyloxy, Aryl C 1 -C 6 Alkoxy, Carboxy, Carboxy C 1 -C 6 Alkoxy, HaloC 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy and hydroxy; R 8 is C 1 -C 6 Alkyl; C 1 -C 6 Alkylcarbonylamino C 1 -C 6 Alkyl; Amino C 1 -C 6 Alkyl; 7 H 15 O 6 ) Amino C 1 -C 6 Alkyl; Aminocarbonyl C 1 -C 6 Alkyl; Aryl C 1 -C 6 Alkyl; Carboxy C 1 -C 6 Alkyl; Heterocyclyl; Heteroaryl C 1 -C 6 Alkyl; and Hydroxy C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of alkyl and arylcarbonylamino C 1 -C 6 The alkyl group may optionally be an amino group. 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkyl, halo, and hydroxy; R 8’ is hydrogen or R 8 and R 8’ together with the atoms to which they are attached, 3 -C 8 forms a cycloalkyl ring; R 9 is C 1 -C 6 Alkyl; Aryl C 1 -C 6 Alkyl; and C 3 -C 8 Cycloalkyl C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from halo and hydroxy; R 10 is C 1 -C 6 Alkyl; C 2 -C 6 Alkynyl; Amino C 1 -C 6 Alkyl; Aminocarbonyl C 1 -C 6 Alkyl; Aryl C 1 -C 6 Alkyl; Carboxy C 1 -C 6 Alkyl; Hydroxy C 1 -C 6 Alkyl; 7 H 15 O 6 ) Amino C 1 -C 6 Alkyl; C 1 -C 6 Alkylcarbonylamino C 1 -C 6 Alkyl; Heteroaryl C 1 -C 6 Alkyl; and NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); aryl C 1 -C 6 The aryl portion of the alkyl is optionally 2 -C 6 Alkynyloxy and Aryl C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy; R 11 is C 1 -C 8 Alkyl; Aryl C 1 -C 6 Alkyl; C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl; and heteroaryl C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, Amino, Amino C 1 -C 6 Alkoxy, Amino C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkylcyano, halo, hydroxy, and trifluoromethyl; R 12 is C 1 -C 6 Alkyl, C 2 -C 6 Alkynyl, Aryl C 1 -C 6 Alkyl, Carboxy C 1 -C 6 Alkyl and Hydroxy C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally 2 -C 6 Alkynyloxy and Aryl C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy; R 13 is C 1 -C 6 Alkyl, C 1 -C 6 Alkylcarbonylamino C 1 -C 6 Alkyl, Amino C 1 -C 6 Alkyl, aminocarbonyl C 1 -C 6 Alkyl, aryl C 1 -C 6 Alkyl, Carboxy C 1 -C 6 Alkyl, haloarylcarbonylamino C 1 -C 6 Alkyl, Heteroaryl C 1 -C 6 Alkyl, Hydroxy C 1 -C 6 Alkyl and NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); aryl C 1 -C 6 The aryl portion of the alkyl is optionally 2 -C 6 Alkynyloxy and Aryl C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy; R 14 is aminocarbonyl; carboxy; or -C(O)NR 14’ CR 15 R 15’ R 15’’ where R 14’ is hydrogen or C 1 -C 6 alkyl or R 15 and R 14’ together with the atoms to which they are attached form an azetidine, morpholine, piperazine, piperidine, or pyrrolidine ring, each ring optionally substituted with an amino or hydroxy group; R 15 is hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkylcarbonylamino C 1 -C 6 Alkyl, C 2 -C 6 Alkynyl, Amino C 1 -C 6 Alkyl, aminocarbonyl C 1 -C 6 Alkyl, aryl C 1 -C 6 Alkyl, azide C 1 -C 6 Alkyl, Carboxy, Carboxy C 1 -C 6 Alkyl, Heteroaryl C 1 -C 6 Alkyl, Hydroxy C 1 -C 6 Alkyl and NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); aryl C 1 -C 6 The aryl portion of the alkyl is optionally aryl C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy and hydroxy; R 15’ is hydrogen or C 1 -C 6 alkyl; or R 15 and R 15’ together with the atoms to which they are attached, 3 -C 8 forms a cycloalkyl ring; and R 15’’ is hydrogen; amine carbonyl, carboxy or -(CH 2 ) n C(O)NHCHR 16 R 16’ where n is 0, 1 or 2; R 16 is hydrogen, C 1 -C 6 Alkoxy C 1 -C 6 Alkyl, C 1 -C 6 Alkyl C 2 -C 6 Alkynyl, C 2 -C 6 Alkynyl, Amino C 1 -C 6 Alkyl, aryl C 1 -C 6 Alkyl, Carboxy, Carboxy C 1 -C 6 Alkyl, Heteroaryl, Heteroaryl C 1 -C 6 Alkyl, Hydroxy C 1 -C 6 Alkyl and NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); aryl C 1 -C 6 The aryl portion of the alkyl and heteroaryl are optionally C 1 -C 6 Alkyl, aryl C 1 -C 6 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkoxy and hydroxy; and R 16’ is hydrogen, C 1 -C 6 Alkyl, aminocarbonyl, carboxy or -(CH 2 ) m C(O)NHCHR 17 R 17’ where m is 0, 1 or 2; R 17 is C 2 -C 6 alkynyl; and R 17’ is aminocarbonyl or carboxy; and R a is hydrogen or C 1 -C 6 alkyl; or R 1 and R a together with the atoms to which they are attached form an azetidine, morpholine, piperidine, piperazine, or pyrrolidine ring, each ring optionally substituted with an amino or hydroxy group. or a pharma- ceutically acceptable salt thereof.

2. R 1 C 1 -C 6 Alkyl, Amino C 1 -C 6 Alkyl, aminocarbonyl C 1 -C 6 Alkyl, aryl C 1 -C 6 Alkyl, Heteroaryl C 1 -C 6 Alkyl, Heterocyclyl C 1 -C 6 Alkyl and Hydroxy C 1 -C 6 alkyl, wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally halo and carboxyC 1 -C 6 substituted with 1, 2, or 3 groups independently selected from alkoxy; and R 1’ is hydrogen, 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

3. R 2 is aryl C 1 -C 6 Alkyl and Heteroaryl C 1 -C 6 alkyl, wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally carboxy, carboxy C 1 -C 6 substituted with 1, 2, or 3 groups independently selected from alkoxy, cyano, halo, hydroxy, and nitro; and R 2’ is hydrogen, 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

4. R 3 Aminocarbonyl C 1 -C 6 Alkyl or Carboxy C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

5. R 4 is aryl C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, substituted with one, two or three groups independently selected from alkyl, halo and trifluoromethyl.

6. R 5 C 1 -C 6 Alkyl or aryl C 1 -C 6 alkyl; wherein aryl C 1 -C 6 The aryl portion of the alkyl is optionally carboxy, carboxy C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, substituted with one, two or three groups independently selected from alkoxy and hydroxy.

7. R 6 Biphenyl C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

8. R 7 C 1 -C 6 Alkyl, aryl C 1 -C 6 Alkyl, Carboxy C 1 -C 6 Alkyl and NH 2 C(X)NHC 1 -C 6 alkyl (wherein X is O or NH); aryl C 1 -C 6 The aryl portion of the alkyl is optionally carboxy, carboxy C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, substituted with one, two or three groups independently selected from alkoxy and hydroxy.

9. R 8 C 1 -C 6 Alkyl or Amino C 1 -C 6 alkyl; and R 8’ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

10. R 9 C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

11. R 10 Amino C 1 -C 6 Alkyl or aminocarbonyl C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

12. R 11 C 1 -C 6 Alkyl or C 3 -C 6 Cycloalkyl C 1 -C 3 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

13. R 12 is C 1 -C 4 Alkyl or Hydroxy C 1 -C 4 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

14. R 13 Amino C 1 -C 6 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, Carboxy C 1 -C 6 Alkyl or Hydroxy C 1 -C 4 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

15. R 14 is aminocarbonyl or -C(O)NHCHR 15 C(O)NH 2 where R 15 is hydrogen, C 1 -C 6 Alkyl, Amino C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

16. R 15 is hydrogen or C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 0 or 1;

17. R 16 is hydrogen or C 2 -C 4 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, which is alkynyl.

18. R a 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

19. R 1’ , R 2’ and R 8’ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein one, two or all of are methyl.

20. R 1 C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, Amino C 1 -C 3 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, aryl C 1 -C 2 Alkyl, arylcarbonylamino C 1 -C 2 Alkyl, carboxypropyl, cyanomethyl; heteroarylmethyl, heterocyclylmethyl, hydroxyC 2 -C 3 Alkyl, methoxy C 1 -C 2 Alkyl, methylamino C 1 -C 2 Alkyl, NH 2 C(X)NHpropyl (wherein X is O or NH) and H 2 NC(X) piperidinyl, wherein aryl C 1 -C 2 Alkyl and aryl carbonyl amino C 1 -C 6 the aryl portion of the alkyl is optionally substituted with one, two, or three groups independently selected from aminocarbonyl, arylmethoxy, carboxy, carboxymethoxy, carboxyphenyl, halo, methoxy, methylcarbonylamino, propynyloxy, and trifluoromethyl; R 1’ is hydrogen or methyl; R 2 is aryl C 1 -C 2 Alkyl, azide C 1 -C 2 Alkyl, biscarboxyethyl, carboxy C 1 -C 3 Alkyl, methoxy C 1 -C 2 Alkyl and Heteroaryl C 1 -C 2 alkyl; wherein aryl C 1 -C 2 The aryl portion of the alkyl and the heteroaryl C 1 -C 2 The heteroaryl portion of the alkyl is optionally 1 -C 4 substituted with 1, 2, 3, 4, or 5 groups independently selected from alkyl, amino, aminocarbonyl, aminomethyl, arylcarbonyl, arylmethoxy, azido, carboxy, carboxymethoxy, carboxymethyl, carboxyphenyl, cyano, halo, hydroxy, methoxy, methylcarbonylamino, nitro, propynyloxy, trifluoromethoxy, and trifluoromethyl; R 2’ is hydrogen or methyl; R 3 is aminocarbonylmethyl, aryl C 1 -C 3 Alkyl, arylmethoxymethyl, carboxy C 1 -C 2 Alkyl, Furyl C 1 -C 3 Alkyl, Hydroxy C 1 -C 2 Alkyl, methoxymethyl and tetrazolylmethyl, HOS(O) 2 C 1 -C 3 Alkyl and CH 3 S (O) 2 NHC(O)(C 1 -C 3 alkyl); wherein aryl C 1 -C 3 The aryl portion of the alkyl optionally contains one, two or three amino C 1 -C 3 is substituted with an alkyl group; R 4 is aryl C 1 -C 2 alkyl and heteroarylmethyl; 1 -C 2 the aryl portion of the alkyl and the heteroaryl portion of the heteroarylmethyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, cyano, halo, hydroxy, methoxy, methyl, and trifluoromethyl; R 5 C 1 -C 5 Alkyl, arylmethyl, cyanomethyl, C 3 -C 6 Cycloalkyl, (C 3 -C 6 cycloalkyl)methyl, heteroarylmethyl, hydroxy C 1 -C 2 alkyl, methoxymethyl and phenyl; wherein the aryl portion of the arylmethyl is optionally selected from amino, aminomethyl, aminocarbonyl, aryl, arylmethoxy, aryloxy, carboxymethoxy, carboxy, cyano, (C 3 -C 6 cycloalkyl)oxy, halo, heteroaryl, hydroxy and propynyloxy; wherein aryl is optionally substituted with one, two, three, four or five groups independently selected from C 1 -C 3 Alkyl, C 1 -C 3 further substituted with 1, 2, or 3 groups independently selected from alkylcarbonylamino, carboxy, and hydroxy; R 6 is biphenylmethyl; R 7 is hydrogen, C 1 -C 5 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonylethyl, aminocarbonylmethyl, arylmethyl, butynyl, C 3 -C 6 Cycloalkyl, (C 3 -C 6 Cycloalkyl)methyl, carboxyethyl, haloarylcarbonylaminopropyl, heteroarylpropyl, hydroxy C 2 Alkyl, methylcarbonylamino C 2 -C 4 Alkyl, phenyl and NH 2 C(X)NHC 2 -C 4 alkyl (wherein X is O or NH); wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy, carboxy, carboxymethoxy, hydroxy, propynyloxy, and trifluoromethoxy; R 8 C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 1 -C 4 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, (C 7 H 15 O 6 ) Aminomethyl, arylmethyl, carboxy C 1 -C 3 selected from alkyl, haloarylcarbonylaminopropyl, heterocyclyl or heteroarylmethyl and hydroxymethyl; the aryl portion of the arylmethyl is optionally substituted with one, two or three groups independently selected from hydroxy and aminomethyl; R 8’ is hydrogen or R 8 and R 8’ together with the atoms to which they are attached form a cyclopropyl ring; R 9 C 1 -C 4 is selected from alkyl, arylmethyl, and cyclohexylmethyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three hydroxy groups; R 10 C 1 -C 4 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, (C 7 H 15 O 6 ) Aminomethyl, arylmethyl, butylcarbonylaminoethyl, butynyl, carboxy C 1 -C 3 Alkyl, heteroarylmethyl, hydroxy C 1 -C 2 Alkyl, NH 2 C(NH)NHmethyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two or three groups independently selected from arylmethoxy and propynyloxy; R 11 C 4 -C 8 Alkyl, aryl C 1 -C 2 Alkyl, C 3 -C 6 Cycloalkyl C 1 -C 2 alkyl and heteroarylmethyl; 1 -C 2 the aryl portion of the alkyl is optionally substituted with one, two, or three groups independently selected from amino, aminoethoxy, aminomethyl, cyano, halo, hydroxy, methoxy, methyl, and trifluoromethyl; R 12 C 3 -C 4 Alkyl, arylmethyl, carboxybutyl, hydroxy C 1 -C 3 alkyl and propynyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy and propynyloxy; R 13 C 3 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, arylmethyl, carboxy C 1 -C 3 Alkyl, haloarylcarbonylaminopropyl, heteroarylmethyl, hydroxy C 1 -C 3 Alkyl and NH 2 C(X)NHpropyl, where X is O or NH; the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy and propynyloxy; R 14 is aminocarbonyl; carboxy; or -C(O)NR 14’ CR 15 R 15’ R 15’’ where R 14’ is hydrogen or methyl; or R 15 and R 14’ together with the atoms to which they are attached form a pyrrolidine ring; R 15 is hydrogen, C 1 -C 2 Alkyl, C 1 -C 4 Alkylcarbonylamino C 1 -C 3 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, arylmethyl, azido C 2 -C 4 Alkyl, Carboxy, Carboxy C 1 -C 3 Alkyl, heteroaryl, methyl, hydroxymethyl, NH 2 C(NH)NH is selected from propyl and propynyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two or three groups independently selected from arylmethoxy and hydroxy; R 15’ is hydrogen or methyl; or R 15 and R 15’ together with the atoms to which they are attached form a cyclopropyl ring; and R 15’’ is hydrogen, aminocarbonyl or carboxy; or -(CH 2 ) n C(O)NHCHR 16 R 16’ where n is 0, 1 or 2; R 16 is hydrogen, amino C 1 -C 4 Alkyl, arylmethyl, carboxy, carboxyethyl, heteroaryl, heteroarylethyl, hydroxymethyl, methoxymethyl, NH 2 C(NH)NH is selected from propyl and propynyl; 1 -C 6 the aryl portion of the alkyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from arylmethoxy, hydroxy, and methyl; and R 16’ is hydrogen, aminocarbonyl, carboxy, methyl or -(CH 2 ) m C(O)NHCHR 17 R 17’ where m is 0, 1 or 2; R 17 is propynyl; and R 17’ is aminocarbonyl or carboxy; and R a is hydrogen or methyl; or R 1 and R a together with the atoms to which they are attached form a piperazine or pyrrolidine ring, each ring being optionally substituted with an amino or hydroxy group; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

21. R 1 C 1 -C 6 Alkyl, Amino C 1 -C 3 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, aryl C 1 -C 2 Alkyl, heteroarylmethyl, heterocyclyl C 1 -C 6 Alkyl and Hydroxy C 2 -C 3 alkyl, wherein Aryl C 1 -C 2 the aryl portion of the alkyl is optionally substituted with 1, 2, or 3 groups independently selected from carboxymethoxy and halo; and R 1’ is hydrogen, 21. The compound of claim 20 or a pharma- ceutically acceptable salt thereof.

22. R a 22. The compound of claim 20 or claim 21, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

23. R 1 C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, Amino C 1 -C 3 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, aryl C 1 -C 2 Alkyl, arylcarbonylamino C 1 -C 2 Alkyl, carboxypropyl, cyanomethyl, heteroarylmethyl, heterocyclmethyl, hydroxyC 2 -C 3 Alkyl, methoxy C 1 -C 2 Alkyl, methylamino C 1 -C 2 Alkyl, NH 2 C(NH)NHpropyl and H 2 NC(NH)piperidinyl; Aryl C 1 -C 2 The aryl portion of alkyl and arylcarbonylamino C 1 -C 2 alkyl is optionally substituted with one, two, or three groups independently selected from aminocarbonyl, carboxy, carboxymethoxy, halo, methoxy, methylcarbonylamino, propynyloxy, and trifluoromethyl; R 1’ is hydrogen; R 2 is aryl C 1 -C 2 Alkyl, azide C 1 -C 2 Alkyl, carboxypropyl, heteroaryl C 1 -C 2 Alkyl and Methoxy C 1 -C 2 alkyl; wherein aryl C 1 -C 2 The aryl portion of the alkyl and the heteroaryl C 1 -C 2 The heteroaryl portion of the alkyl is optionally C 1 -C 4 substituted with one or more groups independently selected from alkyl, amino, aminocarbonyl, aminomethyl, arylcarbonyl, arylmethoxy, carboxy, carboxymethoxy, carboxymethyl, cyano, halo, hydroxy, methoxy, methylcarbonylamino, nitro, propynyloxy, trifluoromethoxy, and trifluoromethyl; R 2’ is hydrogen or methyl; R 3 is aminocarbonylmethyl; aryl C 1 -C 3 Alkyl, carboxymethyl, furyl C 1 -C 3 Alkyl, Hydroxy C 1 -C 3 Alkyl, HOS(O) 2 C 1 -C 3 Alkyl, CH 3 S (O) 2 NHC(O)(C 1 -C 3 alkyl) and tetrazolyl; 1 -C 3 The aryl portion of the alkyl optionally contains one, two or three amino C 1 -C 3 is substituted with an alkyl group; R 4 is aryl C 1 -C 2 alkyl and heteroaryl, methyl and wherein aryl C 1 -C 2 the aryl portion of the alkyl and the heteroaryl portion of the heteroarylmethyl are optionally substituted with one or more groups independently selected from amino, halo, hydroxy, methoxy, methyl and trifluoromethyl; R 5 C 1 -C 5 Alkyl, arylmethyl, C 3 -C 6 Cycloalkyl, (C 3 -C 6 cycloalkyl)methyl, heteroarylmethyl, hydroxy C 2 alkyl, methoxymethyl and phenyl; wherein the aryl portion of the arylmethyl is optionally selected from amino, aminocarbonyl, aminomethyl, aryl, arylmethoxy, aryloxy, carboxy, carboxymethoxy, (C 3 -C 6 cycloalkyl)oxy, cyano, halo, heteroaryl, hydroxy, and propynyloxy; wherein aryl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from C 1 -C 3 Alkyl, C 1 -C 3 further substituted with alkylcarbonylamino, carboxy, and hydroxy; R 6 is biphenylmethyl; R 7 C 1 -C 5 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonylethyl, aminocarbonylmethyl, arylmethyl, butynyl, carboxyethyl, C 3 -C 6 Cycloalkyl, (C 3 -C 6 cycloalkyl)methyl, heteroarylmethyl, hydroxy C 2 Alkyl, methylcarbonylamino C 2 -C 4 Alkyl, phenyl and NH 2 C(X)NHC 2 -C 4 alkyl (wherein X is O or NH); wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy, carboxy, carboxymethoxy, hydroxy, propynyloxy, and trifluoromethoxyl; R 8 C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 1 -C 4 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, (C 7 H 15 O 6 ) Aminomethyl, arylmethyl, carboxy C 1 -C 3 is selected from alkyl, heteroarylmethyl, and hydroxymethyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from aminomethyl and hydroxy; R 8’ is hydrogen; R 9 C 1 -C 4 alkyl, cyclohexylmethyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one or two hydroxy groups; R 10 Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, (C 7 H 15 O 6 ) Aminomethyl, butynyl, butylcarbonylaminoethyl; Carboxy C 1 -C 3 Alkyl, heteroarylmethyl, hydroxy C 1 -C 2 Alkyl and NH 2 C(NH)NHmethyl; R 11 C 4 -C 8 Alkyl, aryl C 1 -C 2 Alkyl, C 3 -C 6 Cycloalkyl C 1 -C 2 alkyl and heteroarylmethyl; 1 -C 2 the aryl portion of the alkyl is optionally substituted with one, two, or three groups independently selected from aminomethyl, chloro, fluoro, hydroxy, methoxy, methyl, and trifluoromethyl; R 12 C 3 -C 4 Alkyl, carboxybutyl, hydroxy C 1 -C 3 alkyl, phenylmethyl, and propynyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three propynyloxy; R 13 C 3 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, arylmethyl, carboxy C 1 -C 3 alkyl, haloarylcarbonylaminopropyl; hydroxyC 1 -C 3 Alkyl, heteroaryl, methyl and NH 2 C(X)NHpropyl (wherein X is O or NH); the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from arylmethoxy and propynyloxy; R 14 is aminocarbonyl or -C(O)NR 14’ CR 15 R 15’ R 15’’ where R 14’ is hydrogen or methyl; R 15 is hydrogen; 1 -C 2 Alkyl, C 1 -C 4 Alkylcarbonylamino C 1 -C 3 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, arylmethyl, azido C 2 -C 3 Alkyl, carboxy; Carboxy C 1 -C 2 Alkyl, heteroarylmethyl, hydroxymethyl, propynyl and NH 2 C(NH)NHpropyl; wherein the aryl portion of the arylmethyl is optionally substituted with one, two or three groups independently selected from arylmethoxy and hydroxy; R 15’ is hydrogen or methyl; or R 15 and R 15’ together with the atoms to which they are attached form a cyclopropyl ring; and R 15’’ is hydrogen, aminocarbonyl, carboxy or -(CH 2 ) n C(O)NHCHR 16 R 16’ where n is 0, 1 or 2; R 16 is hydrogen, amino C 1 -C 4 Alkyl, arylmethyl, carboxy, carboxyethyl, heteroaryl, heteroarylethyl, hydroxymethyl, methoxymethyl, NH 2 C(NH)NH is selected from propyl and propynyl; wherein the aryl portion of the arylmethyl and the heteroaryl are optionally substituted with one or more groups independently selected from arylmethoxy and methyl; and R 16’ is hydrogen, aminocarbonyl, carboxy, methyl or -(CH 2 ) m C(O)NHCHR 17 R 17’ where m is 0, 1 or 2; R 17 is propynyl; and R 17’ is aminocarbonyl or carboxy; and R a is hydrogen or methyl; or R 1 and R a together with the atoms to which they are attached form a pyrrolidine or piperazine ring, each ring being optionally substituted with an amino group; 21. The compound of claim 20 or a pharma- ceutically acceptable salt thereof.

24. R 1 C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, Amino C 1 -C 3 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, carboxypropyl, cyanomethyl, heteroarylmethyl, heterocyclylmethyl, hydroxy C 2 Alkyl;Methoxy C 1 -C 2 Alkyl, methylamino C 1 -C 2 Alkyl, NH 2 C(NH)NHpropyl and H 2 NC(NH) piperidinyl; Aryl C 1 -C 2 alkyl; wherein aryl C 1 -C 2 the aryl portion of the alkyl is optionally substituted with one, two, or three groups independently selected from aminocarbonyl, carboxy, carboxymethoxy, halo, methoxy, methylcarbonylamino, propynyloxy, and trifluoromethyl; R 1’ is hydrogen; R 2 is aryl C 1 -C 2 Alkyl and Heteroaryl C 1 -C 2 alkyl, wherein aryl C 1 -C 2 The aryl portion of the alkyl and the heteroaryl C 1 -C 2 the heteroaryl portion of the alkyl is optionally substituted with one or more groups independently selected from amino, aminocarbonyl, aminomethyl, carboxy, carboxymethyl, carboxymethoxy, cyano, halo, hydroxy, methoxy, methyl, nitro, and propynyloxy; R 2’ is hydrogen or methyl; R 3 is selected from aminocarbonylmethyl, carboxymethyl and tetrazolyl; R 4 is selected from arylmethyl and heteroarylmethyl; where the aryl portion of the arylmethyl and the heteroaryl portion of the heteroarylmethyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, halo, hydroxy, methoxy, methyl, and trifluoromethyl; R 5 C 1 -C 5 Alkyl, arylmethyl, C 3 -C 6 Cycloalkyl, (C 3 -C 6 Cycloalkyl)methyl, hydroxy C 2 alkyl, methoxymethyl, and phenyl; wherein the aryl portion of the arylmethyl is optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from aminomethyl, aminocarbonyl, carboxy, carboxymethoxy, hydroxy, and propynyloxy; R 6 is biphenylmethyl; R 7 C 1 -C 4 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonylethyl, aminocarbonylmethyl, arylmethyl, butynyl, carboxyethyl, C 3 -C 6 Cycloalkyl, heteroarylmethyl, hydroxy C 2 Alkyl, methylcarbonylaminobutyl, phenyl and NH 2 C(X)NHC 2 -C 4 alkyl (wherein X is O or NH); where the aryl portion of the arylmethyl is optionally substituted with one, two, or three groups independently selected from carboxy, carboxymethoxy, hydroxy, propynyloxy, and trifluoromethoxyl; R 8 C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, Amino C 1 -C 4 selected from alkyl, aminocarbonylethyl, carboxypropyl, hydroxymethyl and imidazolylmethyl; R 8’ is hydrogen; R 9 C 1 -C 4 alkyl, cyclohexylmethyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one or two hydroxy groups; R 10 Amino C 1 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, butylcarbonylaminoethyl, butynyl, carboxy C 1 -C 3 Alkyl, Hydroxy C 1 -C 2 Alkyl, imidazolylmethyl and NH 2 C(NH)NHmethyl; R 11 is selected from butyl, cyclohexylmethyl, and phenylmethyl; the phenyl moiety of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from fluoro and methyl; R 12 C 3 -C 4 Alkyl, carboxybutyl, hydroxy C 1 -C 3 alkyl and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two or three propynyloxy groups; R 13 Amino C 1 -C 4 Alkyl, C 1 -C 4 Alkylcarbonylamino C 2 -C 4 Alkyl, aminocarbonyl C 1 -C 2 Alkyl, arylmethyl, butyl, carboxy C 1 -C 2 Alkyl, heteroarylmethyl, hydroxy C 1 -C 3 Alkyl and NH 2 C(X)NHpropyl, where X is O or NH; wherein the aryl portion of the arylmethyl is optionally substituted with one, two or three propynyloxy groups; R 14 is aminocarbonyl or -C(O)NR 14’ CR 15 R 15’ R 15’’ where R 14’ is hydrogen or methyl; R 15 is hydrogen, C 1 -C 2 Alkyl, Amino C 1 -C 4 Alkyl, aminocarbonylmethyl, butylcarbonylaminoethyl, carboxy, carboxyethyl, hydroxymethyl, NH 2 C(NH)NH is selected from propyl and propynyl; R 15’ is hydrogen; methyl; or R 15 and R 15’ together with the atoms to which they are attached form a cyclopropyl ring; and R 15’’ is hydrogen, aminocarbonyl, carboxy or -(CH 2 ) n C(O)NHCHR 16 R 16’ where n is 0, 1 or 2; R 16 is hydrogen, amino C 1 -C 4 Alkyl, arylmethyl, carboxyethyl, heteroaryl, heteroarylethyl, hydroxymethyl, methoxymethyl, NH 2 C(NH)NH is selected from propyl and propynyl; wherein the aryl portion of the arylmethyl and the heteroaryl are optionally substituted with one or more groups independently selected from arylmethoxy and methyl; R 16’ is hydrogen, aminocarbonyl, carboxy, methyl or -(CH 2 ) m C(O)NHCHR 17 R 17’ where m is 0, 1 or 2; R 17 is propynyl; and R 17’ is aminocarbonyl; and R a is hydrogen or methyl; or R 1 and R a together with the atoms to which they are attached form a pyrrolidine ring, wherein the pyrrolidine ring is optionally substituted with an amino group; 24. The compound of claim 23 or a pharma- ceutically acceptable salt thereof.

25. R 1 C 2 -C 4 Alkyl, Amino C 1 -C 2 Alkyl, aminocarbonylmethyl, heteroarylmethyl, hydroxy C 2 Alkyl, morpholinylmethyl, NH 2 C(NH)NHpropyl and phenylmethyl; the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from carboxymethoxy and fluoro; R 1’ is hydrogen; R 2 is selected from phenylmethyl and pyridylmethyl, the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from hydroxy, carboxy, and carboxymethoxy; R 2’ is hydrogen; R 3 is carboxymethyl; R 4 is selected from indolylmethyl and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from hydroxy and methyl; R 5 is selected from phenylmethyl and propyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from carboxy, carboxymethoxy, hydroxy, and propynyloxy; and R 6 is biphenylmethyl; R 7 C 3 -C 4 Alkyl, NH 2 C(O)NHpropyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three groups independently selected from carboxy, carboxymethoxy, hydroxy, and propynyloxy; R 8 is selected from aminopropyl and methyl; R 8’ is hydrogen; R 9 is isobutyl; R 10 is aminoethyl; R 11 is selected from butyl and cyclohexylmethyl; R 12 is selected from hydroxyisopropyl, hydroxypropyl, isopropyl, and propyl; R 13 Aminopropyl, carboxyethyl, hydroxy C 1 -C 2 alkyl, imidazolylmethyl, and phenylmethyl; wherein the phenyl portion of the phenylmethyl is optionally substituted with one, two, or three propynyloxy groups; R 14 is aminocarbonyl or -C(O)NR 14’ CR 15 R 15’ R 15’’ where R 14’ is hydrogen; R 15 is selected from aminocarbonylmethyl, aminoethyl, and methyl; R 15’ is hydrogen; and R 15’’ is hydrogen, aminocarbonyl or -(CH 2 ) n C(O)NHCHR 16 R 16’ where n is 0 or 1; R 16 is propynyl; and R 16’ is hydrogen, aminocarbonyl or carboxy; and R a is hydrogen, 25. The compound of claim 24 or a pharma- ceutically acceptable salt thereof.

26. 26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 25 or a pharma- ceutically acceptable salt thereof.

27. 26. A method of enhancing, stimulating and / or increasing an immune response in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1-25 or a pharma- ceutically acceptable salt thereof.

28. A method for blocking the interaction of PD-1 and PD-L1 in a subject, comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1 to 25 or a pharma- ceutical acceptable salt thereof.